The small GTPASE - ARF like protein 1 (ARL1) is a new regulator of golgi structure and function by LU LEI
  
 
THE SMALL GTPASE – ARF LIKE PROTEIN 1 (ARL1) 
 IS A NEW REGULATOR OF GOLGI  









INSTITUTE OF MOLECULAR AND CELL BIOLOGY 





THE SMALL GTPASE – ARF LIKE PROTEIN 1 (ARL1) 
 IS A NEW REGULATOR OF GOLGI  





UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA 
 
A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
INSTITUTE OF MOLECULAR AND CELL BIOLOGY 
NATIONAL UNIVERSITY OF SINGAPORE 
2003 
 
         i
Acknowledgements 
 
This PhD thesis is impossible without the following people; my deepest and most sincere 
gratitude goes to them: 
My supervisor: Hong Wanjin, for his creative scientific ideas and inspirational guidance 
through out my research project and for his kindness and caring about me.  
My committee members: Manser Edward and Hunziker Walter, for their stimulating 
discussion and critiques during my student annual committee meetings. 
My past and present lab mates, it is them who created collaborating and stimulating 
research environment in HWJ lab: Tang Bor Luen, Chan Siew Wee, Wong Siew Heng, 
Xu Yue and Thuan Bui, for teaching me basic molecular, cell biological and 
biochemical techniques without reservations; Singh Paramjeet and Tang Bor Luen for 
critical and careful reading of my research papers from which this thesis was derived; 
Horstmann Heinz and Ng Cheepeng for collaboration in electron microscopy (EM) in 
Fig 13 and Fig 23;  Wang Tuanlao for the collaboration on VSV-G in vitro ER-to-Golgi 
transport assay in Fig 24;  Tham Jill, Loh Eva, Tai Guihua, Ong Yanshan, Tran Thi 
Ton Hoai, Lim Koh Pang and Huang Bin for sharing critical reagents for this study; 
and other members of HWJ group for discussions and helps.   
 
My special thanks also go to my collaborators: Gleeson Paul (University of Melborne) 
for providing rabbit anti-Golgin-245 polyclonal antibody; and Marvin Fritzler 
(University of Calgary) and Edward Chan (Scripps Institute) for supplying me the full 
length cDNA of Golgin-97. 
         ii
 
I would like to express my gratitude to Yu Xianwen for her help in my yeast two-hybrid 
assays.  My appreciation also goes to the DNA sequencing and protein mass-spectrum 
unit of IMCB for their excellent services.  And for all those people in IMCB, who have 
contributed their support, either directly or indirectly, to my research life in IMCB, please 
accept my deepest thanks. 
 
It is a great opportunity to express my gratitude towards my parents and sisters living far 
away in China, for their encouragement, understanding and most important, their love. 
 








         iii
Table of Contents 
Summary  
List of Tables 
List of Figures  
Abbreviations 
Chapter 1 Introduction of Arl1 and ARF family GTPases 
1.1 Ras superfamily GTPases 
1.2 ARF family GTPases and their classification 













1.4 Rationale of this Study 
         iv
Chapter 2 Materials and Methods 
2.1 Cloning 
2.1.1 DNA manipulations 
2.1.2 Constructs 
2.2 Yeast two-hybrid 
2.2.1 Gal4 based yeast two-hybrid screening 
2.2.2 Yeast two-hybrid assays 
2.2.3 β-galactosidase assays 
2.3 Recombinant fusion proteins 
2.3.1 Production of His-tagged Arl1 fusion protein in bacteria 
2.3.2 Production of GST fusion proteins 
2.4 Antibodies 
2.4.1 Raising rabbit polyclonal antibody against rat Arl1 and human Golgin-97 
2.4.2 Antibodies used in this study 
2.5 Active Arl1 and ARF1 pull down assays 
2.6 In vitro guanine nucleotide exchange reactions of GST fusion proteins 
of Arl1, ARF1 and Arl4 
 
2.7 35S labeling of proteins by in vitro transcription and translation 
2.8 GST fusion proteins pull down in vitro translated POR1 or GGA1 
2.9 GST fusion proteins pull down assays using HeLa cytosol 
2.10 Immunoprecipitation 
2.11 Cell culture and transfection 
2.12 Indirect immunofluorescence microscopy and confocal microscopy 
2.12.1 Paraformaldehyde fixation 
         v
2.12.2 Methanol fixation 
2.12.3 Indirect immunofluorescence labeling 
2.13 VSV-G morphological transport assay 
2.14 VSV-G biochemical transport assay 
2.15 siRNA knock down of Arl1 and Golgin-97 
2.16 SDS-PAGE 
2.17 Coomassie blue staining 
2.18 Western blot 
2.19 Electron microscopy (EM) 
2.20 Preparation of RIPA cell lysate 
Chapter 3 Characterization of Arl1 antibodies and quantification of endogenous 
Arl1 level 
 
3.1 Generation of rabbit anti rat Arl1 polyclonal antibody 
3.2 Characterization of different versions of Arl1 polyclonal antibodies 
3.3 Quantification of endogenous Arl1 and ARF1/3 levels  in cultured 
mammalian cells 
 
3.4 Quantification of active Arl1 content in cultured mammalian cells 
3.5 Arl1 is inactivated by BFA treatment 
3.6 Discussion 
Chapter 4 Arl1 is essential for the structure and function of Golgi apparatus 
4.1 Localization of endogenous Arl1 to the trans-Golgi/TGN in CHO cells 
4.2 Saturable Golgi association of Arl1 
4.3 N-terminal myristoylation of Arl1 is essential for its Golgi association 
4.4 Construction of guanine nucleotide binding mutants of Arl1 
         vi
4.5 Expression of the GDP restricted form of Arl1 (Arl1T31N) causes 
disassembly of the Golgi apparatus 
 
4.6 Expression of GTP restricted form of Arl1 (Arl1Q71L) causes an 
expansion of the Golgi membrane 
 
 
4.7 GTP restricted form of Arl1 causes stable association of COPI, AP-1 
and Golgi ARFs with the expanded Golgi membrane 
 
4.8 Protein trafficking through the Golgi apparatus is inhibited by 
Arl1(Q71L) 
 
4.9 The cisternae of Golgi apparatus disorganized into an extensive 
vesicular-tubular network upon over expression of Arl1(Q71L) 
 
4.10 Arl1 is essential for in vitro VSV-G ER to medial Golgi trafficking 
4.11 Discussion 
Chapter 5 Arl1 and ARF1 have shared and unique effectors 
5.1 Gal4 based yeast two-hybrid screening of a human brain cDNA 
library using the GTP restricted form of Arl1 as bait 
5.2 Initial characterization of the interaction of Arl1 with its putative 
effectors 
5.3 Discussion 
Chapter 6 Active Arl1 interacts with the autoantigens Golgin-97 and Golgin-245, 
and recruits them on to the Golgi membrane 
 
6.1 Arl1 interacts with Golgin-97 through its GRIP domain 
6.2 Arl1 interacts with Golgin-97 and Golgin-245 in pull down and 
immunoprecipitation experiments 
 
6.3 Comparison of GRIP domain sequences 
6.4 Conserved amino acids in GRIP domain are essential for their 
interaction with Arl1-GTP 
 
6.5 The switch II (SWII) region of Arl1 interacts with the GRIP domain 
         vii
6.6 Generation of Golgin-97 polyclonal antibody 
6.7 Golgin-97 is localized to the trans side of the Golgi apparatus or TGN 
6.8 The concerted Golgi dissociation kinetics of Arl1, Golgin-97 and 
Golgin-245 upon BFA treatment 
 
6.9 Arl1-GTP recruits Golgin-97 and Golgin-245 to the Golgi apparatus, 
while Arl1-GDP dissociates them from the Golgi  
 
 
6.11 Golgin-97 and Golgin-245 translocate to endosomes upon artificially 
tethering active Arl1 to the endosome 
 
6.12 Knocking down of Arl1 dissociated Golgin-97 and Golgin-245 from 




Chapter 7 Conclusion and future perspectives 
References 
         viii
Summary 
 
Arls (ARF like proteins) are a group of small GTPases that are homologous to ARFs 
(40~60% in sequence identity), but they do not have the following three activities as all 
ARFs do.  1) They do not serve as ADP ribosyltransferase cofactors.  2) They do not 
rescue lethal phenotype of arf1/arf2 double deletion yeast.  3) And they do not activate 
phospholipase D (PLD).  As the first member of the Arl group to be described, Arl1’s 
cellular and molecular functions, except for its Golgi localization in mammalian cells, are 
still unknown.  The lack of studies of Arl1 is in stark contrast to the extensive work 
conducted on ARFs.  This thesis describes the characterization of Arl1 and its effectors, 
especially GRIP domain Golgins and provides molecular and cell biological evidences 
that Arl1 regulates the structure and function of the Golgi apparatus.  Using an Arl1 
specific polyclonal antibody, the cellular level of Arl1 in several cell lines was estimated 
to be 10-3-10-4 of total cellular proteins, which is in a similar range as ARF1/3.  The 
active GTP-bound form of Arl1 was determined to be ~20% of total Arl1 by a novel pull 
down assay developed in this study.  Electron microscopy (EM) revealed that 
endogenous Arl1 was localized to the trans-side of the Golgi in CHO cells.  The Golgi 
association of Arl1 was found to be saturable and dependent on its N-terminal myristoyl 
lipid group.  The effects of exogenous expression of guanine nucleotide binding mutants 
of Arl1 was characterized in vivo: Arl1T31N, the GDP restricted form, was observed to 
disassemble the Golgi apparatus, while Arl1Q71L, the GTP restricted form, was found to 
expand the Golgi membrane and to recruit COPI and AP-1 coats to the Golgi such that 
the association of these coats became no longer Brefeldin A (BFA) sensitive.  In the 
         ix
Arl1Q71L expressing cells, it was found that the Golgi was transformed to extensively 
vesicular and tubular profiles as observed under EM.  The normal secretory function of 
the Golgi was disrupted and the trafficking of VSV-G was trapped in the vesicularized 
Golgi.  Using a yeast two-hybrid screen, putative effectors of Arl1 were identified.  These 
included, POR1, MKLP1, pericentrin, Golgin-97, Golgin-245, GCC1 and KIAA0336.  
While POR1 and MKLP1 interacted with both Arl1 and ARF1; the others, including 
Golgin-97, Golgin-245, GCC1, KIAA0336 and pericentrin, were found to interact 
exclusively with Arl1, implying that both Arl1 and ARF1 have shared and unique 
effectors.  The existence of shared effectors suggests a possible communication between 
Arl1 and ARF1.  Later studies focused on the GRIP domain containing Golgins, 
including Golgin-97, Golgin-245, GCC1 and KIAA0336.  Arl1-GTP interacted with the 
GRIP domains of Golgin-97 and Golgin-245, a process which was dependent on 
conserved residues of the GRIP domains, which are also important for Golgi targeting.  
The switch II region of Arl1 was found to confer the specificity of this interaction.  Arl1-
GTP (Arl1Q71L) recruited Golgin-97 to the Golgi membrane in a switch II-dependent 
manner.  Artificially tethering of Arl1-GTP onto endosomes resulted in the endosomal 
targeting of Golgin-97 and Golgin-245.  Furthermore, Golgin-97 and Golgin-245 were 
found to dissociate from the Golgi when Arl1 was knocked-down by its siRNA.  Thus, 
one of the functions of Arl1-GTP is to recruit Golgin-97 and Golgin-245 onto the Golgi 
membrane via interaction with their GRIP domains.  Collectively, the research presented 
in this thesis reveals Arl1 as a new regulator of Golgi structure and function, and one 
mechanism of Arl1’s functions is that it recruits its effectors — GRIP domain containing 
Golgins on to the Golgi membrane.
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Introduction of Arl1 and ARF family GTPases 
 
In eukaryotic cells, the dynamic and complex movement of proteins among different 
organelles in the endocytic and secretory pathways is mediated by vesicular transport 
and coordinated by various components of transport machineries belonging to 
different families: SNAREs, Sec1/Munc18 family proteins, tethering molecules, Ras-
like Rab and ARF small GTPases (reviewed by Hong, 1996).  The importance of 
small GTPases, especially those of the ARF and Rab families, in protein trafficking is 
underscored by the fact that each trafficking step examined so far involves an ARF or 
Rab (reviewed by Hong, 1996).  As they function as regulatory switches, ARF and 
Rab family small GTPases have become one of the research foci in the protein 
trafficking field.  Existing data suggest that Rabs are involved in vesicle budding, 
targeting, docking and fusion with acceptor membranes (reviewed by Collins and 
Brennwald, 2000), while ARF GTPases regulate actin cytoskeleton and coat proteins 
recruitment for vesicle budding (reviewed by Roth, 2000). 
 
1.1 Ras superfamily GTPases 
Guanine nucleotide binding proteins (also called GTPases or G proteins) exist in both 
prokaryotic and eukaryotic cells. The GTPase has two states in vivo: the active or 
GTP bound state and the inactive or GDP bound state.  Widely used as molecular 
switches in cells to control biological reactions, GTPases are involved in a myriad of 
cellular processes.  In the translation of mRNA to protein in bacteria, yeast or 
mammalian cells, elongation factor EF-Tu and EF-G, both GTPases, ensure the 
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correct incorporation of aminoacyl tRNA into the ribosome.  The  p54 subunit of 
signal recognition particle (SRP), also a GTPase, mediates the cotranslational 
targeting of secreted and membrane proteins to the endoplasmic reticulum (ER) in 
mammalian cells and to the plasma membrane in bacteria by recognizing the SRP 
receptor (SR) on the target membrane, a subunit of which is also a GTPase (reviewed 
by Hong, 1996).  Diverse GTPases have evolved in eukaryotic organisms to facilitate 
the control of signaling events on their endo-membrane systems.  By their oligomeric 
states, GTPases could be classified into heterotrimeric and monomeric GTPases.  
Monomeric GTPases could be further classified as large GTPases, such as dynamin, 
and small GTPases, such as ARFs.  Small GTPases are monomeric guanine 
nucleotide binding proteins with molecular weights in the range of 20-40 kD.  More 
than 100 small GTPases have been identified in eukaryotes (Takai et al., 2001).  They 
comprise a superfamily of proteins — the Ras superfamily of small GTPases.  
According to their primary sequences and biochemical properties, members of the Ras 
superfamily are classified into 5 families: Ras, Rho, Rab, ARF and Ran (Fig 1). 
Fig 1 Classification of mammalian ARF famlily small GTPases.
Ras superfamily small G protein




































Fig 2 A schematic diagram of Ras structure showing the typical G protein fold: six-stranded β-
sheet surrounded by α-helices and connected by polypeptide loops. Top, structure of Ras, 
which is complexed with a GTP nonhydrolyzable analog GppCp (depicted in ball-and-stick 
model) and is in its active state; Bottom, structure of GDP complexed inactive Ras. The switch 
I and II regions, which change conformation the most between active and inactive Ras, are 
darkened. Secondary structure elements and G-box regions are labeled in the top panel. The 
single solid sphere represents Mg2+. (Adapted from Sprang, 1997.) 
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All small GTPases share consensus primary sequences in some regions, which are 
responsible for guanine nucleotide binding.  These residues form the core of the 
GTPase fold, which, in the high resolution crystallographic structure of Ras, was 
revealed to be a 200-residue domain consisting of a central six-stranded β-sheet 
surrounded by α-helices (Sprang, 1997) (Fig 2).  Those highly conserved amino acids 
are located in five polypeptide loops that form the guanine nucleotide binding sites.  
The five loops are designated the G-1 through G-5 boxes (Table 1 and Fig 3).  The G-
1 box with the consensus sequences, GXXXXGK(S/T), contacts the α- and β-
phosphates of the guanine nucleotide.  The G-2 box contains a conserved Thr residue 
involved in the coordination of Mg2+.  The G-3 box, DXXGQ, is responsible for 
binding of the γ-phosphate of GTP.  The guanine nucleotide ring is partly recognized 
by the G-4 box, NKXD.  The G-5 box, (T/G)(C/S)A, enforces the interaction of 
GTPase with the guanine ring.  Comparison of the structure of the GTP form (active) 
to that of the GDP form (inactive) of small GTPases reveals two regions, switch I and 
switch II, which change conformation drastically upon the hydrolysis GTP to GDP.  
Most effectors of small GTPases utilize these two switch regions for interaction.  For 
example, GGA1, an effector of ARF1, utilizes both switch I and II regions of ARF1 
for GTP-dependent binding (Shiba et al., 2003). 
 
Table 1 Small GTPases have conserved primary sequences in their guanine 
nucleotide binding boxes G1-G5. Sequences are from human correspondent proteins. 
Conserved residues are highlighted. (Modified from Sprang, 1997). 
Small GTPase G1 G2 G3 G4 G5 
Ras-K GAGGVGKS PTI DTAGQ NKCD TSA 
RhoA GDGACGKT PTV DTAGQ NKCD TSA 
Rab1a GDSGVGKS STI DTAGQ NKKD CSA 
ARF1 GLGAAGKT PTI DVGGQ NKQD TCA 






















The well researched structure and function relationship of small GTPases makes it 
possible to design a mutant GTPase, which has altered guanine nucleotide binding 
affinity, specificity or hydrolytic activity.  Some naturally occurred mutations in 
oncogenic Ras GTPases also change their guanine nucleotide binding properties.  In 
the case of RasQ61L, Gln to Leu mutation abolishes the GTPase activity of Ras, 
leaving it in a constitutively GTP bound active form and thus resulting in 
transformation (reviewed by Wittinghofer et al., 1995).  In general, substitution of Ala 
for Ser (Thr) in the G-1 box, GXXXXGK(S/T), increases the affinity of the GTPase 
Fig 3 The conserved guanine nucleotide binding boxes in the structure of Ras complexed with 
a nonhydrolyzable GTP analog, GppCp. Polypeptide loops responsible for the binding of 
gunanine nucleotide are represented in ball-and-stick model. Side chains of the highly 
conserved G-box residues are darkened and labeled with the one-letter amino acid code. 
(Adapted from Sprang, 1997.) 
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towards GDP, thus resulting in a dominant negative mutant.  On the other hand, the 
substitution of Leu for Gln in G-3 box, DXXGQ, abolishes the GTP hydrolysis 
activity of GTPase and locks the small GTPase in its active form, resulting in a 
dominant positive mutant.  The substitution of Asn for Asp in the G-4 box, NKXD, 
greatly weakens the affinity of the small GTPase towards the guanine ring.  Instead, 
the mutant gains affinity towards a xanthine ring, thus creating a mutant which binds 
to XDP or XTP (Zhong et al., 1995; Hoffenberg et al., 1995; Barbieri et al., 1998).  
The cellular levels of both XDP and XTP are very low, thus this mutation offers a 
way to selectively regulate the activation of small GTPase by the addition of xanthine 
nucleotides. 
 
The two inter-convertible forms of small GTPase, GTP and GDP bound forms, are 
generated with the aid of its guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs) (Fig 4).  Upon activation by its upstream signals, the GEF 
promotes the dissociation of GDP and association of GTP with the small GTPase, 
which in turn adopts a conformational change.  An effector (s) subsequently binds to 
the GTP-bound active GTPase to exert its (their) cellular effects.  The Ras-like small 
GTPase has a very low intrinsic GTPase activity; a GTPase activating protein (GAP) 
is thus required to help to terminate its active state by hydrolyzing its bound GTP, 
returning it to a GDP-bound inactive form.  For the Rho and Rab families of small 
GTPases, there exists a third class of regulators, the guanine nucleotide dissociation 




















A common feature of small GTPases is their post translational lipid modification 
(except for Ran and Sar1).  At their C-termini, Ras family members are farnesylated 
and palmitoylated, Rab proteins are geranylgeranylated and Rho family members are 
either geranylgeranylated or farnesylated.  ARF family members are myristoylated at 
their N-termini (Takai et al., 2001).  Lipid modification is believed to facilitate 
membrane association of active small GTPase and to interact with their GEFs, GAPs 
and effectors.  The importance of lipid modification is underscored by the finding that 
inhibition of farnesylation of Ras abolishes its cellular function (Takai et al., 2001). 
 
The functions of small GTPases have been revealed by recent studies on 
representative members of each family: Ras family small GTPases (H-, K- and N-
Fig 4 The conversion of active and inactive small GTPase is regulated by its GTPase activating 
protein (GAP) and guanine nucleotide exchange protein or factor (GEP or GEF). (Adapted 
from the review by Takai et. al., 2001). 
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Ras) mainly regulate gene expression; Rho family members (RhoA/Rac1/Cdc42) 
control both cytoskeleton and gene expression; Rab (Rab1/5/6/7/9) and ARF (ARF1/6 
and Sar1) family small GTPases regulate vesicular membrane trafficking; Ran (Ran) 
family members control protein transport between the nucleus and cytoplasm (Takai 
et al., 2001).  However, the detailed cellular functions of many small G proteins 
remain to be defined.  A majority of the small GTPases in each family are poorly 
characterized.  The study of these small GTPases, which are believed to be key 
regulators of cellular events, will greatly facilitate our understanding of the cell. 
 
1.2 ARF family GTPases and their classification 
The small GTPases of ARF family are classified into the Sar, ARF and Arl 
subfamilies.  The Sar subfamily consists of only one member – Sar1. Sar1 is localized 
at ER exit sites and intermediate compartment (IC).  Active Sar1 is believed to recruit 
the COPII coat for subsequent vesicle budding from ER exit sites or IC membranes 
(Randazzo et al., 2000; Takai et al., 2001). 
 
The prototype of the ARF family small GTPases, ARF1, was purified and cloned 
from bovine brain by tracing its ADP ribosyltransferase cofactor activity (Kahn and 
Gilman, 1984; Kahn and Gilman, 1986; Sewell and Kahn, 1988).  Other mammalian 
ARFs and Arls, were subsequently isolated by low stringency hybridization screening 
[ARF2, 3, 5-6 (Bobak et al., 1989; Tsuchiya et al., 1991), ARD1 (Mishima et al., 
1993)], degenerate PCR [Arl1 (Schurmann et al., 1994), Arl2 (Clark et al., 1993), 
Arl3 (Cavenagh et al., 1994), Arl4 (Schurmann et al., 1994), Arl5 (Breiner et al., 
1996), ARFRP1 (Schurmann et al., 1995)], in silico database searches [Arl4L (Smith 
et al., 1995), Arl7 (Jacobs et al., 1999), Arl8, (Pasqualato et al., 2002; Sebald et al., 
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2003)], differential display cloning [Arl6 (Ingley et al., 1999)], or anchorage-
independent cellular phenotype screening [ARF4 (Kahn et al., 1991)].  
 
The classification of ARF and Arl subfamilies is based on the following three 
activities possessed by all ARFs (Moss and Vaughan, 1998; Takai et al., 2001): 1) to 
serve as cofactors to stimulate the ADP-ribosylation of Gαs by cholera toxin, 2) to 
rescue the lethal phenotype of arf1/arf2 double deletion yeast, and 3) to activate 
Phospholipase D (PLD).  The sequence identities, alignment and phylogenetic tree of 
ARF family members are shown in Table 2, Fig 5 and Fig 6.  In mammals, 6 
members of ARF subfamily have been discovered and they are classified based on 
their sequence identities into 3 classes (Moss and Vaughan, 1998): class I, including 
ARF1, ARF2 and ARF3; class II, including ARF4 and ARF5; and class III, including 
ARF6.  Those members that do not have the above mentioned ARF activities are 
classified as Arls (ARF like proteins).  In the Arl subfamily, there are 11 members 
identified so far: Arl1 (Schurmann et al., 1994), Arl2 (Clark et al., 1993), Arl3 
(Cavenagh et al., 1994), Arl4 (Schurmann et al., 1994), Arl4L (Smith et al., 1995), 
Arl5 (Breiner et al., 1996), Arl6 (Ingley et al., 1999), Arl7 (Jacobs et al., 1999), Arl8 
(Pasqualato et al., 2002; Sebald et al., 2003), ARD1 (Mishima et al., 1993) and 
ARFRP1 (Schurmann et al., 1995).  In the genome of S. cerevisiae, there are 3 ARFs 
and 3 Arls (Takai et al., 2001).  Arf1p and Arf2p belong to class I ARF; Arf3p, the 
homologue of mammalian ARF6, belongs to the class III ARF. The three Arls in 
yeast, Arl1p, Cin4p and Arl3p, are homologues of mammalian Arl1, Arl2 and 











It is over simplified to divide the ARF family small GTPases into Sar, ARFs and Arls.  
Classification of non-ARF activity members into Arl subfamily does not reflect their 
sequence identities and cellular functions.  Recent studies of Arl1, one of the most 
characterized Arls, suggested that the boundary between ARFs and Arls is obscure 
and Arl1 could possibly be merged into the ARF subfamily (Hong et al., 1998; 
Pasqualato et al., 2002).  On the other hand, the sequences of ARFRP1 and ARD1 are 
apparently different from other Arls in two aspects (Fig 5): 1) ARFRP1 has an 8 
amino acids insertion between its G-1 and G-2 boxes; ARD1 has a 46kDN-terminal 
extension which was shown to have specific GAP activity toward its C-terminal ARF 
domain; 2) both ARFRP1 and ARD1 have no N-terminal myristoylation consensus as 
Table 2 A comparison of the identities and divergences of the mammalian ARF and Arl 
subfamily of small GTPases. The alignment was assembled by clustal W method using DNA 










other Arls (except Arl8) do.  Thus, ARFRP1 and ARD1 should be differently 
classified. 
 
Using a structural approach, Pasqualato et al. (2002) suggested the classification of 
the ARF family members by their amphipathic helical N-termini and inter-switch 
toggles, which are the β2-β3 strands connecting switch I and switch II regions.  
Except for Arl4, Arl6, Arl7 and ARD1, all members of ARF family small GTPases, 
including ARFRP1, have inter-switch toggles, which confer on them the ability of 
“front-back communication” (Pasqualato et al., 2002).  Pasquilato et al. proposed that 
Arl4, Arl6 and Arl7 comprise a non-inter-switch toggle group.  Due to the absence of 
inter-switch toggles of this group of small GTPases, it was predicted by these authors 
that the formation of a pocket harboring the N-terminal amphipathic helix, the 
docking of which inhibits the guanine nucleotide exchange of small GTPases, would 
not occur.  This view is supported by the finding that Arl4, Arl6 and Arl7 have fast 
intrinsic guanine nucleotide exchange activity (Jacobs et al., 1999). 
 
Any classification of the ARF family of small GTPases should also take into 
consideration their cellular functions, which are poorly understood for most members 






























1.3 Review of ARF1 and Arl GTPases 
Experiments suggested that the functions of the ARF family of small G proteins are 
truly diverse.  1) They have diverse localizations and have been reported to localize to 
the Golgi apparatus (class I, II ARFs, and Arl1), endosomes (ARF1 and ARF6), 
plasma membrane (ARF1, ARF6 and ARFRP1) including focal adhesions (ARF1) 
and membrane ruffles (ARF1 and ARF6) (Schurmann et al., 1995; Moss and 
Vaughan, 1998; Huang et al., 1999; Chavrier and Goud, 1999; Randazzo et al., 2000; 
Nie et al., 2003), ER (Arl6) (Ingley et al., 1999), nucleus (Alr4, Arl4L and Arl7) 
Fig 6  Phylogenetic tree of the mammalian ARF family of small GTPases assembled 
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(Jacobs et al., 1999), microtublules (Arl2 and Arl3) (Bhamidipati et al., 2000; 
Grayson et al., 2002) and mitochondria (Arl2) (Sharer et al., 2002). 2) They are 
involved in diverse cellular processes, including vesicular membrane trafficking in 
secretory and endocytic pathways (Sar1, ClassI, II and III ARFs and Arl1), actin 
cytoskeleton (ARF1 and ARF6), microtubule networks (Arl2 and Arl3), regulation of 
phospholipid metabolism (Class I, II and III ARFs and Arl1) and signaling (Class I, II 
and III ARFs) (Schurmann et al., 1995; Moss and Vaughan, 1998; Huang et al., 1999; 
Chavrier and Goud, 1999; Randazzo et al., 2000; Takai et al., 2001; Nie et al., 2003).  




As the founding member of the ARF family of small GTPases, ARF1 is the most 
extensively researched member.  ARF1 has been demonstrated to regulate multiple 
cellular events, such as membrane trafficking, organization of the actin cytoskeleton 
and signal transduction.  Many molecular functions of ARF1 have been proposed, 
including recruitment of coat proteins, regulation of phospholipid production, and 
communication with other small GTPases, such as the Rho GTPases [reviewed by 
(Moss and Vaughan, 1998; Chavrier and Goud, 1999; Randazzo et al., 2000; Takai et 
al., 2001; Gasman et al., 2003; Nie et al., 2003)].  ARF1 was reported to be localized 
to the Golgi apparatus (Stearns et al., 1990), but detailed cellular distribution has not 
been reported due to the lack of ARF1 specific antibodies to discriminate it from other 
ARFs.  However, ARF1 has been implicated in regulating various protein trafficking 
steps including those from and at ER-to-Golgi, cis-Golgi, intra-Golgi, trans-Golgi 
(TGN), endosome, synaptic plasma membrane and focal adhesion (Serafini et al., 
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1991; Robinson and Kreis, 1992; Stamnes and Rothman, 1993; Palmer et al., 1993; 
Faundez et al., 1997; Daro et al., 1997; Zhao et al., 1997; Norman et al., 1998; 
Malsam et al., 1999; Gu and Gruenberg, 2000; Stephens and Pepperkok, 2001), 
suggesting that ARF1 is present at multiple endo-membrane systems.  The membrane 
trafficking function of ARF1 could be accomplished mainly through its recruitment of 
coat proteins on to membranes.  The GTP bound form of ARF1 has been shown to 
recruit the coatomer complex (COPI), GGA1/2/3, the AP-1/3/4 clathrin coats and 
endosomal coatomer variants to membranes (Schurmann et al., 1995; Moss and 
Vaughan, 1998; Huang et al., 1999; Chavrier and Goud, 1999; Randazzo et al., 2000; 
Takai et al., 2001; Nie et al., 2003).  In each case, ARF1 was demonstrated to bind to 
coat component(s) directly through either or both of its switch regions.  The classical 
view for ARF1 is that ARF1 initiates and maintains the coat complex on the 
membrane (Fig 7).  ARF1-GDP, a cytosolic protein, is exchanged to ARF1-GTP by 
its GEF(s) at the budding membrane.  Upon GTP binding, ARF1 undergoes 
conformational changes, its N-terminal amphipathic helix and myristoyl lipid protrude 
and anchor the ARF1-GTP on the membrane.  Active ARF1 subsequently recruits 
coat components to form a coat, which provides mechanical deformation of the 
membrane to promote the budding of the vesicle and concentrates transmembrane 
cargos and cargo receptors. After budding, the coat associated ARF GAP promotes 
the hydrolysis of GTP on ARF1. When ARF1 becomes inactive and dissociates from 
the vesicle, the coat is dissembled to facilitate the fusion of the budded vesicle to the 
target membrane (Fig 7) (Schurmann et al., 1995; Moss and Vaughan, 1998; Chavrier 
and Goud, 1999; Huang et al., 1999; Randazzo et al., 2000; Takai et al., 2001; Nie et 




Recent findings have pointed to the importance of the interaction between protein 
coats and lipids.  Phosphoinositides, a family of phospholipids which play essential 
roles in signaling, have been demonstrated to be key components for vesicle 
formation at the TGN and endosomes (Martin, 1997; Simonsen et al., 2001).  The 
GTP bound form of ARF1 has been demonstrated to directly activate phospholipase D 
(PLD), which generates phosphatidic acid (PA).  PA in turn serves as a secondary 
messenger to activate phosphotidylinositol kinases to produce phosphotidylinositol-
4,5-bisphosphate (PI 4,5P2) (Brown et al., 1993; Martin, 1997).  ARF1-GTP also was 
found to induce the recruitment of phosphatidylinositol-4-kinase β (PI4Kβ) and an 
unidentified PI4P 5-kinase to Golgi membrane, resulting in increased PI4P and 
PI4,5P2 levels (Godi et al., 1999).  There is also evidence to show that both PA and 
PI4,5P2 could contribute to coat protein binding and membrane remodeling during the 
vesicle budding process (Randazzo et al., 2000; Takai et al., 2001).  Furthermore, 
most of the actin cytoskeleton regulators contain a PH domain, which binds to 
PI4,5P2.  Thus the local enrichment of PI4,5P2 also modifies the Golgi associated 
actin cytoskeleton to facilitate vesicle formation.  
 
A molecular explanation for ARF1’s involvement in actin cytoskeleton regulation 
utilizes a shared effector, called Arfaptin2/POR1, between ARF1 and the Rho family 
small GTPase Rac1 (Van Aelst et al., 1996; D'Souza-Schorey et al., 1997; Kanoh et 
al., 1997).  Tarricone et al., (2001) found that binding to POR1 by active ARF1 and 
Rac1 was mutually exclusive and thus proposed that active ARF1 binds POR1 to 




Other ARF1 effectors have also been identified, including mitotic kinesin-like protein 
1 (MKLP1) (Boman et al., 1999) and protein interacting with C-kinase 1 (PICK1) 
(Takeya et al., 2000), but the biological significance of these interactions is still not 
clear. 
 
GEFs and GAPs: 
Many GEFs for ARF1 have been identified and they all contain the Sec7 domain, a 
minimal sequence that has in vitro GEF activity toward ARFs.  According to their 
sizes, GEFs are roughly classified into large or small molecular weight GEFs.  The 
GEF activities of large ARF1 GEFs (including Big1/2, Gea1p/2p and Sec7p, except 
for GBF1), but not small ARF GEFs (ARNO/GRP/cytohesin) are sensitive to a fungal 
metabolite  Brefeldin A (BFA).  BFA acts as an non-competitive inhibitor, leading 
to the formation of an abortive ARF1-GDP-GEF-BFA complex, thus disrupting the 
activation of ARF1 and making it an invaluable cellular inhibitor for ARF1 studies 
(Peyroche et al., 1999; Chardin and McCormick, 1999). 
 
The minimal domain possessing ARF GAP activity was found to be the Gcs1p like 
zinc finger domain (Randazzo et al., 2000).  More than a dozen putative ARF1 GAPs 
have been identified to contain the Gcs1p like zinc finger domain, some of which 
seem not to have any GAP activities and were proposed to be more like effectors 
rather than GAPs of ARF1.  ARF1 GAPs have multiple cellular localizations 
conforming to reported ARF1 functions at diverse places, such as ACAP1/2/3 at focal 





The activity of ARF1 at a given cellular localization is regulated by local GEFs and 
GAPs, which are believed to be targets of upstream signaling events.  Most ARF 
GEFs and GAPs contain PH domains, therefore they are likely the targets of these 










Fig 7 A prevailing model for the function of ARF1 in coat protein recruitment. (A), 
Activation of ARF1 by GEF and recruitment to membrane.  (B), ARF1-GTP on 
membrane recruits coat proteins and the ARF1-GTP-coat protein complex captures 
transmembrane cargo (or cargo adaptor) and ARF1 GAP.  (C), Polymerization of the 
coat proteins drives the formation of a complete vesicle.  (D), ARF1-GTP is 
inactivated by vesicle associated ARF1 GAP.  Following ARF1’s dissociation from 
the vesicle, all coat proteins are subsequently disassembled and the uncoated vesicle is 




Arl1 was originally cloned from Drosophila and found to be essential for normal 
development (Tamkun et al., 1991).  The mammalian Arl1 was subsequently 
identified (Schurmann et al., 1994; Zhang et al., 1995; Lowe et al., 1996).  The 
expression of Arl1 is ubiquitous among various tissues in animals (Lowe et al., 1996; 
Hong et al., 1998).  Arl1p, the only yeast homologue of Arl1, was cloned by 
degenerate PCR and shown to be non-essential for yeast viability (Tamkun et al., 
1991; Lee et al., 1997).  Both mammalian and yeast Arl1 could be myristoylated in 
vitro, possibly at Gly of position 2 as in ARFs (Kahn et al., 1988; Lee et al., 1997).  
Arl1 could not rescue the lethal phenotye of arf1/arf2 double deletion in yeast; and it 
was originally reported that Arl1 did not activate PLD and possess ADP-
ribosyltransferase cofactor activity towards cholera toxin, two criteria which 
differentiate Arls from ARFs (Tamkun et al., 1991).  However, later studies 
demonstrated that Arl1 has weak activities in both assays (Hong et al., 1998).  
Endogenous Arl1 was localized to the Golgi apparatus in various cultured cell lines 
using Arl1 specific antibodies (Lowe et al., 1996).  Upon BFA treatment, Arl1 was 
observed to dissociate from Golgi apparatus much slower (>5 min) than ARFs (Lowe 
et al., 1996), which were reported to drop off within 2 min (Klausner et al., 1992).  In 
yeast, Arl1p was also localized to Golgi apparatus (Lee et al., 1997; Setty et al., 2003; 
Panic et al., 2003).  Deletion of yeast Arl1 gene did not affect the conversion of CPY 
(carboxypeptidase Y) from its ER form to its Golgi form, implying that Arl1p is not 







Arl2 is ubiquitously expressed and is predominantly cytosolic, probably due to its 
undetectable N-terminal myristoylation in vivo (Sharer et al., 2002).  Arl2-GDP was 
found to interact with the tubulin specific chaperon protein — cofactor D 
(Bhamidipati et al., 2000). Cofactors C, D and E assemble the α/β-tubulin 
heterodimer and they have GAP activities to stimulate the tubulin GTPase to 
hydrolyze bound GTP, which eventually results in the destruction of the microtubule 
network.  The binding of Arl2-GDP to cofactor D was proposed to prevent the  
microtubule network from destruction.  Regulation of microtubule dynamics through 
the interaction of Arl2 with cofactor D was also observed in other systems.  In C. 
elegans, deletion of evl-20, a homolog of human Arl2, causes defects in the 
microtubule network and consequent cytokinesis and morphogenesis (Antoshechkin 
and Han, 2002).  In Arabidopsis, Titan5 (Arl2 homolog) and Titan1 (cofactor D 
homolog) were isolated from titan mutants of Arabidopsis, which exhibit striking 
defects in seed development, probably due to the malfunction of the microtubule 
network (Tzafrir et al., 2002).  Yeast Arl2 homologs, Alp41 in fission yeast and 
Cin4p in budding yeast were both shown to interact with cofactor D homologs either 
physically or genetically and to regulate the microtubule network (Fleming et al., 
2000; Radcliffe et al., 2000).  In other studies, Arl2-GTP was found to interact with 
BART (binder of Arl two) (Sharer and Kahn, 1999).  A pool of Arl2-GTP and BART 
complex was reported to localize in the mitochondria and interact with adenine 
nucleotide transporter (ANT) (Sharer et al., 2002), suggesting Arl2 may have a 
function in the mitochondria.  Arl2-GTP was also observed to interact with rod 
photoreceptor cGMP phosphodiesterase PDEδ (Hanzal-Bayer et al., 2002) and 
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photoreceptor synaptic protein human retinal gene 4 (HRG4) (Kubota et al., 2002), 
suggesting that Arl2 could regulate visual signal transduction. 
 
1.3.4 Arl3 
Arl3 is ubiquitously expressed in various tissues (Cavenagh et al., 1994).  It is 
localized at microtubules in HeLa cells and human retina (Grayson et al., 2002).  Arl3 
behaved as a microtubule-associated protein (MAP) as it co-purified with 
microtubules from bovine brain.  Arl3-GTP was shown to interact with retinitis 
pigmentosa protein 2 (RP2), a close homolog of cofactor C, which stimulates the 
GTPase activity of tubulin in combination with cofactor D (Grayson et al., 2002).  
RP2 is localized to the plasma membrane in retina cells.  The microtubule association 
of Arl3 links RP2 to cytoskeletal function in photoreceptor cells (Grayson et al., 
2002).  In support of the view that Arl3 regulates microtubule function, the small G 
protein LdARL-3A, an Arl3 homolog in Leishmania donovani, was observed to 
regulate flagellum biogenesis (Cuvillier et al., 2000).  Similar to Arl2, PDEδ was also 
shown to be the effector of Arl3 (Linari et al., 1999). 
 
1.3.5 Arl4 
Arl4 shows tissue specific distribution: it is enriched in heart, liver and especially in 
testis of adult mouse (Lin et al., 2000; Lin et al., 2002).  Arl4 level was observed 
developmentally up regulated in mouse testis, as it was abundantly present in testis of 
pubertal and adult, but absent in prepubertal animals.  Arl4 knock-out mice had low 
sperm count, suggesting it could regulate spermatogenesis (Jacobs et al., 1998; 
Schurmann et al., 2002).  Arl4 level was also increased by the Wnt signaling pathway 
in the early patterning of the somite, implying it to be an indirect target of the Wnt 
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signaling pathway to regulate somite development in mouse (Lin et al., 2002; Buttitta 
et al., 2003).  Arl4 level was also found to be up regulated during the differentiation 
of 3T3-L1 cells to adipocytes (Schurmann et al., 1994). 
 
Endogenous ARL4 in cultured cells was mainly concentrated in the nucleus (Lin et 
al., 2000).  When expressed in COS7 cells, ARL4-T34N mutant, predicted to be GDP 
bound form, was found concentrated in nucleoli.  Yeast two-hybrid screens and in 
vitro protein-interaction assays showed that ARL4 interacted with importin-α through 
its C-terminal NLS region and that the interaction was not nucleotide-dependent (Lin 
et al., 2000).  The distinctive nuclear/nucleolar localization of Arl4 was inferred to 
play an unique role(s) in neurogenesis and somitogenesis during embryonic 
development and in the early stages of spermatogenesis in adults (Lin et al., 2000). 
 
1.3.6 Arl4L 
The recently characterized “Arl6” (Jacobs et al., 1999) and “Arl5” (Lin et al., 2002) 
actually was previously identified as Arl4L.  The sequence of Arl4L is most identical 
to Arl4 (57% in identity).  Similar to Arl4, Arl4L was found to be localized to the 
nucleus and to be developmentally regulated (Jacobs et al., 1999; Lin et al., 2002).  
Consistent with this, it has a C-terminal NLS, which was shown to interact with 
importin-α.  Arl4L has a N-terminal myristoylation site, yet it seemed that very little 
of Arl4L was detected in post nuclear membrane fraction (Lin et al., 2002).  The GTP 
bound form of Arl4L interacted with the heterochromatin protein 1α (HP1α), which is 
known to be associated with telomeres as well as heterochromatin, suggesting that 





Arl5 remained uncharacterized except that it was shown to be enriched in brain, 
intestine, and thymus in rat (Breiner et al., 1996). 
 
1.3.8 Arl6, 
Arl6 was identified as an up-regulated gene during the lineage switch of hemopoietic 
cells (Ingley et al., 1999).  Although not fully characterized, Arl6 was reported to 
localize to the ER and interact with Sec61β, a subunit of the ER translocon (Ingley et 
al., 1999), suggesting that it could function in ER protein translocation. 
 
1.3.9 Arl7 
The distribution of Arl7 was reported to be tissue specific (Jacobs et al., 1999).  
Similar to Arl4 and Arl4L, Arl7 contains a NLS at its C-terminus, which has the 
ability to target GFP to the nucleus, suggesting endogenous Arl7 could be localized to 
the nuclear region (Jacobs et al., 1999). 
 
1.3.10 Arl8 
Initial studies of Arl8 showed that it has expression in many tissues, but its level is 
down regulated during the development of the brain (Sebald et al., 2003).  
 
1.3.11 ARFRP1 
ARFRP1 is different from other members of Arl subfamily in that it has an eight 
amino acid insertion between the G-1 and G-2 boxes and does not posses an N-
terminal myristoylation motif (Fig 5).  During its initial characterization, ARFRP1 
was shown to be ubiquitously expressed and probably localized to the plasma 
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membrane in cell fractionation studies (Schurmann et al., 1995).  A putative binding 
partner for ARFRP1, mSec7-1/cytohesin, was identified by yeast two-hybrid 
screening. Experiments suggested that the GTP form of ARFRP1 interacts with the 
Sec7 domain of ARF-GEF, Sec7-1/cytohesin, and inhibits the ARF/Sec7-dependent 
activation of phospholipase D (Schurmann et al., 1999).  The deletion of ARFRP1 
gene in mice resulted in increased apoptosis of mesodermal cells during gastrulation, 
leading to early embryonic lethality (Mueller et al., 2002).  The molecular and cellular 
functions of ARFRP1 were suggested by studies in yeast.  Arl3p is the only yeast 
homolog of mammalian ARFRP1 and is not essential for yeast viability (Huang et al., 
1999).  Unlike ARFRP1’s reported plasma membrane localization, Arl3p was shown 
to be localized in the Golgi apparatus (Bonangelino et al., 2002; Setty et al., 2003; 
Panic et al., 2003).  Deletion of Arl3p results in miss sorting of vacuolar enzyme CPY 
(Huang et al., 1999; Bonangelino et al., 2002), implying that Arl3p (ARFRP1) is 




ARD1 is an ubiquitously expressed 64 kD bifunctional protein consisting of a 46 kD 
N-terminal GTPase activating (GAP) domain, which contains a zinc finger and a 
critical Arg residue that would supposedly form a catalytic “Arginine finger”, and an 
18 kD C-terminal ARF GTPase domain (Mishima et al., 1993; Vitale et al., 1996).  
Unlike other ARF GAPs which have a broad spectrum towards ARFs, the GAP 
activity of N-terminal part of ARD1 was found to be specific for its C-terminal ARF 
domain (Ding et al., 1996).  In addition to other ARFs, Cytohesin-1 was reported to 
have GEF activity for ARD1 (Pacheco-Rodriguez et al., 1998).  ARD1 was detected 
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in Golgi apparatus and lysosome (Vitale et al., 1998).  Truncation and mutagenesis 
studies demonstrated that the sequence 369KQQQQ373 in the GAP domain and two 
tyrosine-based motifs in the ARF domain are responsible for ARD1’s lysosome and 
Golgi targeting, respectively (Vitale et al., 1998; Vitale et al., 2000). 
 
1.4 Rationale of this Study 
This study was a continuation of research on the mammalian small GTPase Arl1, 
which was first cloned and characterized in this lab.  At the time when this project 
started in 1999, not much had been learnt about Arl1 since its identification in 
Drosophila in 1991 (Tamkun et al., 1991).  Work on Arl1 was mainly focused on its 
biochemistry, such as its guanine nucleotide binding properties (Tamkun et al., 1991; 
Lowe et al., 1996), ADP-ribosyltransferase co-factor activities (Tamkun et al., 1991; 
Hong et al., 1998) and PLD stimulation activities (Zhang et al., 1995; Hong et al., 
1998).  Nothing was known about the cellular roles of Arl1, except the observation 
that Arl1 is localized to Golgi and its Golgi localization is relatively resistant to BFA 
treatment compared to ARF1 (Lowe et al., 1996).  There were no Arl1 effectors 
identified except for PLD, which was shown to interact weakly with Arl1 (Hong et 
al., 1998).  In stark contrast to the extensively research done on ARF1, the lack of 
cellular studies made Arl1 one of the least known ARF family small GTPases.  
 
My project entails a systematic characterization of Arl1 using cellular and molecular 
approaches and a search for its putative effectors that would lead to clues on its 
cellular functions.  The following approaches were planned, 
1) Generation of Arl1 specific polyclonal antibody and examination of 
endogenous Arl1 distribution under EM. 
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2) Introduction of dominant negative and dominant active Arl1 into mammalian 
cells to investigate their effects on cellular organelles. 
3) Screening for putative effectors of Arl1, using dominant active Arl1 





Materials and methods 
 
This chapter describes various techniques and reagents used in this study. 
 
2.1 Cloning 
2.1.1 DNA manipulations 
Dephosphorylation of vectors: 
Calf intestinal alkaline phosphotase (CIAP, New England Biolab, Beverly, MA, 
USA) was added to the digestion mixture of vector and incubated for 1 hour at 
37°C.  The vector DNA was then purified by QIAEX Gel Extraction Kit 
(QIAGEN, Hilden, Germany). 
 
End Blunting of DNA: 
For a 100 µl final volume of DNA digestion mixture, about 3 units of T4 DNA 
polymerase (New England Biolab), 1 µl of 10 mM dNTP (New England Biolab), 
1µl of appropriate NE Buffer (New England Biolab) and 7 µl of water were added 
and the mixture was incubated at 12 °C for 20 min before heat inactivation of the 
T4 DNA Polymerase at 75 °C for 10 min.  The DNA can be subjected to further 
treatment, such as restriction enzyme digestion or dephosphorylation before being 





All PCR reactions performed in this study was done using high fidelity Pfu DNA 
polymerase (Promega, Madison, WI, USA) unless otherwise indicated, with 
PTC225 Thermal Cycler (MJ Research, Waltham, MA, USA).  The cycle 
parameters are as follows: 
94°C 45 sec 
94°C 45 sec 
55°C 45 sec 
72°C X sec 
72°C 10 min 
The extension time X was calculated based on 2 min per 1 kb of amplified DNA. 
For Advantage 2 cDNA polymerase (BD Clontech, Palo Alto, CA, USA), the 
extension time is determined based on 1 min per 1 kb. 
 
ABI prism sequencing: 
The PCR sequencing reaction was assembled as follows: 8 µl of BigDye 2 
sequencing mix (Perkin Elmer, Wellesley, MA, USA), 2 µl of DNA template 
(diluted to 0.1 µg/µl), 1 µl of primer (3 µM) and 9 µl water.  The PCR reaction 
was carried as recommended by manufacture’s protocol, i.e.  25 cycles of the 
following steps: (ramp 1 °C/sec): 96 °C for 10 sec, 50 °C for 5 sec and 60 °C for 4 
min.  The PCR product was then purified by isopropanol precipitation.  
Sequencing data was collected in ABI Prism 377 DNA sequencer (Perkin Elmer) 
by DNA Sequencing Unit of IMCB.  The sequences of all PCR products 






Using the techniques described above, various DNA plasmid constructs were 
made or acquired for this study.  These constructs include 1) constructs for protein 
expression in bacteria, 2) constructs for protein expression in cultured mammalian 




The following vectors are available commercially: pGEX-KG and pGEX-4T3 
were from Amersham (Little Chalfont, Buckinghamshire, UK); pET37b was from 
Novagen (Madison, WI, USA); pGBKT7, pGADT7, pEGFP-C1, C2 and C3, 
pEGFP-N1 and pDsRed1-N1 were from BD Clontech; pCI-neo was from 
Promega. 
 
The Tet-on mammalian expression vector pSTAR was a gift from Dr Qi Zeng 
(Zeng et al., 1998).  The N-terminal double Myc tagged mammalian expression 
vector pDMyc-neo, a pCI-neo based vector, containing a tandem repeat of myc 
tags upstream of the multiple cloning site (MCS), was from Dr Siew Heng Wong. 
 
The following vectors were specifically modified from the commercial vectors to 
suit this study: 
1) pGEB:  
The vector pGEX-KG was digested by EcoRI and BamHI, and then ligated 
with the annealed product of two oligonucleotides [primer1 (28-mer): 5'-
GAT CAG AAT TCG CTA GCG GAT CCT TAA C-3' and primer2 (28-
mer): 5'-AAT TGT TAA GGA TCC GCT AGC GAA TTC T-3']. The 
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MCS of this modified vector contains a functional thrombin cleavage site 
and the following cloning sites: EcoRI, BamHI, NheI, BamHI, XbaI, NcoI, 
SalI, XhoI, SacI and HindIII.  The major change is that EcoRI is now 
upstream of BamHI in the modified vector and the reading frame is 
GAA/TTC/ with reference to the EcoRI site. 
2) pSTAR-MCS: 
A small linker with MCS made by annealing two synthetic 
oligonucleotides (5’-AAT TCG CTA GCG GAT CCG ATA TCG CGG 
CCG CA-3’ and 5’-GAT CTG CGG CCG CGA TAT CGG ATC CGC 
TAG CG-3’) was ligated into EcoRI/BamHI digested pSTAR vector to 
construct a modified pSTAR vector which has additional cloning sites: 
EcoRI, NheI, BamHI, EcoRV and NotI. 
3) pSTAR-EGFP: 
A DNA fragment encoding EGFP, which was obtained by digesting 
pEGFP-N1 vector (BD Clontech) by BamHI and NotI, was ligated into 
BamHI and NotI digested pSTAR-MCS to create pSTAR-EGFP. 
4) pSTAR-DsRed: 
pDsRed1-N1 was digested by BamHI/NotI.  The resulting insert containing 
DsRed gene was ligated into BamHI/NotI digested and CIP 
dephosphorylated pSTAR-MCS vector. 
 
Table 3 List of DNA plasmid constructs made for this study. 
 
Name Insert Vector purpose in this study 
Arl1 pET37b rat Ar1l(wt) pET37b Expression of the C-terminal 6×His tagged Arl1 fusion protein in bacteria. 
Ar1l-wt pGEX-KG rat Ar1l(wt) pGEX-KG 
Expression of the N-terminal GST 




rat Ar1l(T31N) (the GDP 
restricted form) pGEX-KG 
Expression of the N-terminal GST 






rat Ar1l(Q71L) (the GTP 
restricted form) pGEX-KG 
Expression of the N-terminal GST 
tagged Ar1l-Q71L fusion protein in 
bacteria. 
ARF1-wt pGEB mouse ARF1(wt) pGEB 
Expression of the N-terminal GST 
tagged ARF1-wt fusion protein in 
bacteria. 
Arl4-wt pGEB human Arl4(wt) pGEB 
Expression of the N-terminal GST 
tagged Ar14-wt fusion protein in 
bacteria. 
C971 pGEX-4T3 human Golgin-97 central coiled-coil region pGEX-4T3 
Expression of the N-terminal GST 
tagged fusion protein in bacteria. 
GGA1-GAT pGEX-
KG human GGA1 GAT domain pGEX-KG 
Expression of the N-terminal GST 
tagged fusion protein in bacteria. 
Golgin-97 pET28a human Golgin-97 full length pET28a Cloning intermediate. 
Arl1-wt-EGFP 
pSTAR rat Arl1-wt-EGFP pSTAR 
Expression of the C-terminal EGFP 




rat Arl1-T31N-EGFP (GDP 
restricted form) pSTAR 
Expression of the C-terminal EGFP 




rat Arl1-Q71L-EGFP (GTP 
restricted form) pSTAR 
Expression of the C-terminal EGFP 





(myristoylation site abolished 
form) 
pSTAR 
Expression of the C-terminal EGFP 
tagged Ar1l-G2A-Q71L fusion 
protein in mammalian cells. 
Ar1l-wt pSTAR rat Arl1 (wt) pSTAR Expression of the Ar1l-wt protein in mammalian cells. 
Arl1-T31N pSTAR rat Arl1(T31N) (GDP restricted form) pSTAR 
Expression of the Ar1l-T31N protein 
in mammalian cells. 
Arl1-Q71L pSTAR rat Arl1(Q71L) (GTP restricted form) pSTAR 
Expression of the Ar1l-Q71L protein 
in mammalian cells. 
Arl1-D129N 
pSTAR 
rat Arl1(D129N) (xanthine 
nucleotide restricted form) pSTAR 
Expression of the Ar1l-D129N 
protein in mammalian cells. 
EGFP-Arl1 pSATR EGFP-Arl1 (wt) (myristoylation site abolished) pSTAR 
Expression of the N-terminal EGFP 
tagged Ar1l fusion protein in 
mammalian cells. 
Arl1SIIm pSTAR Arl1SIIm (switch II region exchanged with ARF1Q71L) pSTAR 
Expression of the Ar1lSIIm protein in 
mammalian cells. 
SNX3 pDMyc-neo mouse SNX3 pDMyc-neo 
Expression of the N-terminal double 




SNX3 and Arl1-Q71L 
chimera pDMyc-neo 
Expression of the N-terminal double 
Myc tagged SNX3-Arl1-Q71L 
chimeric protein in mammalian cells. 
Myc-SNX3-ARF1-
Q71L pDMyc-neo 
SNX3 and ARF1-Q71L 
chimera pDMyc-neo 
Expression of the N-terminal double 
Myc tagged SNX3-ARF1-Q71L 
chimeric protein in mammalian cells. 
Arl1-wt pGBKT7 Arl1(wt) pGBKT7 For yeast two-hybrid as Gal4-BD fusion protein. 
Arl1-T31N 
pGBKT7 
Arl1(T31N) (GDP restricted 
form) pGBKT7 




Arl1(Q71L) (GTP restricted 
form) pGBKT7 





nucleotide restricted form) pGBKT7 
For yeast two-hybrid as Gal4-BD 
fusion protein. 
ARF1-wt pGBKT7 mouse  ARF1(wt) pGBKT7 For yeast two-hybrid as Gal4-BD fusion protein. 
ARF1-T31N 
pGBKT7 
mouse ARF1(T31N) (GDP 
restricted form) pGBKT7 




mouse ARF1(Q71L) (GTP 
restricted form) pGBKT7 





(xanthine nucleotide restricted 
form) 
pGBKT7 For yeast two-hybrid as Gal4-BD fusion protein. 
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GGA1 pGADT7 human GGA1 (full length) pGADT7 For yeast two-hybrid as Gal4-AD fusion protein. 
POR1 pACT2 human POR1 (full length) pACT2 For yeast two-hybrid as Gal4-AD fusion protein. 
MKLP1 pGADT7 C-terminal part of human MKLP1 pGADT7 




the GRIP domain of human 
Golgin-97 pGADT7 




the GRIP domain of human 
Golgin-245 pGADT7 




the GRIP domain of human 
KIAA0336 pGADT7 
For yeast two-hybrid as Gal4-AD 
fusion protein. 
GCC1 GRIP  
pGADT7 
the GRIP domain of human 
GCC1 pGADT7 
For yeast two-hybrid as Gal4-AD 
fusion protein. 
Golgin-97 pGADT7 human Golgin-97 full length pGADT7 For yeast two-hybrid as Gal4-AD fusion protein. 
Golgin-97∆GRIP 
pGADT7 
human Golgin-97 without 
GRIP domain pGADT7 




Golgin-97 GRIP domain with 
E696A mutation pGADT7 




Golgin-97 GRIP domain with 
Y697A mutation pGADT7 




Golgin-97 GRIP domain with 
K699A mutation pGADT7 




Golgin-97 GRIP domain with 
Q728A mutation pGADT7 





A chimera with N-terminal 
half from ARF1 and C-
terminal half from Arl1 
pGBKT7 For yeast two-hybrid as Gal4-BD fusion protein. 
Arl1(Q71L, T72D) 
pGBKT7 rat Arl1(Q71L, T72D) pGBKT7 
For yeast two-hybrid as Gal4-BD 
fusion protein. 
Arl1(Q71L, S73K) 
pGBKT7 rat Arl1(Q71L, S73K) pGBKT7 
For yeast two-hybrid as Gal4-BD 
fusion protein. 
Arl1(Q71L, Y77L) 
pGBKT7 rat Arl1(Q71L, Y77L) pGBKT7 
For yeast two-hybrid as Gal4-BD 
fusion protein. 
Arl1(Q71L, C80H) 
pGBKT7 rat Arl1(Q71L, C80H) pGBKT7 
For yeast two-hybrid as Gal4-BD 
fusion protein. 
Arl1(Q71L, A87G) 
pGBKT7 rat Arl1(Q71L, A87G) pGBKT7 
For yeast two-hybrid as Gal4-BD 
fusion protein. 
Arl1SIIm pGBKT7 Arl1 with the switch II region exchanged with ARF1Q71L pGBKT7 




ARF1 with the switch II 
region exchanged with 
Arl1Q71L 
pGBKT7 For yeast two-hybrid as Gal4-BD fusion protein. 
Arl1-wt pBSK Ar1l(wt) pBSK Cloning intermediate and for in vitro transcription and translation. 
Ar1l-T31N pBSK Ar1l(T31N) (GDP restricted form) pBSK 
Cloning intermediate and for in vitro 
transcription and translation. 
Arl1-Q71L pBSK Arl1(Q71L) (GTP restricted form) pBSK 
Cloning intermediate and for in vitro 
transcription and translation. 
Arl1-D129N pBSK Arl1(D129N) (xanthine nucleotide restricted form) pBSK 
Cloning intermediate and for in vitro 
transcription and translation. 
Arl1-G2A pBSK Ar1l(G2A) (myristoylation site abolished form) pBSK 
Cloning intermediate and for in vitro 
transcription and translation. 
ARF1-wt pBSK mouse ARF1(wt) pBSK Cloning intermediate and for in vitro transcription and translation. 
ARF1-G2A pBSK 
mouse ARF1(G2A) 
(myristoylation site abolished 
form) 
pBSK For in vitro transcription and translation. 






The following DNA constructs were made for this study using the vectors 
described above (Table 3). 
B) Constructs for protein expression in bacteria: 
1) Arl1-pET37b 
The coding sequence of Arl1 was PCR amplified from Arl1-wt pSTAR 
(described below) using primers E6-NdeI-F (30-mer): 5'-GTC AGG CAT 
ATG GGT GGC TTT TTC TCA AGT-3', and E6-C-term-6His (58-mer): 
5'-AGG CGT CTC GAG ATT AGT GAT GGT GAT GGT GAT GCT 
GTC TGC TTT TCA GTG TTT CAA C-'3.  The PCR product was 
digested by NdeI/XhoI and subsequently ligated into NdeI/XhoI digested 
and CIP dephosphorylated pET37b vector. 
2) Arl1-wt pGEX-KG  
The E6-GST-pGEM7 construct from Dr Stephen Lowe was digested by 
EcoRI/XhoI.  The insert was then ligated into EcoRI/XhoI digested and 
CIP dephosphorylated pGEX-KG vector. 
3) Arl1-T31N pGEX-KG 
The Arl1-T31N pBSK construct (described below) was digested by 
EcoRI/XhoI.  The insert was subsequently ligated into EcoRI/XhoI 
digested and CIP dephosphorylated pGEX-KG vector. 
4) Arl1-Q71L pGEX-KG 
The Arl1-Q71L pBSK construct (described below) was digested by 
EcoRI/XhoI.  The insert was subsequently ligated into EcoRI/XhoI 
digested and CIP dephosphorylated pGEX-KG vector. 
5) ARF1-wt pGEB 
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The ARF1-wt pGBKT7 construct was digested by EcoRI/BamHI.  The 
insert was subsequently ligated into EcoRI/BamHI digested and CIP 
dephosphorylated pGEB vector. 
6) Arl4-wt pGEB 
The coding sequence of human Arl4 was PCR amplified from an EST 
clone (GenBank Access No.: T85847) using primers hARL4kozEcoRI-F 
(41-mer): 5'-GTA CCT GAA TTC GCC ACC ATG GGG AAT GGG 
CTG TCA GAC CA-3' and hARL4-BamHI-R (37-mer): 5'-GGT CAG 
GGA TCC TCA TCT TTT CTT TTT CTG TTG CCG C-3'.  The PCR 
product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and CIP dephosphorylated pGEB vector. 
7) C971 pGEX-4T3 
Part of central coiled-coil region of human Golgin-97 was PCR amplified 
from an EST clone (GenBank Accession No.: AI803928) using primers 
C97-EcoRI-F (33-mer): 5'-GCA CGA GAA TTC GGA GGC ACG AAC 
CAG AGA ACT-3' and C97-XbaI-R1 (37-mer): 5'-GCA CAC TCT AGA 
TTA GAC TTC GAA GAG CTC ATT ATC G-3'.  The resulting PCR 
product was digested by EcoRI/XbaI and ligated into dephosphorylated 
pGEX-4T3 vector. 
8) GGA1-GAT pGEX-KG 
This construct was a gift from Tran Thi Ton Hoai in this lab. 
9) Golgin-97 (full length) pET28a 
This was a gift from Dr Edward K.L. Chan (Scripps Institute) and Dr 




C) Constructs for protein expression in cultured mammalian cells:  
1) Arl1-wt, Arl1-T31N, Arl1-Q71L and Arl1-D129N pSTAR 
Arl1 coding sequences were PCR amplified from the constructs Arl1-wt, 
Arl1-T31N, Arl1-Q71L and Arl1-D129N pBSK respectively (described 
below) using primers E6-N1-Koz-EcoRI-F (48-mer): 5'-GTC AGT GAA 
TTC GCC ACC ATG GGT GGC TTT TTC TCA AGT ATA TTT TCC-3' 
and E6-C1-BamHI-R (36-mer): 5'-ATG TGA GGA TCC TCA CTG TCT 
GCT TTT CAG TGT TTC-3'.  The PCR products were then digested by 
EcoRI/BamHI and subsequently ligated into EcoRI/BamHI digested and 
CIP dephosphorylated pSTAR vector, respectively. 
2) Arl1-wt-EGFP, Arl1-T31N-EGFP and Arl1-Q71L-EGFP pSTAR 
The coding sequences of Arl1 from the constructs Arl1-wt, Arl1-T31N and 
Arl1-Q71L pSTAR were PCR amplified respectively using primers E6-
N1-Koz-EcoRI-F and E6-BamHI-R2 (44-mer): 5'-ACG TCG AGG ATC 
CGA CTG TCT GCT TTT CAG TGT TTC AAC TAA CC-3'.  The PCR 
products were then digested by EcoRI/BamHI and subsequently ligated 
into EcoRI/BamHI digested and CIP dephosphorylated pSTAR-EGFP 
vector, respectively. 
3) Arl1-G2A-Q71L-EGFP pSTAR 
The coding sequence of Arl1 from the construct Arl1-Q71L pSTAR was 
PCR amplified using primers E6KozG2AEcoRIF (48-mer): 5'-GTC AGT 
GAA TTC GCC ACC ATG GCC GGC TTT TTC TCA AGT ATA TTT 
TCC-3' and E6-BamHI-R2.  The PCR product was then digested by 
EcoRI/BamHI and subsequently ligated into EcoRI/BamHI digested and 
CIP dephosphorylated pSTAR-EGFP vector. 
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4) EGFP-Arl1 pSTAR 
To create the N-terminal EGFP-tagged Arl1 (EGFP-Arl1), coding 
sequence of Arl1 was PCR amplified and subcloned into pEGFP-C1 
between the XhoI and BamHI sites using primers E6-C1-XhoI-F (42-mer): 
5'-CTG ACT CGA GAA ATG GGT GGC TTT TTC TCA AGT ATA 
TTT TCC-3' and E6-C1-BamHI-R.  The digestion of the resulting 
construct by NheI (end blunted) and BamHI yielded an insert containing 
EGFP and Arl1, which was then subcloned into EcoRI (end 
blunted)/BamHI digested and dephosphorylated pSTAR vector. 
5) Arl1SIIm pSTAR 
The construct Arl1SIIm pGBKT7 (described below) was digested by 
EcoRI/BamHI and subsequently ligated into EcoRI/BamHI digested and 
dephosphorylated pSTAR vector. 
6) SNX3 pDMyc-neo 
The mouse SNX3 coding region was PCR amplified from the SNX3 
construct (Xu et al., 2001b) using primers SNX3-EcoRI-F (33-mer): 5'-
CAG TAC GAA TTC GGC GGA GAC GGT AGC GGA CAC-3' and 
SNX3-XbaI-R (35-mer): 5'-GTC GTC TCT AGA GGC ATG TCT TAT 
TTT AGA TGG AG-3'.  The PCR product was then digested by 
EcoRI/XbaI and subsequently ligated into EcoRI/XbaI digested and 
dephosphorylated pDMyc-neo vector. 
7) Myc-SNX3-Arl1-Q71L pDMyc-neo 
The coding region of Arl1 was PCR amplified from the construct Arl1-
Q71L pBSK (described below) using primers Arl1-XbaI-F (41-mer): 5'-
GAC TAG TCT AGA GGT GGC TTT TTC TCA AGT ATA TTT TCC 
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AG-3' and Arl1-NotI-R (35-mer): 5'-CTC TAG TGC GGC CGC TCA 
CTG TCT GCT TTT CAG TG-3'.  The PCR product was then digested by 
XbaI/NotI and subsequently ligated into XbaI/NotI digested and 
dephosphorylated SNX3 pDMyc-neo construct. 
8) Myc-SNX3-ARF1-Q71L pDMyc-neo 
The coding region of ARF1 was PCR amplified from the construct ARF1-
Q71L pBSK (described below) using primers ARF1-XbaI-F (40-mer): 5'-
GAT CAC TCT AGA GGG AAT ATC TTT GCA AAC CTC TTC AAG 
G-3' and ARF1-NotI-R (36-mer): 5'-CTC TAG TGC GGC CGC TCA 
CTT CTG GTT CCG GAG CTG-3'.  The PCR product was then digested 
by XbaI/NotI and subsequently ligated into XbaI/NotI digested and 
dephosphorylated SNX3 pDMyc-neo vector. 
 
D) Constructs for yeast two-hybrid assays: 
1) Arl1-wt, Arl1-T31N, Arl1-Q71L and Arl1 D129N pGBKT7 
The constructs Arl1-wt, Arl1-T31N, Arl1-Q71L and Arl1-D129N pSTAR 
were digested by EcoRI/BamHI respectively, the resulting inserts were 
subsequently ligated into EcoRI/BamHI digested and dephosphorylated 
pGBKT7 vector. 
2) ARF1-wt pGBKT7 
The coding region of ARF1 was PCR amplified from an EST clone 
(GenBank Accession No.: AA266176) using primers ARF1-Koz-EcoRI-F 
(48-mer): 5'-TCC AGC GAA TTC GCC ACC ATG GGG AAT ATC TTT 
GCA AAC CTC TTC AAG-3' and ARF1-BamHI-R (44-mer): 5'-CGT 
ATC GGG ATC CGA CTT CTG GTT CCG GAG CTG ATT AGA CAG 
  
38
CC-3'.  The PCR product was then digested by EcoRI/BamHI and 
subsequently ligated into EcoRI/BamHI digested and CIP 
dephosphorylated pSTAR-DsRed vector. The resulting construct was then 
cut by EcoRI/BamHI and the insert was ligated into EcoRI/BamHI 
digested and dephosphorylated pGBKT7 vector. 
3) ARF1-T31N pGBKT7 
The PCR mutagenesis was generated from an EST clone (GenBank 
Accession No.: AA266176) using two primer pairs: 
Pair 1: primers ARF1-Koz-EcoRI-F and ARF1-T31N-R (30-mer): 5'-GTA 
TAG AAT TGT ATT CTT CCC TGC AGC ATC-3' and  
Pair 2: primers ARF1-T31N-F (30-mer): 5'-GAT GCT GCA GGG AAG 
AAT ACA ATT CTA TAC-3' and ARF1-BamHI-R.  
The two PCR products were combined for the second round of PCR 
amplification using primers ARF1-Koz-EcoRI-F and ARF1-BamHI-R.  
The resulting PCR product was digested by EcoRI/BamHI and 
subsequently ligated into EcoRI/BamHI digested and CIP 
dephosphorylated pSTAR-DsRed vector.  The construct was then cut by 
EcoRI/BamHI and the insert was ligated into EcoRI/BamHI digested and 
dephosphorylated pGBKT7 vector. 
4) ARF1-Q71L pGBKT7 
The PCR mutagenesis was generated from an EST clone (GenBank 
Accession No.: AA266176) using two primer pairs: 
Pair 1: primers ARF1-Koz-EcoRI-F and ARF1-Q71L-R (29-mer): 5'-CCG 
GAT CTT GTC CAG GCC GCC CAC ATC CC-3 and  
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Pair 2: primers ARF1-Q71L-F (29-mer): 5'- GGG ATG TGG GCG GCC 
TGG ACA AGA TCC GG-3' and ARF1-BamHI-R. 
The two PCR products were combined for the second round of PCR 
amplification using primers ARF1-Koz-EcoRI-F and ARF1-BamHI-R.  
The resulting PCR product was digested by EcoRI/BamHI and 
subsequently ligated into EcoRI/BamHI digested and CIP 
dephosphorylated pSTAR-DsRed vector.  The construct was then cut by 
EcoRI/BamHI and the insert was ligated into EcoRI/BamHI digested and 
dephosphorylated pGBKT7 vector. 
5) ARF1-D129N pGBKT7 
The PCR mutagenesis was generated from an EST clone (GenBank 
Accession No.: AA266176) using two primer pairs: 
Pair 1: primers ARF1-Koz-EcoRI-F and ARF1-D129N-R (30-mer): 5'-
CAT GGC ATT GGG GAG GTT CTG CTT GTT GGC-3' and  
Pair 2: primers ARF1-D129N-F (30-mer): 5'-GCC AAC AAG CAG AAC 
CTC CCC AAT GCC ATG-3' and ARF1-BamHI-R. 
The two PCR products were combined for the second round of PCR 
amplification using primers ARF1-Koz-EcoRI-F and ARF1-BamHI-R.  
The resulting PCR product was digested by EcoRI/BamHI and 
subsequently ligated into EcoRI/BamHI digested and CIP 
dephosphorylated pSTAR-DsRed vector.  The construct was then cut by 
EcoRI/BamHI and the insert was ligated into EcoRI/BamHI digested and 
dephosphorylated pGBKT7 vector. 
6) GGA1 pGADT7 
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The coding region of human GGA1 was PCR amplified from an EST 
clone (GenBank Access No.: B347585) using primers GGA1-EcoRI-F 
(36-mer): 5'-GCA AGT GAA TTC ATG GAG CCC GCG ATG GAG 
CCG GAG-3' and GGA1-BamHI-R (38-mer): 5'-CGA CTG GGA TCC 
CTA GAG GCT ACC CCA GGT TTC AGG TG-3'.  The PCR product 
was then digested by EcoRI/BamHI and ligated into EcoRI/BamHI 
digested and dephosphorylated pGADT7 vector. 
7) POR1 pACT2 
This construct was one of the positive clones initially retrieved from yeast 
two-hybrid screen.  It contains the full length coding sequence of human 
POR1. 
8) MKLP1 pGADT7 
The C-terminal 400 amino acids of human MKLP1 was PCR cloned from 
an EST clone (GenBank Accession No.: AA044628) using primers 
MKLP-R1-F (43-mer): 5'-CTG GTC GAA TTC GCC ACC ATG CGC 
AGA TTA GAA GCC AGG TTG C-3' and MKLP-BamHI-R (35-mer): 5'-
CAT GCA GGA TCC TTC AGA CCA GGG CTG GAG AAG TC-3'.  
The PCR product was digested by EcoRI/BamHI and subsequently ligated 
into EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
9) Golgin-97 GRIP pGADT7 
The GRIP domain coding region of human Golgin-97 was PCR amplified 
from an EST clone (GenBank Accession No.: AI803928) using primers 
97-EcoRI-F (36-mer): 5'-GGT CAC GAA TTC GAT AAT GAG CTC 
TTC GAA GTC CGG-3' and 97-BamHI-R (36-mer): 5'-CAT GCT GGA 
TCC CTC TAG GAC CAT GGT ATCCGA GGG-3'.  The PCR product 
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was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
10) Golgin-245 GRIP pGADT7 
The GRIP domain coding region of human Golgin-245 was PCR amplified 
from an EST clone (GenBank Accession No.: AA626910) using primers 
230-EcoRI-F (33-mer): 5'-GGTCAC GAA TTC GAG CAA GAG TTC 
AGA GAA CAG-3' and 230-BamHI-R (35-mer): 5'-CAT GCT GGA TCC 
TCA GAA GAT ACC ACT GCG AGG TG-3'.  The PCR product was 
digested by EcoRI/BamHI and subsequently ligated into EcoRI/BamHI 
digested and dephosphorylated pGADT7 vector. 
11) KIAA0336 GRIP pGADT7 
The coding region of human KIAA0336 GRIP domain was PCR amplified 
from KIAA0336 clone (Kazusa DNA Research Institute) using primers 
K336-EcoRI-F (36-mer): 5'-GGT CAC GAA TTC CTG CTT CGG GAA 
ACA GAA GCA ACC-3' and K336-BamHI-R (36-mer): 5'-CAT GCT 
GGA TCC CAT CAA CCT ATC GAA GTC CAG ACC-3'.  The PCR 
product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
12) GCC1 pGADT7 
The coding region of human GCC1 GRIP domain was PCR cloned from 
an EST clone (GenBank Accession No.: Z43507) using primers  
GCC1-EcoRI-F (5'-GGT CAC GAA TTC GTG CAT CAG CTG CAG 
GAT CGG CTG-3' and GCC1-BamHI-R (36-mer): 5'-CAT GCT GGA 
TCC TCA TCT CTT GCC AGA AGG CCA CCA-3'.  The PCR product 
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was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
13) Golgin-97 (full length) pGADT7 
The insert was prepared by digesting the construct Golgin-97 (full length) 
pET28a (described above) by NotI (end blunted)/EcoRI.  The vector 
pGADT7 was digested by BamHI (end blunted)/EcoRI and then 
dephosphorylated, the resulting vector was then ligated with insert to make 
this construct. 
14) Golgin-97∆GRIP pGADT7 
The coding region of Golgin-97 without GRIP domain was PCR amplified 
(Advantage 2 cDNA Polymerase Mix, BD Clontech) from the construct 
Golgin-97 (full length) pET28a (described above) using primers 
dGRIPNdeI-F (50-mer): 5'-GAC TCG CAT ATG TTT GCA AAA CTG 
AAG AAG AAA ATT GCA GAA GAG ACT GC-3' and dGRIPEcoRI-R 
(37-mer): 5'-GCA CAC GAA TTC TTA GAC TTC GAA GAG CTC ATT 
ATC G-3'.  The PCR product was digested by NdeI/EcoRI and 
subsequently ligated into NdeI/EcoRI digested and dephosphorylated 
pGADT7 vector. 
15) E696A Golgin-97 GRIP pGADT7 
The PCR mutagenesis was done by amplification of the GRIP domain 
from the construct Golgin-97 GRIP pGADT7 using two pairs of primers: 
Pair 1: primers 97-EcoRI-F and E696A-R  (26-mer): 5'-CCA CAT GTT 
TAA GGT AAG CAA AGT TG-3' and  
Pair 2: primers E696A-F (26-mer): 5'-CAA CTT TGC TTA CCT TAA 
ACA TGT GG-3' and 97-BamHI-R. 
  
43
Two PCR products were combined and subjected to another round of PCR 
amplification using primers 97-EcoRI-F and 97-BamHI-R.  The resulting 
PCR product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
16) Y697A Golgin-97 GRIP pGADT7 
The PCR mutagenesis was done by amplification of the GRIP domain 
from the construct Golgin-97 GRIP pGADT7 using two pairs of primers: 
Pair 1: primers 97-EcoRI-F and 97-Y697A-R (23-mer): 5'-CCA CAT GTT 
TAA GGG CCT CAA AG-3' and 
Pair 2: primers 97-Y697A-F (23-mer): 5'-CTT TGA GGC CCT TAA 
ACA TGT GG-3' and 97-BamHI-R. 
Two PCR products were combined and subjected to another round of PCR 
amplification using primers 97-EcoRI-F and 97-BamHI-R.  The resulting 
PCR product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
17) K699A Golgin-97 GRIP pGADT7 
The PCR mutagenesis was done by amplification of the GRIP domain 
from the construct Golgin-97 GRIP pGADT7 using two pairs of primers: 
Pair 1: primers 97-EcoRI-F and K699A-R (26-mer): 5'-CCA CAT GTG 
CAA GGT ACT CAA AGT TG-3' and 
Pair 2: primers K699A-F (26-mer): 5'-CAA CTT TGA GTA CCT TGC 
ACA TGT GG-3' and 97-BamHI-R. 
Two PCR products were combined and subjected to another round of PCR 
amplification using primer 97-EcoRI-F and 97-BamHI-R.  The resulting 
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PCR product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
18) Q728A Golgin-97 GRIP pGADT7 
The PCR mutagenesis was done by amplification of the GRIP domain 
from the construct Golgin-97 GRIP pGADT7 using two pairs of primers: 
Pair 1: primers 97-EcoRI-F and Q728A-R  (23-mer): 5'-CCT CCT CTG 
CGG AAA AGT TCA GC-3' and  
Pair 2: primers Q728A-F (23-mer): 5'-GCT GAA CTT TTC CGC AGA 
GGA GG-3' and 97-BamHI-R. 
Two PCR products were combined and subjected to another round of PCR 
amplification using primer 97-EcoRI-F and 97-BamHI-R.  The resulting 
PCR product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pGADT7 vector. 
19) ARF1(Q71L)(1-92)Arl1(93-181) pGBKT7 
The N-terminal half coding sequence of ARF1 was PCR amplified from 
the construct ARF1-Q71L pGBKT7 using primers ARF1-Koz-EcoRI-F 
and FL-R (37-mer): 5'-GGT CTC GGT CAC AAC TGT CCA CTA CGA 
AGA TCA AGC C-3'. 
The C-terminal half coding sequence of Arl1-Q71L was PCR amplified 
from the construct Arl1-Q71L pGBKT7 using primers FL-F (37-mer): 5'-
GGC TTG ATC TTC GTA GTG GAC AGT TGT GAC CGA GAC C-3' 
and E6-C1-BamHI-R.  
The two PCR products were combined and subjected for another round of 
PCR amplification using primers ARF1-Koz-EcoRI-F and E6-C1-BamHI-
  
45
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
20) Arl1(Q71L, T72D) pGBKT7 
The coding sequence was PCR amplified from the construct Arl1-Q71L 
pBSK using two pairs of primers: 
Pair 1: primers E6-N1-Koz-EcoRI-F and QL-T72D-R (21-mer): 5'-TGG 
CCT GAT ACT GTC CAG TCC-3' and  
Pair 2: primers QL-T72D-F (21-mer): 5'-GGA CTG GAC AGT ATC 
AGG CCA-3' and E6-C1-BamHI-R. 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers E6-N1-Koz-EcoRI-F and E6-C1-BamHI-
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
21) Arl1(Q71L, S73K) pGBKT7 
The coding sequence was PCR amplified from the construct Arl1-Q71L 
pBSK using two pairs of primers: 
Pair 1: primers E6-N1-Koz-EcoRI-F and QL-S73K-R (21-mer): 5'-TGG 
CCT GAT CTT TGT CAG TCC-3' and  
Pair 2: primers QL-S73K-F (21-mer): 5'-GGA CTG ACA AAG ATC 
AGG CCA-3' and E6-C1-BamHI-R. 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers E6-N1-Koz-EcoRI-F and E6-C1-BamHI-
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
22) Arl1(Q71L, Y77L) pGBKT7 
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The coding sequence was PCR amplified from the construct Arl1-Q71L 
pBSK using two pairs of primers: 
Pair 1: primers E6-N1-Koz-EcoRI-F and Y77L-R (24-mer): 5'-TAA TAA 
CAT CTC CAG AGT GGC CTG-3' and  
Pair 2: primers Y77L-F (24-mer): 5'-CAG GCC ACT CTG GAG ATG 
TTA TTA-3' and E6-C1-BamHI-R (36-mer). 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers E6-N1-Koz-EcoRI-F and E6-C1-BamHI-
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
23) Arl1(Q71L, C80H) pGBKT7 
The coding sequence was PCR amplified from the construct Arl1-Q71L 
pBSK using two pairs of primers: 
Pair 1: primers E6-N1-Koz-EcoRI-F and C80H-R (24-mer): 5'-TAA TAA 
TGT CTC CAG TAT GGC CTG-3' and  
Pair 2: primers C80H-F (24-mer): 5'-CAG GCC ATA CTG GAG ACA 
TTA TTA-3' and E6-C1-BamHI-R. 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers E6-N1-Koz-EcoRI-F and E6-C1-BamHI-
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
24) Arl1(Q71L, A87G) pGBKT7 
The coding sequence was PCR amplified from the construct Arl1-Q71L 
pBSK using two pairs of primers: 
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Pair 1: primers E6-N1-Koz-EcoRI-F and A87G-R (22-mer): 5'-GAC ATA 
GAT GAC ACC ATC TGT G-3' and  
Pair 2: primers A87G-F (22-mer): 5'-CAC AGA TGG TGT CAT CTA 
TGT C-3' and E6-C1-BamHI-R. 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers E6-N1-Koz-EcoRI-F and E6-C1-BamHI-
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
25) Arl1SIIm pGBKT7 
The coding sequence was PCR amplified from the construct Arl1-Q71L 
pBSK using two pairs of primers: 
Pair 1: primers E6-N1-Koz-EcoRI-F and SWII-R (66-mer): 5'-TGC CTG 
TGT GTT CTG AAA ATA ATG TCT CCA GAG TGG CCT GAT CTT 
GTC CAG TCC GCC TAC GTC CCA-3' and  
Pair 2: primers SWII-F (66-mer): 5'-GAC GTA GGC GGA CTG GAC 
AAG ATC AGG CCA CTC TGG AGA CAT TAT TTT CAG AAC ACA 
CAG GCA GTC-3' and E6-C1-BamHI-R. 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers E6-N1-Koz-EcoRI-F and E6-C1-BamHI-
R.  The PCR product was subsequently digested by EcoRI/BamHI and 
ligated into EcoRI/BamHI digested and dephosphorylated pGBKT7. 
26) ARF1SIIm pGBKT7 
The coding sequence was PCR amplified from the construct ARF1-Q71L 
pGBKT7 using two pairs of primers: 
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Pair 1: primers ARF1-Koz-EcoRI-F and FSWII-R (66-mer): 5'-GCC ATC 
GGT GTT CGA GTA GTA GCA GCG CCA GTA CGG CCG GAT CGA 
GGT CAG GCC GCC CAG ATC CCA-3' and  
Pair 2: primers FSWII-F (69-mer): 5'-GAT CTG GGC GGC CTG ACC 
TCG ATC CGG CCG TAC TGG CGC TGC TAC TAC TCG AAC ACC 
GAT GGC TTG ATC-3' and ARF1BamHIstop-R (42-mer): 5'-GAC CTC 
GGA TCC TCA CTT CTG GTT CCG GAG CTG ATT AGA CAG-3'. 
The two PCR products were combined and subjected for another round of 
PCR amplification using primers ARF1-Koz-EcoRI-F and 
ARF1BamHIstop-R.  The PCR product was subsequently digested by 
EcoRI/BamHI and ligated into EcoRI/BamHI digested and 
dephosphorylated pGBKT7. 
 
F) intermediate subclones in pBSK vector. 
1) Arl1-wt pBSK 
The E6-GST-pGEM7 construct from Stephen Lowe was digested by 
EcoRI/XhoI. The insert was then ligated into EcoRI/XhoI digested and 
dephosphorylated pBSK. 
2) Arl-T31N pBSK 
The PCR mutagenesis was conducted using Arl1-wt pBSK construct by 
two pairs of primers:  
Pair 1: primers E6-N-terminal (38-mer): 5'-CAG GTG AAT TCT CAT 
GGG TGG CTT TTT CTC AAG TAT AT-3' and T31N (AS): (28-mer): 
5'-CTG TAC AAA ATT GTG TTT TTT CCA GCA C-3' and  
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Pair 2: primers T31N (S) (28-mer): 5'-GTG CTG GAA AAA ACA CAA 
TTT TGT ACA G-3 and E6-C-terminal (39-mer): 5'-AGG CGT CTC 
GAG TCA CTG TCT GCT TTT CAG TGT TTC AAC-3'. 
These two PCR products were combined and used for another round of 
PCR amplification by primers E6-N-terminal and E6-C-terminal. The PCR 
product was digested by EcoRI/XhoI and ligated to EcoRI/XhoI digested 
and dephosphorylated pBSK vector. 
3) Arl1-Q71L pBSK 
The PCR mutagenesis was conducted using Arl1-wt pBSK construct by 
two pairs of primers: 
Pair 1: primers E6-N-terminal and Q71L (AS) (25-mer): 5'- CCT GAT 
ACT TGT CAG TCC GCC TAA G-3' and  
Pair 2: primers Q71L (S) (25-mer): 5'- CTT AGG CGG ACT GAC AAG 
TAT CAG G-3' and E6-C-terminal. 
These two PCR products were combined and used for another round of 
PCR amplification by primers E6-N-terminal and E6-C-terminal.  The 
PCR product was digested by EcoRI/XhoI and ligated to EcoRI/XhoI 
digested and dephosphorylated pBSK vector. 
4) Arl1-D129N pBSK 
The PCR mutagenesis was conducted using Arl1-wt pBSK construct by 
two pairs of primers: 
Pair 1: primers E6-N-terminal and D129N (AS) (24-mer): 5'-CTG CTC 
CAT GTT CTG TTT ATT TGC-3' and  
Pair 2: primers D129N (S) (24-mer): 5'-GCA AAT AAA CAG AAC ATG 
GAG CAG-3' and E6-C-terminal. 
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These two PCR products were combined and used for another round of 
PCR amplification by primers E6-N-terminal and E6-C-terminal.  The 
PCR product was digested by EcoRI/XhoI and ligated to EcoRI/XhoI 
digested and dephosphorylated pBSK vector. 
5) Arl1-G2A pBSK 
The coding region was PCR amplified from the construct Arl1-wt pBSK 
using primers E6KozG2AEcoRIF and E6-C1-BamHI-R.  The PCR 
product was digested by EcoRI/BamHI and subsequently ligated into 
EcoRI/BamHI digested and dephosphorylated pBSK vector. 
6) ARF1-wt pBSK 
The coding region of ARF1 was PCR amplified from ARF1-wt pGBKT7 
construct using primers ARF1-Koz-EcoRI-F and ARF1BamHIstop-R.  
The PCR product was digested by EcoRI/BamHI and subsequently ligated 
into EcoRI/BamHI digested and dephosphorylated pBSK vector. 
7) ARF1-G2A pBSK 
The coding region of ARF1 was PCR amplified from ARF1-wt pGBKT7 
construct using primers ARF1kozEcoRIG2A-F (45-mer): 5'-TCC AGC 
GAA TTC GCC ACC ATG GCA AAT ATC TTT GCA AAC CTC TTC-
3' and ARF1BamHIstop-R.  The PCR product was digested by 
EcoRI/BamHI and subsequently ligated into EcoRI/BamHI digested and 
dephosphorylated pBSK vector. 
8) POR1 pBSK 
The construct POR1 pACT2 was digested by EcoRI/XhoI (end blunted) 
and subsequently ligated into EcoRI/BamHI (end blunted) and 




2.2 Yeast two-hybrid 
2.2.1 Gal4 based yeast two-hybrid screening 
The yeast two-hybrid assays and screening were done according to protocols provided 
by BD Clontech.  The Gal4-DNA BD fused Arl1-Q71L in pGBKT7 was used to 
transform the yeast strain AH109 (BD Clontech).  The resulting transformed AH109 
yeast cells (MATa) were mated with Gal4-DNA AD fused Human Brain 
Pretransformed Matchmaker cDNA library in Y187 yeast cells (MATα) (BD 
Clontech).  The interaction positive diploid yeast cells were selected on the highest 
stringency SD/-Trp/-Leu/-His/-Ade (QDO) (synthetic drop out medium without Trp, 
Leu, His and Ade) plates.  The Gal4-AD fused cDNA was extracted from those 
positive clones and subsequently sequenced.  Those partial sequences were subjected 
to BLAST (Basic Local Alignment Search Tool) search at NCBI (National Center for 
Biotechnology and Information) website to identify the corresponding cDNAs. 
 
2.2.2 Yeast two-hybrid assays 
Gal4-BD constructs in pGBKT7 and Gal4-AD constructs in pGADT7 (or in pACT2 
vector for those positive clones from yeast two-hybrid screening) were transformed 
into AH109 and Y187 yeast cells respectively.  Transformed AH109 and Y187 yeast 
cells were mated as indicated in figures and the resulting diploid yeast cells 
containing DNA-BD and DNA-AD fusion constructs were selected on SD/-Trp/-Leu 
medium and then the cells were streaked on the SD/-Trp/-Leu/-His/-Ade (QDO) plate.  
Sometimes, after selection on SD/-Trp/-Leu medium, the diploid yeast cells were 
assayed by streaking them on QDO plates containing 20 µg/ml X-α-gal (BD 
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Clontech).  The interaction positive diploid yeast cells grew and turned blue in 3 to 4 
days. 
 
2.2.3 β-galactosidase assays 
Selected diploid yeast cells were subjected to ONPG (o-nitrophenol β-D-
galactopyranoside, Sigma, St. Louis, MO, USA) β-galactosidase assays, which were 
performed according to Yeast Protocols Handbook (BD Clontech).  β-galactosidase 
units were calculated as  
1000×OD420/(t×V×OD600) 
where  t =  elapsed time (in min) of incubation with ONPG 
  V = yeast culture volume (in ml) 
  OD600 = Absorption at 600 nm of 1 ml of yeast culture 
  OD420 = Absorption at 420 nm after incubation for elapsed time t 
 
2.3 Recombinant fusion proteins 
2.3.1 Production of His-tagged Arl1 fusion protein in bacteria 
Full length rat Arl1 in pET37b with a C-terminal 6 × His tag was used to transform 
BL21DE3 E coli cells and the resulting colonies were screened by mini scale 
expression followed by SDS-PAGE and Coomassie blue staining.  The Arl1 
expressing BL21DE3 clone was cultured at a large scale to an OD600 of about 0.6 and 
induced over night at room temperature with 0.25 mM IPTG (isopropyl β-D-
thiogalactopyranoside, Invitrogen, Grand Island, NY).  The bacteria was then pelleted 
and resuspended in Cracking Buffer containing 100 mM Hepes pH 7.3, 5 mM MgCl2, 
500 mM KCl, 0.1% Triton X-100, 0.5 mM PMSF, Complete Protease Inhibitor 
(Roche, Basel, Switzerland) and 2 mM β-Mercaptoethanol.  Cell lysis was induced by 
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sonicating the bacterial suspension at 4°C and the lysate was cleared by 
centrifugation.  The Nickel NTA agarose beads (QIAGEN, Hilden, Germany) was 
pre-equilibrated in Washing Buffer (100 mM Hepes, pH 7.3, 200 mM KCl, 10% 
Glycerol and 2 mM β-Mercaptoethanol) with 10 mM Imidazole and then incubated 
with cleared lysate at 4°C for 2 hours.  The beads were then washed by Washing 
Buffer with 25 mM Imidazole and eluted by Washing Buffer with 250 mM Imidazole. 
The elute was extensively dialyzed against phosphate buffered saline (PBS) at 4°C.  
The purified His-tagged Arl1 protein was quantified by Bradford assay (Bio-Rad, 
Hercules, CA, USA) or SDS-PAGE Coomassie blue staining using BSA as standard. 
 
2.3.2 Production of GST fusion proteins 
Constructs in pGEX-KG, pGEX-4T3 and pGEB were transformed into DH5α E coli 
and Ampicillin resistant colonies expressing the GST fusion proteins were screened 
by testing mini scale cultures using SDS-PAGE Coomassie staining.  For purification 
of GST fusion protein, bacteria cultures were grown to an OD600 of 0.5-1 before 
overnight induction with 0.25 mM IPTG at room temperature.  Bacteria cells were 
then pelleted and resuspended in lysis buffer: PBS containing 50 mM Tris-HCl, pH 8, 
0.1% Triton X-100, 0.5 mM MgCl2, 1 mg/ml lysozyme, 5 mM dithiothreitol (DTT), 
0.5 mM phenylmethylsulfonyl fluoride (PMSF) and Complete Protease Inhibitors 
(Roche).  Cell lysis was achieved by sonication as described previously.  The 
resulting lysates were clarified by centrifugation and applied to a Glutathione 
Sepharose 4B column (Amersham). After washing with GST Washing Buffer (PBS 
containing 50 mM Tris-HCl, pH 8, 0.1% Triton X-100, 0.5 mM MgCl2), the bound 
GST fusion protein was eluted with 10 mM reduced Glutathione (Sigma) in GST 
Washing Buffer.  The elute was concentrated by centrifugation using a Centriprep 
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concentration device (Millipore, Berllerica, MA, USA) and subsequently dialyzed 
extensively in PBS at 4 °C.  The purified GST fusion proteins were quantified by 
Bradford assay or SDS-PAGE Coomassie blue staining using BSA as standard. 
 
2.4 Antibodies 
2.4.1 Raising rabbit polyclonal antibody against rat Arl1 and human Golgin-97 
400 µg of purified His tagged Arl1 or GST-C971 fusion protein was diluted in 1ml of 
PBS.  The protein in PBS was emulsified with equal volume of Fruend’s Adjuvant 
(complete adjuvant for the first injection and incomplete adjuvant for the subsequent 
booster injections) (Invitrogen or Pierce, Rockford, IL, USA).  The emulsified antigen 
was injected subcutaneously into female New Zealand White Rabbit (Sembawang 
Laboratory Animals Centre, Singapore) once every 10 days.  Rabbit blood was 
collected after the fifth injection and subsequently after each booster injection. The 
blood was allowed to clot at room temperature for 2 hours before transferring to 4°C 
over night.  The blood clots were pelleted and the serum was collected, frozen in 
liquid nitrogen and stored at –80 °C until used. 
 
Recombinant GST, GST-Arl1, and GST-C971 proteins on Glutathione Sepharose 4B 
beads were washed thoroughly by cold Sodium Borate Buffer (0.2 M Sodium Borate, 
pH 9.0) to remove trace amount of amine based buffer.  The beads were then 
incubated with 50 mM DMP (dimethyl pimelidate) (Sigma) in Sodium Borate Buffer 
at 4°C over night.  The beads were subsequently washed by Sodium Borate Buffer 
and the trace amount of cross linker DMP was quenched by incubation with 0.2 M 
ethanolamine pH 8.0 at room temperature for 2 hours.  After washing away the 
ethanolamine with cold PBS, non cross-linked proteins on beads were eluted by 50 
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mM Glycine, pH 2.8.  The beads were then washed with PBS and incubated with 
about 5 ml of serum.  For His-tagged Arl1 generated serum, GST-Arl1 coupled beads 
were used.  For GST-C971 generated serum, it was first incubated with GST coupled 
beads to absorb antibody against GST before incubation with GST-C971 coupled 
beads to affinity purify Golgin-97 specific antibody.  These beads were washed with 
cold PBS extensively and eluted with 50 mM Glycine, pH 2.8.  The elute was 
neutralized to pH 7 to 8 using 1M Tris pH 8.0, concentrated and dialyzed extensively 
in cold PBS.  The purified antibodies were quantified by Bradford assay or SDS-
PAGE Coomassie blue staining with IgG standards. 
 
2.4.2 Antibodies used in this study 
The peptide-specific rabbit polyclonal antibody against Arl1  E6P1 and E6P3 have 
been previously described (Lowe et al., 1996).  Rabbit polyclonal antibody against β-
1,4 galactosyltransferase (GT) was produced in this lab previously (Subramaniam et 
al., 1992).  Rabbit polyclonal antibody against Golgin-245 was a gift from Dr Paul 
Gleeson (University of Melbourne).  Monoclonal antibody (Mab), CDF4, against 
Golgin-97 was from Molecular Probe Inc (Eugene, OR, USA).  Mab against a Golgi 
SNARE, GS28, has been described previously (Subramaniam et al., 1996).  Mab 
against VSV-G (P5D4) was from Roche.  Mabs against γ-adaptin, α-adaptin, Golgin-
245, p115, and GM130 were from BD Transduction Laboratory (San Diego, CA, 
USA).  Rabbit polyclonal anti-Myc and sheep polyclonal anti-ARF1/3 antibodies 
were from Upstate Biotechnology (Charlottesville, VA, USA).  Mab 1D9 (Cavenagh 
et al., 1996) against ARFs, which recognizes all ARFs but does not react with Arls, 
was from BioAffinity Reagent Inc (Golden, CO, USA).  Mabs against β-COP (Mad) 
and β-tubulin were from Sigma.  Rabbit polyclonal antibody against EGFP was from 
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BD Clontech.  Sec31 mouse polyclonal antibodies have been previously described 
(Tang et al., 2000).  Goat polyclonal antibodies against EEA1 were from Santa Cruz 
Biotechnology Inc (Santa Cruz, CA, USA). 
 
2.5 Active Arl1 and ARF1 pull down assays 
Cells grown on petri-dishes were first chilled on ice.  For cells grown on φ10 cm 
petri-dishes, 450µl cold Lysis Buffer G (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM 
MgCl2, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol) 
supplemented with Complete Protease Inhibitor (Roche) was added to each dish and 
scraped on ice to collect the cell lysate.  The lysate was centrifuged briefly to separate 
cell debris. Then 100 µl of Lysis Buffer G pre-washed Glutathione Sepharose 4B was 
used to preclear the lysate at 4°C for 10 min.  400µl of the precleared lysate was 
added to each tube containing Lysis Buffer G washed GST-Golgin-245-GRIP on 
Glutathione Sepharose 4B beads (equivalent to 30µl of dry beads).  An aliquot of the 
precleared lysate was set aside as loading controls.  After rotating the mixture at 4 °C 
for 30 min, the beads were subsequently washed 3 times with cold Lysis Buffer G.  
The bound Arl1 protein was eluted by boiling in SDS sample buffer and resolved in a 
12% SDS-PAGE.  The Western Blot analysis was performed using the E6P3 
polyclonal antibody. 
 
The active ARF1 pull down assay used the same protocol, except GST-GGA1-GAT 
fusion protein on beads was used and the bound ARF1-EGFP fusion proteins, 
introduced into 293T cells by transfection, were detected by anti-EGFP antibody in 




2.6 In vitro guanine nucleotide exchange reactions of GST fusion proteins of 
Arl1, ARF1 and Arl4 
GST fusion proteins of Arl1, ARF1 and Arl4 were kept on the Glutathione Sepharose 
beads without elution.  The in vitro GTPγS (or GDP) exchange reactions were 
conducted according to previously described methods (Randazzo et al., 1995; 
Christoforidis and Zerial, 2000) with modifications.  The protein bound beads 
equilibrated in NE Buffer (20 mM Hepes, pH 7.5, 100 mM NaCl, 10 mM EDTA, 5 
mM MgCl2, 1 mM DTT) supplemented with 0.1% sodium cholate and 10 µM of 
GTPγS (or GDP) were incubated with NE Buffer containing 1 mM GTPγS (or GDP), 
0.1% (w/v) sodium cholate and 3 mM L-α-dimyristoylphosphatidylcholine (DMPC) 
(30 mM DMPC stock was freshly prepared by sonication in NE buffer) for 1.5 hour at 
room temperature.  The beads were then washed and equilibrated with NS buffer (20 
mM Hepes, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT) supplemented with 10 
µM GTPγS (or GDP) and were stored at 4 °C until used. 
 
2.7 35S labeling of proteins by in vitro transcription and translation 
In vitro translation was done using the TNT T7 Quick Coupled 
Transcription/Translation System (Promega) according to manufacture’s protocol.  
Briefly, the reaction mixture containing 20 µl of TNT Quick Master Mix, 1 µl of 0.5 
µg/µl plasmid DNA (pBSK constructs in this study), 1 µl of [35S] Methionine (10 
mCi/ml) (Amersham) and 3 µl of RNase free water was incubated at 37 °C for 1 hour 




2.8 GST fusion proteins pull down in vitro translated POR1 or GGA1 
Arl1-T31N, Arl1-Q71L and ARF1 GST fusion proteins on Glutathione Sepharose 
beads were exchanged with GTPγS or GDP in vitro.  60 µg of guanine nucleotide 
exchanged GST fusion protein was incubated in NS Buffer containing 2 mg/ml BSA 
and 100 µM of GDP or GTPγS at 4°C for 1 hour to block the beads before the 
addition of 10 µl in vitro translated and 35S labeled POR1 or GGA1 produced from the 
constructs POR1 pBSK or GGA1 pBSK, respectively.  After an over night incubation 
at 4°C, the beads from each reaction were washed three times with cold NS buffer.  
Proteins bound to the beads were eluted by boiling in 2 × SDS sample buffer and 
resolved by 12% SDS-PAGE.  Autoradiography was performed using the 
PhosphoImager (Molecular Dynamics, Sunnyvale, CA, USA). 
 
2.9 GST fusion proteins pull down assays using HeLa cytosol 
HeLa cells were homogenized in cold NS buffer. After a low speed centrifugation, the 
post nuclear supernatant was subsequently centrifuged at 55k rpm in a TLA100.2 
rotor (Beckman Coulter) for 1.5 hours to remove all membrane debris.  The cytosol 
was pre-cleared by beads with immobilized GST protein.  BSA was added to the 
cytosol at a final concentration of 4 mg/ml as a blocking reagent.  GST fusion proteins 
of Arl1-wt, Arl1-T31N, Arl1-Q71L, ARF1-wt and Arl4 on beads were exchanged 
with GDP or GTPγS as described above.  Around 60 µg of exchanged beads were first 
blocked for non-specific binding sites by incubating with 4 mg/ml BSA in NS buffer 
at 4°C for 2 hours before incubation with the precleared HeLa cytosol at 4°C over 
night.  For GST Golgin-245 GRIP domain pull down experiment, 100 mM final 
concentration of GTPγS was added to the HeLa cytosol during the incubation.  The 
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next day, after washing with NS buffer, proteins retained on the beads were eluted by 
boiling in 2 × SDS sample buffer and analyzed by Western Blot analysis. 
 
2. 10 Immunoprecipitation 
pSTAR constructs expressing the C-terminal EGFP tagged Arl1-wt, Arl1-T31N and 
Arl1-Q71L were transfected into 293T cells using Effectene Transfection Reagent 
(QIAGEN) according to the manufacturer’s protocol.  After 28 hours of incubation at 
37°C in the presence of 12 µg/ml Doxycyclin (BD Clontech) to induce the expression 
of transgenes, cells were lysed in 25 mM Hepes, pH 7.4, 125 mM KAc, 1.0% Triton 
X-100, 1 mM DTT, with Complete Protease Inhibitor (EDTA-Free) (Roche) and 1 
mM PMSF.  After centrifugation, the supernatant of each cell lysate was collected and 
pre-cleared by human IgG Sepharose Fast Flow (Amersham) at 4°C for 1 hour.  BSA 
was added to each lysate to a final concentration of 2 mg/ml.  The lysates were then 
incubated with 2.5 µl of rabbit anti-GFP polyclonal antibody (BD Clontech) at 4°C 
over night and subsequently with 40µl of Protein A Sepharose (Amersham) (50% 
slurry) at room temperature for 3 hours.  The beads were washed three times with 25 
mM Hepes, pH 7.4, 125 mM KAc, 0.1% Triton X-100 and the bound 
immunoprecipitates were eluted by boiling in 2 × SDS sample buffer and subjected to 
Western Blot analysis. 
 
2.11 Cell culture and Transfection 
A431, L2 and NRL cells were grown in Dulbecco’s modified Eagles medium (DME) 
supplemented with 10% fetal bovine serum; CHO and HeLa cells were maintained in 
Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal 
bovine serum.  Cells were cultured at 37°C with 5% CO2 and 95% humidity. 
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Transfections were performed using either Lipofectamine (Invitrogen) for stable 
transfection of Arl1 and Arl1(Q71L), or Effectene Transfection Reagent (QIAGEN) 
for transient transfection of other constructs.  The stable transfectants of CHO cells 
with pSTAR-Arl1-wt or -(Q71L) were maintained in RPMI supplemented with 10% 
tetracycline-free fetal bovine serum (BD Clontech) and 1 mg/ml G418 (Invitrogen).  
For immunofluorescent studies, cells were grown on φ12 mm cover slips (Number 
one and a half, Fisher Scientific, Pittsburgh, PA, USA) seeded in a 24-well-plate.  For 
those constructs in Tet-on vector pSTAR, the expression of transgene was achieved 
by the addition of 8 µg/ml to 12 µg/ml final concentration of Doxycyclin (BD 
Clontech) into the culture medium and incubated for 12 to 20 hours.  For BFA 
treatments, cells grown on the cover slips were incubated with medium containing 10 
µg/ml BFA (Epicentre Technologies, Madison, WI) at 37°C for various periods of 
time before termination by transferring the cover slips into cold PBS. 
 
2.12 Indirect immunofluorescence microscopy 
2.12.1 Paraformaldehyde fixation 
Cells on cover slips were washed with PBS containing 1 mM CaCl2 and 1 mM MgCl2 
(PBSCM) at room temperature before fixation in 4% paraformaldehyde (4% 
paraformaldehyde in PBSCM) for 15 min at room temperature.  The cells were then 
washed twice by PBSCM, twice by 200 mM NH4Cl in PBSCM and twice by PBSCM 
at room temperature, and subsequently permeabilized by incubation with 0.1% 
Saponin (Sigma) in PBSCM for 20 min at room temperature. 
 
2.12.2 Methanol fixation 
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After washing by PBSCM, cover slips were immersed in methanol at – 20°C for 5 
min and the system was then transferred to room temperature for another 5 min.  The 
fixed cells were washed extensively by PBSCM to remove trace amount of methanol 
and then were ready for immunofluorescence labeling. 
 
2.12.3 Indirect immunofluorescence labeling 
Fixed and permeabilized cells were incubated with primary antibodies using 
appropriate dilution in Fluorescence Dilution Buffer (PBSCM with 5% fetal bovine 
serum and 2% BSA) for 1 hour at room temperature.  Cells were then washed by 
PBSCM and incubated with FITC, Rhodamine or Texas-red conjugated secondary 
antibodies diluted (usually 100 times) in Fluorescence Dilution Buffer at room 
temperature for 1 hour.  After extensive washing by PBSCM, the cells were then 
mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, 
USA) on microscopic glass slides.  Confocal microscopy was performed with a Zeiss 
Axioplan II microscope equipped with a Bio-Rad MRC1024 confocal scanning laser 
(Bio-Rad, Hercules, CA, USA).  The images were displayed and analyzed using the 
LaserSharp (Bio-Rad) and Adobe Photoshop (Adobe) softwares.  Images shown are 
combinations of 3-4 optical sections 0.3 µm apart. 
 
2.13 VSV-G morphological transport assay 
Arl1 transfected CHO cells were grown on cover slips and induced with 8 µg/ml 
Doxycyclin for about 12 hours.  Cover slips were transferred to φ3.5 cm petri-dishes 
and washed by serum-free RPMI.  400 µl RPMI (without serum) and an appropriate 
amount of VSVts045 virus were added to the dish.  After incubation at 32°C with 
gentle agitation for 1 hour, 1.5 ml RPMI containing 10% fetal bovine serum was 
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added and the cells were incubated for a further 2 hours at 32°C without agitation. 
Cycloheximide (Sigma) was added to a final concentration of 10 µg/ml and the cells 
were incubated for another 1 hour before being fixed and processed for indirect 
immunofluorescence microscopy. 
 
2.14 VSV-G biochemical transport assay 
NRK cells were grown on φ10 cm petri-dishes to form a confluent monolayer and 
infected with VSVts045 at 32 °C for 3-4 h.  The cells were pulse labeled with 35S 
Methionine (100 µCi/ml) (Amersham) at the restrictive temperature 40 °C for 10 min 
and perforated on ice by hypotonic swelling (in 10 mM HEPES, pH 7.2 and 18 mM 
KAc) and scraping.  These semi-intact cells were then incubated in a complete assay 
cocktail of 40 µl containing (in final concentrations) 25 mM HEPES-KOH, pH 7.2, 
90 mM KAc, 2.5 mM MgAc2 , 5 mM EGTA, 1.8 mM CaCl2, 1 mM ATP, 5 mM 
Creatine phosphate (Roche), 0.2 U of rabbit muscle Creatine phosphokinase (Roche), 
25 µg of rat liver cytosol, 5 µl of semi-intact cells and 5 µl of antibodies to be tested 
(dialyzed in 25 HEPES, pH 7.2 and 125 KAc).  For a standard assay, samples were 
incubated for 90 min at 32 °C and transport was terminated by transferring to ice.  
The membranes were collected by a brief centrifugation and solubilized in 60 µl of 
0.2% SDS, 50 mM Sodium Citrate, pH 5.5.  After boiling for 5 min, the samples were 
digested over night at 37 °C in the presence of 2.5 U of endoglycosidase H (endo-H) 
(Roche) and the reaction was terminated by adding SDS-PAGE sample buffer.  The 
samples were then analyzed by 7.5% SDS-PAGE and autoradiography. 
 
2.15 siRNA knock down of Arl1 and Golgin-97 
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siRNA targeting human Arl1 (5’-AAG AAG AGC UGA GAA AAG CCA-3’), 
Golgin-97 (5’-AAG AUC ACA GCC CUG GAA CAA-3’) and control siRNA (5’-
AAG UCG GUG UGC UCU UGU UGG-3’) were synthesized by Dharmacon 
Research Inc (Lafayette, CO, USA).  HeLa cells were transfected with siRNA using 
OligofectamineTM transfection reagent (Invitrogen) according to protocol provided by 
Dharmacon Research Inc.  Cells were processed for immunofluorescence or 
immunoblotting after 48 hours of incubation. 
 
2.16 SDS-PAGE 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to 
the method of Laemmli (Laemmli, 1970).  Discontinuous SDS-PAGE with a stacking 
gel (pH6.8, 0.125 M Tris-HCl, 0.1% SDS and 3.9% acrylamide) and separating gel 
(pH 8.8, 0.375 M Tris-HCl, 0,1% SDS and 7-12% acrylamide) was conducted in 1 × 
SDS Running Buffer (20 mM Tris Base, 200 mM glycine, 0.1% SDS) at 150 volts 
(constant voltage). 
 
2.17 Coomassie blue staining 
After SDS-PAGE, the gel was soaked in Coomassie staining buffer [50% methanol, 
10% acetic acid and 0.25% Coomassie Brilliant Blue R-250 (Bio-Rad)] for 10 min, 
then destained with 50% methanol and 10% acetic acid.  The destained gel was 
washed in water to remove organic solvent before drying.  For quantification of 
protein or antibody, BSA or IgG standards were run in parallel with the samples for 
later comparison by Coomassie blue staining. 
 
2.18  Western blot 
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The SDS-PAGE gel was electro-blotted onto nitrocellulose membrane (Amersham) in 
ice cold 1 × Transfer Buffer (20 mM Tris Base, 200 mM glycine and 10% methanol) 
with a constant voltage of 100 volts for 1 or 2 hours.  The membrane was blocked in 
5% fat free milk in PBST (PBS with 0.05% Tween-20) over night at 4°C.  The 
membrane was subsequently incubated at room temperature with primary antibody 
diluted appropriately in PBST with 5% milk for 1 hour, washed with PBST for 30 min 
and subsequently incubated with HRP conjugated secondary antibody diluted 
appropriately in PBST with 5% milk for 1 hour.  After 30 min washing with PBST, 
the membrane was incubated with the chemiluminescent detection substrate 
Luminol/Enhancer and Hydrogen Peroxide for 5 min (SuperSignal West PicoTM 
Chemiluminescent Substrate, Pierce).  The chemiluminescence from the blots is 
detected by overlaying with Hyperfilm (Amersham) and the films were developed 
using a Kodak X-ray film developer (Kodak).  If probing by another antibody was 
required for the same blot, the membrane was stripped using RestoreTM Western Blot 
Stripping Buffer (Pierce) before another round of blocking and subsequent antibody 
incubation. 
 
2.19 Electron Microscopy (EM) 
The EM localization of endogenous Arl1 in CHO cells was conducted by Horstmann 
Heinz and Ng Cheepeng of the EM unit of IMCB. 
 
2.20 Preparation of RIPA cell lysate 
Cultured mammalian cells were scraped and incubated with RIPA 
(Radioimmunoprecipitation) buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS) on ice with occasional vortex.  
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After centrifugation, the supernatant was used for quantification of cellular levels of 





Characterization of Arl1 antibodies and quantification of endogenous 
Arl1 level 
 
3.1 Generation of rabbit anti rat Arl1 polyclonal antibody 
A good antibody is invaluable for studying the function of a protein in cell biology.  
The high identities between Arl1 and other ARFs (Table 2 and Fig 5) make the 
production of Arl1 specific antibody a great challenge.  Previous researchers in this 
laboratory have raised rabbit polyclonal antibodies against rat Arl1 using the peptides 
E6P1 (residue 130  150) or E6P3 (residue 167  181) (Fig 9), two peptide 
sequences with minimal identities to ARFs (Lowe et al., 1996).  The two antibodies, 
thus named E6P1 and E6P3, were shown to recognize Arl1 but not ARF1.  To 
facilitate the subsequent studies of Arl1, it was important to raise more Arl1 specific 
antibody as both E6P1 and E6P3 antibodies were limited.  A C-terminal 6 × His 
tagged full length Arl1 fusion protein was used to immunize rabbit and the polyclonal 
antibody was purified using GST-rat Arl1 conjugated column and characterized by 
Western Blot analysis as shown in Fig 8a.  The affinity purified antibody detected a 
single 20 kD band, which migrated slightly faster than the antigen — Arl1-6 × His 
(lane 3) in L2 and CHO cell lysates (Lane 1 and 2).  With the same amount of protein 
loading, the antibody did not recognize GST-mouse ARF1 (lane 4), indicating that the 
antibody is specific to Arl1.  The crude serum did not pick up GST-mouse ARF1 in 










Fig 8 Characterization of polyclonal antibody against full length Arl1. (a), The rabbit 
serum after 9th antigen injection was purified and used to probe the membrane blot 
containing 60 µg L2 cell lysate (lane 1), 60 µg CHO cells lysate (lane 2), 150 ng 
recombinant antigen Arl1-6×His (lane 3), and negative control — 150 ng recombinant 
GST-mARF1 (lane 4). The unpurified crude serum easily recognized its antigen — 
150 ng Arl1-6×His (lane 5), but not 150 ng recombinant GST-mARF1 (lane 6). As a 
control, the antibody against ARF1/3 reacted with 150 ng of GST-mARF1 (lane 8), 
but not the same amount of Arl1-6×His (lane 7).  (b), In NRL cells, the 
immunofluorescent staining of purified Arl1 antibody (A) had a perinuclear 
distribution and was colocalized with the cis-Golgi marker GM130 (B). Panel C is a 
merge of A and B. Bar, 10µm. 
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suggesting there is no anti-ARF1 IgGs in the serum.  As control, a commercialized 
sheep polyclonal antibody against ARF1/3 (Upstate Biotechnology) recognized the 
GST-mouse ARF1 (lane 8) but not Arl1-6 × His (lane 7).  In indirect 
immunofluorescence analysis, the purified Arl1 antibody strongly labeled perinuclear 
membrane structure in NRL cells.  This labeling was colocalized with the cis-Golgi 
marker GM130 (Fig 8b), consistent with previous report of Arl1 on Golgi apparatus 
(Lowe et al., 1996). 
 
Potential cross reactivity is a major consideration in generating antibodies against 
members of ARF family small GTPases.  It is quite a surprise that, despite the very 
high level of identity between Arl1 and ARF1 in their primary amino acid sequence 
(57%), the polyclonal antibody generated using full length of Arl1 did not cross react 
with ARF1 at all.  Collectively, these data demonstrated that the recombinant full 
length Arl1 generated polyclonal antibody can specifically recognize endogenous 
Arl1 but not closely related ARFs. 
 
3.2 Characterization of different versions of Arl1 polyclonal antibodies 
The three versions of Arl1 polyclonal antibodies, E6P1, E6P3 and the Arl1 full length 
antibodies, were found to behave differently in Western Blot analysis.  The E6P3 
antibody recognized both human and rat Arl1 equally well (Fig 9A, upper panel).  
Because the loading of both HeLa (lane 1) and NRK (lane 2) lysates was the same (30 
µg), the upper panel probed with E6P3 antibody also showed that the endogenous 
Arl1 levels in both HeLa and NRK cells are similar.  In contrast, E6P1 and the Arl1 
full length antibodies were found to be about 5 fold more sensitive for rat Arl1 (lane 











Fig 9 Full length, E6P1 and E6P3 Arl1 antibodies react differently towards human 
and rat Arl1. (A), While E6P3 antibody (upper panel) recognized both human (30 µg 
HeLa lysate, lane 1) and rat (30µg NRK lysate, lane2) Arl1 equally well, E6P1 
(middle panel) and full length antibodies (lower panel) are 5 fold less sensitive 
towards human Arl1 (lane 1) than rat Arl1 (lane 2). (B), the alignment shows that only 
two amino acids (boxed) are different between human and rat Arl1 sequences. Both 
amino acids are located within the P1 peptide region. The sequences of P1 and P3 
peptides, which were used as antigens for raising the E6P1 and E6P3 antibodies 
respectively, were underlined.  
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immunofluorescence (IF) studies, E6P3 antibody also stained the Golgi equally well 
in both HeLa and NRK cells.  While E6P1 and full length Arl1 antibodies gave good  
Golgi staining in NRL, NRK, L2, CHO and AtT20 cells, they showed weak Golgi 
staining with backgrounds in HeLa and A431 cells (data not shown).  Under the same 
condition, these two antibodies could detect the transfected rat Arl1 mutants in A431 
cells (Fig17, Fig35 and Fig 36).  In NRK cells, when the endogenous Arl1 was 
knocked down by its siRNA (small interference RNA), both the Western blot and the 
immunofluorescence staining signals detected by these two antibodies were also much 
reduced accordingly (data not shown).  Thus these experiments implied that E6P1 and 
the Arl1 full length antibodies were rodent specific with some cross reactivity towards 
human Arl1.  From the sequence alignment of human and rat Arl1 (Fig 9B), the two 
molecules differ only in two amino acids, at position 136 and 142, both of which are 
in the sequence of peptide P1, the antigen of E6P1 antibody.  The antigen of E6P3 
antibody, peptide P3, is from amino acids 167 to 181 of rat Arl1, in which both 
human and rat Arl1 molecules have exactly the same sequence.  The difference in two 
amino acids could account for the less reactivity of E6P1 antibody towards human 
Arl1.  The similar behaviors of E6P1 and the Arl1 full length generated antibodies in 
Western Blot and immunofluorescence studies suggested that the major epitopes 
recognized by the full length polyclonal antibody are within the P1 peptide region.  
The endogenous Arl1 in CHO (hamster cell line) and AtT20 (mouse cell line) cells 
was recognized by E6P3, E6P1 and the full length Arl1 antibodies in both Western 
Blot and immunofluorescence studies (data not shown), probably because hamster 
and mouse Arl1 are identical in sequence at both P3 and P1 peptides position.  Indeed, 
mouse has the same amino acid sequence as rat Arl1 at both P1 and P3 regions.  Thus, 
E6P3 recognizes endogenous Arl1 in all the mammalian cells examined (human, rat,  
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mouse and hamster); while E6P1 and Arl1 full length antibodies are more rodent 
specific (rat, mouse and hamster). 
 
3.3 Quantification of endogenous Arl1 and ARF1/3 levels in cultured mammalian 
cell lines 
The endogenous level of Arl1 was quantified by Western Blot analysis using full 
length Arl1 antibody with recombinant GST-rat Arl1 as standards.  As shown in Fig 
10A, L2, NRK and CHO cells have very similar levels of endogenous Arl1.  
Considering the nitrocellulose transfer efficiency is inversely proportional to the 
molecular weight and GST-rat Arl1 has twice the weight of Arl1, the level of 
endogenous Arl1 was thus estimated to be 5×10-4 (0.05%) of total cellular protein in 
mass.  The Arl1 levels in HeLa (Fig 9A, upper panel) and other mammalian cells 
(293T, A431 and COS7) (data not shown) were also similar.  The endogenous levels 
of ARF1/3, was also estimated in this manner to be between 10-4 to 10-3 (0.01% to 
0.1%) in L2, NRK, CHO (Fig 10B), 293T, A431 and COS7 cells (data not shown).  
The quantitative analysis demonstrated that both Arl1 and ARF1 have similar cellular 
levels  10-4 to 10-3 of total cellular protein in various mammalian cells.  In 
agreement with that result, the endogenous ARF1 was also reported by Van 
Valkenburg et al. to be 10-3 (0.1%) of total cellular protein in NRK cells (Van 
Valkenburgh et al., 2001).  However, the endogenous Arl1 was undetectable in their 
assays (<10-4).  Therefore, they proposed that Arl1 plays a minor role in maintaining 
the structure and function of Golgi apparatus [over expression of exogenous Arl1 or 








Fig 10 Quantification of endogenous Arl1 and ARF1/3 levels in various cell lines. 
(A), 30 µg RIPA lysates of L2 (lane1), NRK (lane 2), CHO (lane 3) cells and Arl1 
standards, 10 ng (lane 4), 20 ng (lane 5), 40 ng (lane 6) and 80 ng (lane 7) of 
recombinant GST-rat Arl1 were transfered on to nitrocellulose membrane and blotted 
with full length Arl1 antibody. (B), 30 µg RIPA lysates of L2 (lane1), NRK (lane 2), 
CHO (lane 3) cells and 100 ng ARF1 standard (lane 4) of recombinant GST-mARF1 
were transfered on to nitrocellulose membrane and blotted with ARF1/3 antibody.  
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(Lu et al., 2001; Van Valkenburgh et al., 2001).  This discrepancy in terms of cellular 
levels of Arl1 could possibly be explained if their Arl1 polyclonal antibody was 
human specific, likely due to their use of full length human Arl1 recombinant protein 
as the antigen to raise antibody.  The data presented here strongly suggest that 
endogenous levels of both Arl1 and ARF1/3 are similar in various cultured 
mammalian cells.  On that basis at least, Arl1 might play a role as important as ARF1 



















Fig 11  Quantification of active Arl1 in 293T cells using the GRIP-domain pull down 
assay. (A), 293T cells were transiently transfected with Arl1-wt-GFP (lane 1), Arl1-
T31N-GFP (GDP restricted form mutant) (lane 2) and Arl1-Q71L-GFP (GTP 
restricted form mutant) (lane 3). The resulting cell lysates were incubated with GRIP 
domain on Glutathione Sepharose beads. The retained active Arl1 (upper panel) and 
5% lysate loading were probed in Western Blot by full length Arl1 antibody (note that 
the transfected Arl1 gene was of rat origin.). (B), 293T cell lysate was incubated with 
GST-GRIP domain (lane 1) or as negative control, GST-GGA1-GAT domain (lane 2) 
immobilized on glutathione beads. Proteins retained on the beads were subsequently 




3.4 Quantification of active Arl1 content in cultured mammalian cells 
In mammalian cells, an endogenous small GTPase can either be in the GTP form (the 
active state), or the GDP form (the inactive state).  The balance of these two forms is 
controlled by the activities of its GAPs or GEFs, which, in turn, are targets regulated 
by upstream signaling events.  Knowing the content of the active GTP-bound form of 
a small GTPase can provide some insights into its cellular regulation.  There are 
several methods developed for measuring the content of the active form of cellular 
small GTPases and all utilize their effectors, which specifically bind to their GTP 
forms.  For examples, Raf RBD domain could be used to pull down active Ras (de 
Rooij and Bos, 1997), PBD domain of PAK were used to pull down active Rho 
(Benard and Bokoch, 2002) and GAT domain of GGA1 pulled down active ARF1 
(Santy and Casanova, 2001; Shinotsuka et al., 2002).   A similar protocol was thus 
adopted to quantify the endogenous GTP-bound, active form of Arl1, taking 
advantage of the finding that recombinant Golgin-245 GRIP domain specifically 
binds the GTP form of Arl1 with a relative high affinity (see Chapter 6).  Cells were 
lysed by Lysis Buffer G (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM MgCl2, 0.1% 
SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol) to extract the 
active Arl1, which is membrane bound.  After pre-clearing by Glutathione Sepharose 
4B beads, the lysate was incubated with 30 µg of recombinant GST Golgin-245 GRIP 
domain fusion protein on Glutathione Sepharose 4B beads.  The active Arl1 retained 
on the beads was then quantified by Western blot analysis.  The protocol was first 
tested using Arl1 guanine nucleotide binding mutants.  293T cells were transiently 
transfected to express C-terminal EGFP tagged wild type Arl1, Arl1-T31N (GDP 
restricted form of Arl1) or Arl1-Q71L (GTP restricted form of Arl1).  The exogenous 
expressed active Arl1-EGFP was then assessed by the GRIP pull down assay as 
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shown in Fig 11A.  While a fraction of wild type and most of the active form of Arl1 
were retained on GRIP beads (Fig 11A, lane 1 and 3, respectively), the GDP form of 
Arl1 was not pulled down by the Golgin-245 GRIP domain (Fig 11A, lane 2).  The 
retention of active Arl1 (Arl1-Q71L-EGFP) was not expected to be 100% for the 
following reasons.  Firstly, Arl1-Q71L-EGFP was over expressed and therefore might 
not be completely charged to GTP bound form by the limited exchanging machinery 
in the cells.  Secondly, the C-terminal EGFP tag might reduce the affinity of binding 
between active Arl1 and the Golgin-245 GRIP domain.  The endogenous active Arl1 
level was then quantified as shown in Fig 11B, with GST-GGA1-GAT pull down 
serving as a negative control.  Typically, around 20% of total cellular Arl1 was 
retained on the GRIP beads, implying that around 20% of total Arl1 in 293T cells was 
in the GTP-bound active form.  A similar result was also obtained in NRK cells (see 
chapter 3.5).  Although the lack of other more precise experiments precludes a 
definite measurement of the percentage of active Arl1 and furthermore the Arl1 pulled 
down efficiency probably varies in different experiments, the data is in agreement 
with the findings that, generally 20-30% of Ras is in their respective active forms in 
mammalian cells (Burgering et al., 1991; Osterop et al., 1992).  This method could be 
useful in the future to assay the relative GTP loading of Arl1 in response to its GEF or 
extra-cellular stimuli. 
 
3.5 Arl1 is inactivated by BFA treatment 
The fungal metabolite BFA is a specific inhibitor of ARF1 guanine nucleotide 
exchange factor (GEF) (Peyroche et al., 1999; Chardin and McCormick, 1999).  
When mammalian cells are treated with BFA, ARF1 and its effectors, such as GGA1, 










Fig 12 Cellular Arl1 is inactivated by BFA treatment. (a), CHO cells were treated 
with 10 µg/ml of BFA for 0 min and 5 min, cells was then fixed and processed for 
indirect immunofluorescence labeling with Arl1 antibody (E6P1) (A and D) and β-
COP antibody (B and E). Compared with β-COP, Arl1 was still localized on Golgi 
after 5 min of BFA treatment. The green dots seen in β-COP labeled cells (E) were 
non-specific stains. Bar, 10 µm. (b), NRK cells were treated with 10 µg/ml of BFA 
for 0 min (lane 1), 5 min (lane 2), 10 min (lane 3), 30 min (lane 4) and 60 min (lane5) 
or were allowed to recover in normal medium for 60 min after 60 min of BFA 
treatment (lane 6). The active Arl1 content was subsequently measured by the GRIP 
domain pull down assay. Lane 7 was a negative control without cytosol. Lane 8, 5% 
of cytosol input.  
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(Klausner et al., 1992).  Prolonged treatment of cells with BFA leads to disassembly 
of the Golgi apparatus and its membrane proteins are redistributed to ER.  In contrast 
to ARF1 and its effectors, Arl1 was observed to dissociate from Golgi apparatus only 
after 5 min of BFA treatment in NRK cells (Lowe et al., 1996).  A similar result was 
obtained in CHO cells (Fig 12a) and in A431 cells (Fig 34).  Because the Golgi 
apparatus begins to disassemble after 5 min of BFA treatment, the slow kinetics of 
Arl1 dissociation could simply reflect the debacle of the Golgi membrane network.  It 
could also be possible that Arl1 becomes inactivated and thus dissociates from the 
Golgi membrane under this condition.  To sort out these two possibilities, the kinetics 
of the changes in active Arl1 content was quantified in BFA treated NRK cells (Fig 
12b).  In NRK cells without BFA treatment, around 20~30% of Arl1 is active 
measured by GRIP domain pull down assay (compare lane 1 to the loading control of 
lane 8), in agreement with previous results (see Chapter 3.4).  The level of active Arl1 
was greatly reduced after 5 min of BFA treatment (lane 2) and further reduced at 10 
min (lane 3).  After 10 min of BFA treatment, the level of active Arl1 dropped to a 
plateau, which was around 2% of total cellular Arl1.  These data suggest that Arl1 is 
inactivated during BFA treatment, resulting in its dissociation from Golgi membrane.  
 
3.6 Discussion 
An Arl1 specific antibody was generated using a full length recombinant protein.  
Despite the high identity in primary sequences between Arl1 and ARF1, the full 
length Arl1 antibody, whether in purified or crude serum form, did not cross react 
with ARF1.  Considering its preferred reactivity, the epitopes of this polyclonal 
antibody were apparently concentrated within P1 peptide region (Fig 9B).  It is not 
known if this is because of the idiosyncrasy of the rabbit used or it is a general 
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phenomenon.  Using recombinant full length yeast Arl1 protein as an antigen, Lee at 
al. (1997) also reported a polyclonal antibody that did not cross react with yeast 
ARF1p (55% identity to yeast Arl1p).  This finding would make it easier for the 
generation of Arl1 specific antibody in future in that it is not necessary to use a 
peptide as an immunogen.  The high specificity of full length Arl1 polyclonal 
antibody suggests that there is a possibility that specific antibodies could be raised to 
discriminate closely related proteins using full length proteins as antigens. 
 
The endogenous concentration of Arl1 is about 0.05% of total protein in various 
mammalian cell lines, a level that is similar to that of ARF1/3.  Another member of 
the ARF family of small G proteins, Arl2, was reported to have a concentration of 
0.01% total cellular protein in various cell lines (Cavenagh et al., 1994), which is also 
in the range of the concentrations of Arl1 and ARF1/3.  Arl1 and ARF1 share some 
similar cellular effects when their mutants were over expressed.  For example, the 
Golgi membrane becomes expanded in cells expressing their GTP forms.  And the 
Golgi apparatus collapses when their GDP forms are over expressed (see the next 
chapter).  The comparable endogenous levels of Arl1 and ARF1/3 suggest that Arl1 
might play an equally essential role as ARF1 in maintaining Golgi structure and 
function. 
 
A GRIP domain pull down protocol was developed to measure the cellular level of 
active GTP-bound form of Arl1.  In mammalian cells, about 20% of total cellular Arl1 
was found to be active.  The disappearance of GRIP domain binding, active Arl1 in 
BFA treatment suggests that Arl1 was inactivated and thus dissociated from Golgi 
apparatus.  BFA is known to inhibit the GEFs of ARFs (Peyroche et al., 1999; 
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Chardin and McCormick, 1999).  As there has been no report of an Arl1 GEF at the 
time this thesis was being written, it is not clear whether Arl1 GEFs are BFA 
sensitive.  From the slow Golgi dissociation rate of Arl1, it is tempting to speculate 





Arl1 is essential for the structure and function of Golgi apparatus 
 
4.1 Localization of endogenous Arl1 to the trans-Golgi/TGN in CHO cells 
Arl1 was previously reported to associate with the Golgi apparatus (Lowe et al., 
1996), but the exact distribution of Arl1 at the Golgi has not been examined 
ultrastructurally by electron microscopy (EM).  To this end, cryosections derived 
from CHO cells were immunolabeled with Arl1 antibodies (E6P1) followed by 
protein A-conjugated with 9 nm gold particles and examined by transmission electron 
microscopy.  As shown in Fig 13A, the gold particles are enriched on the Golgi 
apparatus.  Often, the gold particles are preferentially detected on vesicular-tubular 
profiles on one side of the stack, suggesting that Arl1 is enriched either on the cis- or 
the trans-side of the Golgi stack.  Cryosections were then double-labeled using E6P1 
antibodies against Arl1 and a monoclonal antibody against γ-adaptin (a component of 
AP-1 clathrin coat), an established marker for the trans-Golgi or TGN (Kirchhausen, 
1999).  Importantly, Arl1 labeling is enriched on the same side of the Golgi stack, as 
is AP-1 (Fig 13B).  Furthermore, Arl1 and AP-1 seem to be enriched in the same 
vesicular-tubular structures on the trans-side of the Golgi apparatus, suggesting the 
residence of Arl1 in AP-1 clathrin coated profiles, but the significance of this 
observation remains to be investigated. 
 
4.2 Saturable Golgi association of Arl1 
Perinuclear Golgi localization of Arl1 was also detected when CHO cells were 
examined by indirect immunofluorescence microscopy (Fig 14A).  Arl1 labeling 































Fig 13 Enrichment of Arl1 on vesicular-tubular structures on the trans-side of the 
Golgi.  (A), Arl1 was mainly detected on one side of Golgi apparatus. Cryosection 
derived from CHO cells were labeled with Arl1 antibodies followed by 9 nm-gold 
particle-conjugated protein A (large arrowheads). (B), Arl1 colocalized with the trans-
Golgi or TGN marker γ-adaptin.  Cryosection was double-labeled with Arl1 
antibodies followed by 14 nm gold particle-conjugated protein A (large arrowheads) 
as well as a monoclonal antibody against γ -adaptin followed by 9 nm gold particle-
conjugated protein A (small arrowheads). Note that some Arl1 and γ-adaptin stained 





























Fig 14 Saturable association of Arl1 with the Golgi apparatus. Control CHO cells (A-
C) were processed for double-labeling to reveal the colocalization of endogenous Arl1 
(A) and Golgi SNARE GS28 (B). With the increasing amount of exogenous Arl1 in 
cells, Golgi association of Arl1 became saturated and Arl1 began to accumulate in 
cytosol. Pooled Arl1 transfected (D-F) or Arl1-wt-EGFP transiently transfected CHO 
cells (G-J) were fixed and double-labeled with a monoclonal antibody against GS28 
(E and H) and a limiting amount of Arl1 antibody or EGFP fusion to reveal the 
exogenously expressed Arl1 (D, G and J). Arrows indicate the Golgi marked by GS28 





14B-C).  To minimize the side effects of using protein tags, Arl1 and its mutants were 
cloned into mammalian expression vector without tags. When CHO cells were 
 transfected with these constructs expressing wild type Arl1 and processed for indirect 
immunofluorescence microscopy using a limiting amount of Arl1 antibody (E6P1), 
Arl1 labeling was detected in transfected cells (Fig 14D-F).  In non-transfected cells, 
there was very weak labeling of endogenous Arl1 (Fig 14D-F).  Golgi labeling, as 
colocalized with GS28, was clearly detected when Arl1 expression levels were 
moderate.  At high expression levels, a majority of Arl1 was distributed into the 
cytosol.  Similarly, when CHO cells were transfected to express C-terminal EGFP 
tagged wild type Arl1 (Arl1-wt-EGFP), Golgi association, as colocalized with GS28, 
was clearly observed in cells expressing moderate levels of Arl1-wt-EGFP (Fig 14G-
J).  Again, the majority of the expressed protein was distributed in the cytosol in cells 
where Arl1-wt-EGFP was expressed at high levels (Fig 14J).  These results suggest 
that exogenously expressed Arl1 is targeted to the Golgi apparatus as endogenous 
Arl1 and that this Golgi association is mediated by a saturable mechanism, because 
over expressed protein failed to associate with the Golgi apparatus. The saturable 
mechanism could be explained in two possible ways.  The first is that Golgi 
association of Arl1 depends on its activation by guanine nucleotide exchange of GDP 
for GTP, catalyzed by its GEF(s), and that this activation step is rate-limiting.  
Alternatively, the activation step is not rate-limiting but there exists only a limited 
amount of docking sites or “membrane receptors” for the activated form of Arl1. 
 
4.3 N-terminal myristoylation of Arl1 is essential for its Golgi association 
Most small GTPases are post-translationally modified by lipid attachments, which are 
essential for their membrane association.  For example, through the recognition of 
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Cys motifs at their extreme C-termini, Ras and Rab GTPases are farnesylated and 
geranylgeranylated at their C-termini respectively.  ARFs are myristolated at their N-
termini as directed by their N-terminal myristoylation motifs, which have the 
consensus in amino acid sequence — MG.  Arl1 also contains a consensus 
myristoylation motif (Lowe et al., 1996) and has been shown to be myristoylated in 
vitro (Lee et al., 1997).  To examine whether its Golgi association depends on 
myristoylation, two mutants of Arl1 were created.  Arl1-G2A-EGFP was derived by 
substituting Gly at position 2, which is essential for all known myristoylation, with 
Ala in the context of Arl1-wt-EGFP.  In vitro transcription and translation assays 
demonstrated that Arl1 with G2A mutation migrated significantly slower than the 
wild type Arl1, as in the case of ARF1 (Fig 15a).  Wild type of Arl1 and ARF1 were 
probably modified by N-myristoyl transferase after their in vitro translation and the 
added myristoyl groups could make them migrate faster in SDS-PAGE than non 
modified molecules, possibly due to increased interaction with SDS.  Thus, the 
experiment supported the view that the Gly to Ala mutation at position 2 abolished the 
myristoylation of Arl1.  EGFP-Arl1 was made by a fusion of the C-terminus of EGFP 
to the N-terminus of wild type Arl1 so that the myristoylation signal is blocked.  As 
shown in Fig 15b, both Arl1-G2A-EGFP (panel A, Fig 15b) and EGFP-Arl1 (panel 
D, Fig 15b) were found in the cytosol and enriched in the nuclei, with no detectable 
labeling of the Golgi apparatus marked by GS28, regardless of the expression levels.  















Fig 15  The Golgi association of Arl1 depends on its N-terminal myristoylation. (a), 
G2A mutation abolished N-terminal myristoylation of Arl1 and ARF1. Arl1-wt (lane 
1), Arl1-G2A (lane 2), ARF1-wt (lane 3) and ARF1-G2A (lane 4) cloned in pBSK 
vector were in vitro translated and labeled with 35S-Methionine in rabbit reticulocyte 
lysate. For Arl1-G2A and ARF1-G2A, Gly to Ala mutation abolished their 
myristoylation, thus they migrated differently from their corresponding wild type 
proteins. (b), CHO cells were transiently transfected with constructs expressing 
Arl1(G2A)-EGFP (A-C), or EGFP-Arl1 (D-F).  Cells were then processed to reveal 
EGFP fusion (A and D) as well as endogenous GS28 (B and E).  In contrast to Arl1-
EGFP, these myristoylation-defective Arl1 mutants were not associated with the 
Golgi apparatus regardless of their expression levels. Bars, 10 µm. 
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4.4 Construction of guanine nucleotide binding mutants of Arl1 
To understand the potential involvement of Arl1 in regulating Golgi structure and 
function, mutant forms of Arl1 that exist either preferentially in the GDP or GTP 
restricted bound form were created.  The mutant forms were constructed according to 
other reported mutants of small GTPases, such as Rabs and ARFs (Zhang et al., 1994; 
Dascher and Balch, 1994; Chavrier and Goud, 1999).  The 3 conserved GTPase 
motifs GXXXXGK(S/T), DXXGQ and NKXD, which are important for guanine 
nucleotide binding and hydrolysis, were located accordingly as shown in Fig 16. 
Arl1(T31N) was created by replacing the Thr residue at position 31 in GXXXXGKT 
motif with Asn.  This mutant is expected to have much higher affinity towards GDP 
than GTP and to function as a dominant-negative mutant of Arl1.  Arl1(Q71L) was 
created by replacing the Gln at position 71 in DXXGQ motif with Leu and this mutant 





























Fig 16 The construction of Arl1 guanine nucleotide binding mutants. The sequences for 
GDP/GTP-binding and GTPase activities, boxes G-1 to G-5, are identified and boxed in 
















due to its impaired GTP hydrolysis activity.  Arl1(D129N) was generated by 
substituting the Asp with Asn at position 129 in NKXD motif and this mutant is 
expected to lose affinity towards guanine nucleotides.  Instead the mutation confers 
affinity towards xanthine nucleotides. Since the cytosolic xanthine nucleotide 
concentration is very low, it is expected to be nucleotide empty form when expressed 
in mammalian cells. 
 
4.5 Expression of GDP restricted form of Arl1 (Arl1T31N) causes disassembly of 
the Golgi apparatus 
When expressed after transfection, Arl1(T31N) resulted in complete disassembly of 
the Golgi apparatus marked by GS28 (panel A-C, Fig 17) and β1,4-
galactosyltransferase (GT) (D-F).  This effect is similar to those observed in cells 
treated with drug BFA (Klausner et al., 1992) or cells expressing dominant negative 
mutants of ARF1 (Dascher and Balch, 1994) or Sar1 (Storrie et al., 1998).  
Furthermore, perinuclear Golgi localization of γ-adaptin was also disrupted in cells 
expressing Arl1(T31N) (G-I), suggesting that Arl1 is either directly or indirectly 
involved in Golgi recruitment of AP-1.  Recent studies suggest that unlike β-1,4 
galactosyltransferase (GT) and GS28, Golgi matrix proteins such as GM130, Giantin 
and p115 remain associated with Golgi-like structures when the Golgi is disassembled 
by BFA or mutant Sar1 (Seemann et al., 2000; Pelletier et al., 2000).  Consistent with 
these recent observations, the perinuclear Golgi-like labeling of p115 (panel J-L, Fig 
17) and GM130 (data not shown) was not affected by the over expression of 
Arl1(T31N).  These results demonstrated that the expression of Arl1(T31N) 
disassembles the Golgi apparatus in such a way that the Golgi matrix remained intact.  
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Since the GDP forms of small GTPases are generally regarded as dominant negative 
forms that compete with wild type proteins for GEFs essential for their activation, the 
observations can be explained by proposing that the activation as well as the 
membrane recruitment of endogenous Arl1 was perturbed by the over expressed 
Arl1(T31N).  The results imply a role for Arl1 in maintaining the normal structure of 
the Golgi apparatus. 
 
4.6 Expression of GTP restricted form of Arl1 (Arl1Q71L) causes an expansion 
of the Golgi membrane 
Since the Golgi apparatus became disassembled when activation of endogenous Arl1 
was potentially affected by exogenous Arl1(T31N), expression of the constitutively 
active species of Arl1, by restricting it to the GTP-bound form, should have the 
opposite effect.  This was indeed the case.  Over expression of Arl1(Q71L) resulted in 
an expanded perinuclear Golgi-like membrane structure labeled by Arl1(Q71L) 
(panels A of Fig 18, Fig 19, Fig 20 and Fig 21) and this expanded structure was 
positive for various Golgi markers, such as GS28 (panel B of Fig 18), β-COP (panel 
B of Fig 19), γ-adaptin (panel B of Fig 20), ARFs (panel B of Fig 21), GS15, Syn6, 
p115, GM130 and GT (data not shown),  suggesting that the expanded structure 
consists of Golgi membrane.  Although less potent, expression of a fusion of C-
terminus of Arl1(Q71L) with EGFP {Arl1(Q71L)-EGFP} similarly caused a visible 
expansion of the Golgi-like structure marked by the expressed protein (panel D, Fig 
18) and GS28 (panel E of Fig 18).  Unlike wild type Arl1 or Arl1-wt-EGFP, Golgi 
association of Arl1(Q71L) or Arl1(Q71L)-EGFP is not saturable because both were 
associated with the Golgi regardless of the expression levels.  This result indicates 




























Fig 17 The GDP restricted form of Arl1 (Arl1T31N) disassembles the Golgi 
apparatus.  CHO (A-C) or A431 cells (D-L) were transiently transfected with a 
construct expressing Arl1(T31N) (A-C and G-L) or Arl1(T31N)-EGFP (D-F). Cells 
were then processed for double-labeling using a limiting amount of Arl1 antibody (A, 
G and J) and antibodies against GS28 (B), GT (β-1,4-galactosyltransferase) (E), γ-
adaptin (H) or p115 (K). The Golgi labeling of GS28 and GT were disrupted in cells 
over expressing Arl1(T31N) (A-F).  γ-adaptin (AP-1) was dissociated from 
perinuclear Golgi structure in Arl1(T31N) expressing cells (G-I). Over expression of 
Arl1(T31N) did not affect the Golgi-like distribution of p115 (K), a Golgi-matrix 




























Fig 18 Expression of the GTP restricted form of Arl1 (Arl1Q71L) causes a massive 
association of Arl1 with the Golgi membrane.  Pooled Arl1(Q71L) transfected CHO 
cells were double-labeled with antibody against GS28 (A-C) and a limiting amount of 
Arl1 antibody to reveal exogenous Arl1(Q71L). Arl1(Q71L) was associated with 
Golgi (A) and caused an expansion of Golgi apparatus marked by GS28 (B).  CHO 
cells were transiently transfected with constructs expressing Arl1(Q71L)-EGFP (D-F) 
or Arl1(G2A, Q71L)-EGFP (G-I).  Cells were then processed to reveal expressed 
protein as well as endogenous GS28. In contrast to Arl1(Q71L)-EGFP, Arl1(G2A, 
Q71L)-EGFP was not detected in the Golgi apparatus and had no effect on the Golgi 




limiting step in its guanine nucleotide exchange and activation.  Once activated via 
guanine nucleotide exchange or point mutation [in the case of Arl1(Q71L) and 
Arl1(Q71L)-EGFP], Golgi association is no longer rate-limiting or saturable.  
Consistent with the fact that myristoylation is necessary for Golgi association of wild-
type Arl1, the non-saturable Golgi association of the active form of Arl1 was also 
dependent on myristoylation, because when the essential Gly at position 2 was 
replaced by Ala, the resulting mutant protein Arl1(G2A, Q71L)-EGFP was not 
detected in the Golgi (panel G, Fig 18).  Rather, the mutant was distributed in the 
cytosol and enriched in the nucleus.  These results suggest that the Golgi apparatus is 
under tight regulation by Arl1 activities and that the role of Arl1 in regulating Golgi 
structure depends on its N-terminal myristoylation. 
 
4.7 GTP restricted form of Arl1 causes stable association of COPI, AP-1 and 
Golgi ARFs with the expanded Golgi membrane 
COPI is not only involved in intra-Golgi movement of cargo proteins but also 
responsible for controlling the export of traffic destined for retrograde transport back 
to the ER (Pelham and Rothman, 2000).  The retrograde export occurs predominantly 
on the cis-face of the Golgi.  On the trans-face of the Golgi, AP-1 participates in 
exporting cargo proteins to post-Golgi structures such as the lysosome via the 
endosome (Kirchhausen, 1999).  The functions of COPI and AP-1 are both under the 
tight regulation of ARF1, whose activation depends on BFA-sensitive GEFs in many 
cell types (Donaldson et al., 1992; Helms and Rothman, 1992).  In this regard, Golgi 
association of COPI and AP-1 and the formation of their respective vesicles are 
quickly inhibited (within 5 min) when cells are treated with BFA (Klausner et al., 
1992).  Previous studies have shown that expression of the activated form of ARF1 
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could confer Golgi association of COPI and AP-1 in a manner that is no longer 
sensitive to BFA (Zhang et al., 1994; Dascher and Balch, 1994).  Since expression of 
the activated form of Arl1 resulted in an expanded Golgi structure, the effect of 
Arl1(Q71L) on the distribution of COPI and AP-1 was thus examined.  As shown, the 
expression of Arl1(Q71L) caused a massive recruitment of both COPI (β-COP) (Fig 
19) and AP-1 (γ-adaptin) (Fig 20) onto the expanded Golgi.  Furthermore, the 
recruited COPI and AP-1 could not be dissociated by BFA treatment, even during 
prolonged treatments of up to 30 min (Fig 19 and Fig 20).  This observation is 
interesting because ARF1 has been established to be the key direct regulator for both 
COPI and AP-1 mediated vesicle formation.  Therefore, it is surprising to note that the 
activated form of Arl1 could similarly result in a massive recruitment of both COPI 
and AP-1 coat proteins in a BFA-resistant manner.  Several possibilities can explain 
these observations.  The first is that the activated form of Arl1 independently drives 
the recruitment of COPI and AP-1.  Alternatively, Arl1 acts together with or through 
ARF1 in mediating the recruitment of COPI and AP-1.  In order to examine these 
possibilities, the effect of over expressed Arl1(Q71L) on the distribution of Golgi-
localized ARFs recognized by monoclonal antibody 1D9 (Cavenagh et al., 1996) was 
examined.  As shown in Fig 21, 1D9 labels the Golgi region of CHO cells (panel B, 
Fig 21).  In cells over expressing Arl1(Q71L), extensive association of ARFs with the 
expanded Golgi-like structure was observed (panel A-C, Fig 21), suggesting that 
Arl1(Q71L) could stimulate Golgi recruitment of ARFs.  ARFs redistribute from the 
Golgi to the cytosol within 2 min of BFA treatment (Klausner et al., 1992).  When 
cells were treated with BFA for 5 min, ARFs dissociated from the Golgi and 
distributed in the cytosol in cells not expressing Arl1(Q71L) (panel E, Fig 21).  




























Fig 19 Arl1(Q71L) causes massive BFA-resistant Golgi recruitment of COPI coat (β-
COP).  Pooled Arl1(Q71L) transfected inducible CHO cells were treated with 10 
µg/ml BFA for 0 min (A-C), 5 min (D-F) and 30 min (G-I) and then double-labeled 
with a limiting amount of Arl1 antibody to reveal expressed Arl1(Q71L) and with 





























Fig 20 Arl1(Q71L) causes massive BFA-resistant Golgi recruitment of AP-1 coat (γ-
adaptin).  Pooled Arl1(Q71L) transfected inducible CHO cells were treated with 10 
µg/ml BFA for 0 min (A-C), 10 min (D-F) and 30 min (G-I) and then double-labeled 
with a limiting amount of Arl1 antibody to reveal expressed Arl1(Q71L) and with 





























Fig 21 Arl1(Q71L) causes massive BFA-resistant recruitment of Golgi ARFs to the Golgi 
membrane.  Pooled Arl1(Q71L) transfected CHO cells were treated with 10 µg/ml BFA for 0 
min (A-C), 5 min (D-F) and 60 min (G-I) and then double-labeled with a limiting amount of 
Arl1 antibody to reveal expressed Arl1(Q71L) and with monoclonal antibody against Golgi 




Arl1(Q71L) (panel D-F, Fig 21).  Association of ARFs with the expanded Golgi 
could still be observed after 30 min of treatment with BFA (panel G-I, Fig 21).  These 
observations suggest activated Arl1 {Arl1(Q71L)} can stimulate activation and Golgi 
recruitment of ARFs in a BFA-resistant manner and this could be the molecular basis 
for the observed massive recruitment of COPI and AP-1 in cells over expressing 
Arl1(Q71L). 
 
In marked contrast to COPI and AP-1 which mediate export from the Golgi, the 
distributions of COPII (Sec31) mediating ER export and AP-2 (α-adaptin) mediating 
endocytosis from the plasma membrane were not affected by the over expression of 
Arl1(Q71L) (data not shown).  These results suggest that Arl1 regulates membrane 
traffic selectively at the Golgi apparatus. 
 
4.8 Protein trafficking through the Golgi apparatus is inhibited by Arl1(Q71L) 
To study the effect of expression of Arl1(Q71L) on protein trafficking along the 
secretory pathway, the transport of the envelope protein (VSV-G) of VSVts045 was 
studied in Arl1(Q71L) expressing cells.  Cells were infected with VSVts045 at 32°C 
for 1 hour and then incubated for another 2 hours to allow sufficient VSV-G protein 
to be produced and followed by an additional 1 hour incubation in the presence of 
cycloheximide to chase VSV-G along the pathway.  As shown in panel B, E, H, Fig 
22, VSV-G was almost completely transported to the cell surface in cells not 
expressing Arl1(Q71L).  However, the transport of VSV-G to cell surface was 
essentially abolished in cells expressing Arl1(Q71L) (panel A-C), and VSV-G now 
accumulated in the expanded Golgi-like structure marked by Arl1(Q71L).  These 
results suggest that export of VSV-G from the ER mediated by COPII coat proteins 
occurred normally, while subsequent transport through the Golgi and/or from the 
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Golgi to the cell surface was blocked.  Similarly, VSV-G transport was arrested upon 
over expression of Arl1(Q71L)-EGFP (panel D-E, Fig 22), although its effect was not 
as potent as Arl1(Q71L).  The effect of the activated form of Arl1 on VSV-G 
transport was also dependent on myristoylation, because VSV-G was transported 
normally to the cell surface in cells over expressing Arl1(G2A, Q71L)-EGFP (panel 
G-I, Fig 22). 
 
4.9 The cisternae of Golgi apparatus is disorganized into an extensive vesicular-
tubular network upon over expression of Arl1(Q71L) 
To gain more detailed understanding about the effects of over expressed Arl1(Q71L) 
on the organization of the Golgi, the ultra-structure of the Golgi apparatus was 
examined by immunogold EM.  Cells were infected with VSVts045 at 32°C for 1 
hour followed by 2 hours incubation in the absence, and a further 1 hour incubation in 
the presence, of cycloheximide so that VSV-G is transported to the expanded Golgi-
like structure in cells over expressing Arl1 (Q71L).  Cryosections derived from these 
cells were then double-labeled with antibodies against Arl1 and VSV-G to reveal the 
expanded structures (Fig 23).  In contrast to highly ordered stacks of Golgi cisternae 
observed in control CHO cells, the stacked cisternae of Arl1(Q71L) expressing cells, 
although still visible, were significantly disorganized.  The cisternae now became 
more dilated and expanded in cells expressing moderate levels of Arl1(Q71L) (panel 
A).  Both Arl1(Q71L) and VSV-G (arrowheads) were detected in the dilated Golgi.  
Strikingly, the Golgi apparatus became transformed into an extensive vesicular-
tubular network in cells expressing high levels of Arl1(Q71L) (panel B).  Arl1(Q71L) 
decorated the entire vesicular-tubular network (smaller arrowheads) and VSV-G 




























Fig 22 Transport of VSV-G to the cell surface is inhibited at the Golgi stage in 
Arl1(Q71L) expressing cells.  Pooled Arl1(Q71L) transfected (A-C), Arl1(Q71L)-
EGFP (D-F), or Arl1(G2A, Q71L)-EGFP (G-I) transiently transfected CHO cells were 
infected with VSVts045 at 32°C for 1 hour and followed by 2 hours chase in the 
absence and a 1 hour chase in the presence of 10 µg/ml cycloheximide. Cells were 
fixed and processed to reveal over expressed proteins (A, D, G) and VSV-G (B, E, H).  





























Fig 23  Over expression of Arl1(Q71L) transforms the Golgi into an extensive 
vesicular-tubular network.  Pooled Arl1(Q71L) transfected CHO cells were infected 
with VSVts045 at 32°C for 1 hour and followed by 2 hours chase in the absence and 1 
hour chase in the presence of 10 µg/ml cycloheximide.  Cryosections derived from 
these cells were processed for immunogold EM to detect Arl1(Q71L) and VSV-G. In 
cells expressing moderate levels of Arl1(Q71L) (A), Golgi cisternae became more 
dilated and expanded. 9 nm and 14 nm gold particles represent Arl1(Q71L) and VSV-
G (arrowheads), respectively.  In cells expressing high levels of Arl1(Q71L) (B), the 
Golgi apparatus was transformed into an extensive tubular-vesicular network. 
Arl1(Q71L) (9 nm gold particles, small arrowheads) decorated the entire network with 
VSV-G (14 nm gold particles, large arrowheads) being accumulated in the structure. 





(V) were often seen and Arl1(Q71L) was also detected on vacuolar membranes.  This 
result indicates that the organization of the Golgi apparatus into ordered stack of 
cisternae depends on the proper function of Arl1.  Since Arl1 is enriched in the 
vesicular-tubular profiles on the trans-side of the Golgi, the observed Golgi 
transformation could be due to massive unproductive formation of vesicular-tubular 
profiles caused by activated Arl1(Q71L), leading to the formation of a tangled 
vesicular-tubular network. 
 
4.10 Arl1 is essential for VSV-G in vitro ER to medial Golgi trafficking 
To use the loss of function approach to verify Arl1’s role in protein trafficking along 
secretory pathway, a well established in vitro ER to Golgi transport assay by 
monitoring the glycosylation of VSV-G was used.  Briefly, NRK cells were infected 
by VSVts045 and subsequently pulse-labeled with [35S] Methionine at 40 °C so that 
the labeled protein G of virus is restricted to the ER.  After perforation and depletion 
of endogenous cytosol from these NRK cells, synchronized transport of VSV-G was 
reconstituted at the permissive temperature (32 °C) supplemented with exogenous rat 
liver cytosol, ATP regenerating system and Arl1 polyclonal antibody.  ER to Golgi 
transport was measured by following the conversion of endo-H sensitive ER-form 
VSV-G into endo-H resistant Golgi form VSV-G, which is taken place at medial 
Golgi cisternae.  As shown in Fig 24 lanes1 and 2, the trafficking of VSV-G was 
temperature and cytosol dependent as VSV-G was in ER form when transport was 
conducted on ice or without cytosol.  At the permissive temperature 32°C, more than 
70% of VSV-G was converted to Golgi form when rat liver cytosol was supplied (lane 
3).  The transport, as assessed by the appearance of the Golgi form, was almost 
completed inhibited by 1 µg (lane 4) and 1.8 µg (lane5) of Arl1 polyclonal antibody 
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E6P3, suggesting that Arl1 function is essential for ER to medial Golgi trafficking of 
VSV-G protein.  
 
4.11 Discussion 
The subcellular localization of Arl1 was first investigated using immunogold labeling 
of cryosections derived from CHO cells and it was shown that the majority of Arl1 is 













Fig 24 Arl1 polyclonal antibody inhibited the trafficking of VSV-G from ER to the 
Golgi in vitro.  The above panel shows the autoradiograph of VSV-G protein which 
was pulse labeled by 35S Methionine. Lane 1, the transport assay was conducted on 
ice, as negative control. Lane 2, without cytosol, as negative control. Lane 3, the 
complete reaction, as positive control. The transport assays conducted in lane 4 and 5 
contained 1 and 1.8 µg of Arl1 E6P3 antibody respectively.  
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labeling with γ-adaptin revealed that Arl1 is enriched on the side that is marked by γ-
adaptin, suggesting that Arl1 is enriched on the trans-side of the Golgi or TGN.  Since 
ARFs have been implicated in regulating traffic in the cis-, intra and trans-Golgi, and 
endosomes (Serafini et al., 1991; Robinson and Kreis, 1992; Stamnes and Rothman, 
1993; Palmer et al., 1993; Zhao et al., 1997; Daro et al., 1997; Malsam et al., 1999; 
Gu and Gruenberg, 2000; Stephens and Pepperkok, 2001), they may have a global 
role in regulating membrane traffic.  Based on its known functions, ARF1 may not be 
restricted in particular subcompartments of the Golgi apparatus, although earlier 
localization studies suggested that ARF1 is enriched in the cis-Golgi (Stearns et al., 
1990).  The enrichment of Arl1 on the trans-side of the Golgi is of interest because it 
suggests that one of its key functions may be to regulate traffic around the trans-side 
of the Golgi, although it remains possible that it may also regulate other traffic linked 
to the function of the Golgi apparatus.  The molecular basis for Golgi association of 
Arl1 was thus examined and it was found that Golgi association of Arl1 is mediated 
by a saturable mechanism in intact cells.  The basis for this saturable recruitment is 
likely to be a rate-limiting step in the activation (GDP-GTP exchange) of Arl1 
catalyzed by its GEF(s), because Golgi association of activated forms Arl1(Q71L) and 
Arl1(Q71L)-EGFP is not saturable.  Furthermore, Golgi association of Arl1 depends 
on its N-terminal myristoylation and myristoylation is essential not only for the 
saturable recruitment of wild-type Arl1 but also for non-saturable association of 
activated Arl1(Q71L).  This notion is further supported by the fact that the inhibitory 
effect of Arl1(Q71L)-EGFP on VSV-G transport is abolished when the conserved Gly 
at position 2 responsible for myristoylation is replaced by Ala.  Thus, these data 
suggest that a concerted action of the N-terminal myristoylation and its activation via 
guanine nucleotide exchange is the underlying mechanism for Golgi association of 
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Arl1 and that the activation by its GEF(s) represents the rate-limiting step for 
regulating its activity. 
 
The functional importance of Arl1 was then established by the expression of two 
different mutant versions of Arl1.  The Golgi apparatus marked by GT and GS28 
disassembled when Arl1(T31N), expected to be restricted to the GDP-bound status, 
was expressed.  Since the rate-limiting step in Arl1 Golgi recruitment is at the step of 
activation mediated by its GEF(s), the likely explanation for the observed effect of 
Arl1(T31N) is that it competes with endogenous Arl1 for the limiting amount of 
GEF(s), resulting in an inhibition on activation and Golgi recruitment of endogenous 
Arl1.  The failure of recruitment of Arl1 onto the Golgi may also lead to defective 
Golgi association of its putative effectors, which, together with Arl1, play a key role 
in maintaining the normal structure and function of the Golgi apparatus.  On the other 
hand, expression of Arl1(Q71L), expected to be restricted to the GTP-bound activated 
form, led to an expansion of the Golgi membrane as marked by various Golgi 
markers.  The ordered stacks of the Golgi were transformed into an extensive 
vesicular-tubular network upon expression at high levels.  Although the molecular 
mechanism remains to be established, it is plausible that uncontrolled Golgi 
association of Arl1(Q71L) leads to a massive recruitment of its effectors onto the 
Golgi and alteration of the normal structure of the stacked cisternae of the Golgi 
apparatus.  Since the ordered and stacked cisternae are believed to facilitate efficient 
traffic through this compartment and to govern effective sorting on both the cis- as 
well on the trans-side of the Golgi, the transformation of Golgi into an extensive 
vesicular-tubular network may interfere with the normal function and lead to an 
inhibition of protein transport through the compartment and/or export from the Golgi.  
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In support of this interpretation, transport of VSV-G from the ER to the cell surface 
was arrested at the stage of the expanded structure upon over expression of 
Arl1(Q71L).  The accumulation of VSV-G protein in this vesicular-tubular network 
indeed indicates that transport through or export from the altered Golgi is blocked.  
Arl1 specific antibody (E6P3) inhibited the trafficking of VSV-G protein from ER to 
medial-Golgi in a biochemical in vitro transports assay.  Considering Arl1’s Golgi 
localization, the data could be explained that Arl1 is essential for the protein 
trafficking from cis to medial Golgi, where the Endo H resistant polysaccharide 
modification takes place.  These results implied that one of the mechanisms for the 
cell to regulate the size and the stacked cisternae structure of the Golgi apparatus is by 
controlling the activation and Golgi recruitment of Arl1 and its effectors. 
 
Over expressing the dominant active and dominant negative mutant is a very 
commonly used approach to research a protein.  The over expression of GDP or GTP 
form small GTPase is widely accepted in this field and were of great help to deduce 
their cellular roles.  However, it should be noted that over expression could produce 
artifacts.  Under this condition, the over expressed protein could have non-
physiological interaction by pushing the equilibrium using large amount of over 
expressed reactant.  It is thus necessary to use loss of function approaches, such as 
siRNA knock down (see chapter 6.12) or microinjection of neutralizing antibody, to 
corroborate the over expression data. 
 
The cellular effects of the two Arl1 mutants resemble the correspondent ARF1 
mutants (Dascher and Balch, 1994; Zhang et al., 1994).  The massive recruitment of 
COPI and AP-1 onto the expanded Golgi apparatus upon over expression of 
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Arl1(Q71L) is interesting because a similar effect was observed upon expression of 
ARF1(Q71L) (Stearns et al., 1990; Dascher and Balch, 1994; Zhang et al., 1994).  
ARF1 has been demonstrated to directly interact with COPI and AP-1 subunits 
(Randazzo et al., 2000).  Since COPI and AP-1 are redistributed from the Golgi to the 
cytosol within 2 min of BFA treatment, while Golgi association of Arl1 remains after 
5 min of BFA treatment (Lowe et al., 1996), it is unlikely that Golgi recruitment of 
COPI and AP-1 are directly regulated by Arl1.  One possibility to explain the 
remarkable similarity of GTP form of Arl1 as compared to ARF1 with regards to 
Golgi recruitment of COPI and AP-1, is that Arl1 and ARF1 share some common 
effectors in addition to effectors that are unique to each of them (see the next chapter).  
Upon expression of the active form of Arl1 and its Golgi recruitment, the common 
effectors could be activated and exert positive feed back to and then activate ARF1.  
Indeed, the Arl1-GTP mutants activated endogenous ARFs and conferred them the 
BFA resistance.  Furthermore, overexpression of active ARF1 (ARF1-Q71L) also 
recruited, thus activated, endogenous Arl1 to Golgi (data not shown). Thus the 
common effectors between Arl1 and ARF1 are crucial for their cellular 
communication.  The screening and initial characterization of Arl1 effectors is 





Arl1 and ARF1 have shared and unique effectors 
 
5.1 Gal4 based yeast two-hybrid screening of a human brain cDNA library using 
the GTP restricted form of Arl1 as bait  
To understand the molecular mechanism underlying the action of Arl1 in regulating 
Golgi structure and function, a Gal4 based yeast two-hybrid screen for proteins 
interacting with activated Arl1 was performed.  After confirming that Arl1-Q71L in 
pGBKT7 has no transcription autoactivating activity, Arl1-Q71L containing yeast 
cells (AH109) were mated with yeast Y187 pretransformed with human brain cDNA 
library (titer was determined to be 4×107 colonies/ml) and subsequently plated on the 
selective medium with the highest stringency (SD/-Leu/-Trp/-His/-Ade, Quadruple 
Drop Out medium, QDO).  It was estimated that 2 × 106 cDNA clones were screened.  
Altogether, 18 colonies appeared after 2 weeks of selection.  The plasmids carried by 
these yeast cells were subsequently extracted and sequenced.  Initial characterizations 
of the 18 clones revealed the presence of POR1 (partner of Rac1)/arfaptin-2, Golgin-
97, pericentrin (PCNT), Molybdenum cofactor biosynthesis protein E (MCBPE), Big-
2 (brain-derived immunoglobulin protein-2) and one unknown gene (clone G) with 













Clones No. of appearance Identity of gene GenBank No. 
A, C, H, I, J, K, L, M, N, O, P, Q, R 13 POR1/arfaptin2 U52522 
B 1 Big-2 U35371 
D 1 pericentrin U51587 
E 1 MCBPE AF155659 
F 1 Golgin-97 U52962 
G 1 Unkown EST AW081081 
 
 
While other clones were represented only once, POR1 appeared 13 times.  
POR1/arfaptin-2 has been shown to interact with multiple activated forms of small 
GTPases, such as Rac1, ARF1, ARF3 and ARF6 (Van Aelst et al., 1996; D'Souza-
Schorey et al., 1997; Kanoh et al., 1997).  Golgin-97 is a Golgi localized peripheral 
membrane protein of 97 kD with unknown function (Griffith et al., 1997).  Its 
extensive coiled-coils and identity to vesicle tethering and Golgi matrix molecules, 
such as Giantin, GM130 and p115, is suggestive of its similar functions.  The 
characterization of the interaction of Golgin-97 and Arl1 will be described in detail 
(see next chapter).  Pericentrin (PCNT) is a centrosome localized protein with a 
molecular weight of 370 kD.  Together with γ-tubulin, it forms a reticular lattice 
complex, which plays an important role in microtubule nucleation and organization 
(Dictenberg et al., 1998).  MCBPE is an uncharacterized protein with a molecular 
weight of 21 kD.  It has a predicted single transmembrane domain from the SMART 
software server (http://samrt.embl-heidelberg.de/smart).  Big-2 (brain-derived 
immunoglobulin protein 2) is a glycosyl phosphatidylinositol (GPI) anchored 
immunoglobulin family neuronal cell surface adhesion molecular with a molecular 
Table 4 Positive clones from yeast two-hybrid screening of pretransformed human brain 
cDNA yeast library using Arl1-Q71L as the bait. 
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weight of 113 kD (Yoshihara et al., 1995).  Given the exclusively extracellular 
(luminal) location of Big-2, it is impossible for a cytosolic molecule, Arl1 in this case, 
to interact with it physiologically.  It thus could represent an artifact of yeast two-
hybrid screen.  
 
5.2 Initial characterization of the interaction of Arl1 with its putative effectors 
The interactions of Arl1 with its putative effectors were initially characterized.  A 
canonical effector of a small GTPase should interact with its GTP form rather than its 
GDP form.  Some previously reported ARF1 effectors, such as MKLP1 (mitotic 
kinesin-like protein 1) (Boman et al., 1999), PICK1 (protein interacting with C kinase 
1) (Takeya et al., 2000) and GGA1 (Golgi-associated, γ-adaptin ear homology and 
ARF binding protein 1) (Poussu et al., 2000; Hirst et al., 2000; Dell'Angelica et al., 
2000; Boman et al., 2000), were also included in this study. 
 
The interaction of POR1 with Arl1 was dependent on the guanine nucleotide state of 
Arl1 as shown in the yeast two-hybrid assays (Table 5).  POR1 and Arl1-Q71L 
diploid yeast grew robustly in the QDO synthetic medium plate, while the diploid 
yeast containing both POR1 and Arl1-wt, Arl1-T31N or Arl1-D129N failed to grow.  
Very similar results were obtained for POR1 and ARF1 guanine nucleotide mutants, 
which served as controls here (Table 5).  On the other hand, under identical 
conditions, the activated form of ARF1 but not Arl1 interacted with GGA1.  
Furthermore, in a pull down assay, similar to ARF1 (Fig 25, lane 4 and 5), in vitro 
translated and 35S labeled POR1 was retained very efficiently by immobilized GST-
Arl1 in its GTPγS charged (lane 2) but not in GDP charged form (lane 3).  
Collectively, these results suggest that the GTP form of Arl1 could interact 
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specifically with POR1.  Thus, while GGA1 is a specific effector for ARF1, POR1 is 
a common shared effector for both Arl1 and ARF1. 
 
Big-2 interacted with almost equal strength toward Arl1 and ARF1 regardless of their 
guanine nucleotide binding states (Table 6).  So did Clone G, which represents an 
unknown gene (Table 6).  The non-guanine nucleotide dependent interaction of clone 
G and Big-2 with Arl1 suggests that they might not be Arl1’s effectors. 
 
The Golgin-97 clone retrieved from yeast two-hybrid screen contained only its C-
terminus GRIP domain (Golgin-97, RanBP2α, Imh1p and p230/Golgin-245) (Munro 
and Nichols, 1999; Kjer-Nielsen et al., 1999; Barr, 1999).  The four GRIP domains of 
other GRIP containing Golgins — Golgin-245, GCC1 and KIAA0336 were thus also 
included in the analysis (Table 6).  Contrasting to POR1, MKLP1, and MCBPE, 
which interacted with active forms of both Arl1 and ARF1, and thus suggesting they 
could be shared effectors of both small GTPases, Golgin-97, Golgin-245, GCC1, 
KIAA0336, and pericentrin only showed interaction with the active Arl1 but not any 
form of ARF1 mutants, implying that they are specific effectors of Arl1. 
 
Among these putative Arl1 effectors, the GRIP domain containing Golgins — Golgin-
97, Golgin-245, GCC1 and KIAA0336 were focused on in later studies because of 
their localization of Golgi apparatus, their GTP dependent and specific interaction 
with Arl1 but not its close homolog ARF1, and their potential involvement in the 
maintenance of Golgi structure and function.  Studying these GRIP Golgins would 










Arl1 ARF1  
WT T31N Q71L D129N WT T31N Q71L D129N 
POR1 − − + − − − + − 












Arl1 ARF1  
WT T31N Q71L D129N WT T31N Q71L D129N 
POR1 − − ++ − − − ++ − 
Golgin-97 − − ++ − − − − − 
Golgin-245 − − ++ − − − − − 
GCC1p − − + − − − − − 
KIAA0336 − − + − − − − − 
Pericentrin + − ++ + − − − − 
Big-2 ++ ++ ++ + + ++ ++ ++ 
MCBPE − − ++ − − − + − 
Clone G ++ ++ ++ − − ++ ++ ++ 
MKLP1 ND − ++ ND ND + ++ ND 





Table 5 Arl1 and ARF1 have unique and shared effectors.  Interactions were assayed by mating 
indicated Gal4-BD/AH109 yeast cells with respective Gal4-AD/Y187 yeast cells and growing 
the resulting diploid yeast cells on the selection medium (QDO).  The diploid yeast cells were 
assayed on QDO plate containing X-α-gal.  “−”: no growth on QDO plate after 4 days; “+”: 
growth and strong blue coloration by 4 days.  In yeast two-hybrid assays, POR1 interacted with 
GTP form of both Arl1 and ARF1, while GGA1 interacted only with GTP form of ARF1.  
Table 6 The yeast two-hybrid interaction assays of Arl1 and ARF1 with their putative 
effectors. Interactions were tested by mating the indicated Gal4-BD/AH109 yeast cells with the 
respective Gal4-AD/Y187 yeast cells and growing the resulting diploid yeast cells on the 
selective medium (QDO).  The diploid yeast cells were assayed on QDO plate containing X-α-
gal.  “−”: no growth on QDO plate after 4 days; “+”: growth and blue coloration by 4 days.  






















Although extensive studies have shown that Arl1 is different from ARF1 (and other 
ARFs) in some properties, such as its inabilities to serve as ADP ribosylation cofactor 
for Cholera toxin (Tamkun et al., 1991), rescue arf1/arf2 double deletion yeast 
(Tamkun et al., 1991), interact with cytohesin-1 (Pacheco-Rodriguez et al., 1999), 
and regulate ER to Golgi transport in yeast (Lee et al., 1997), it was surprising to 
observe that over expressed Arl1 mutants, compared to ARF1, had very similar 
cellular effects in mammalian cells.  Both GTP forms cause the expansion of Golgi 
membrane and vesicularize the whole Golgi apparatus; recruit COPI and AP-1 coats 
Fig 25 In vitro binding assay showed that POR1 interacts with both Arl1 and ARF1 in 
a guanine nucleotide dependent manner.  60 µg GDP or GTPγS exchanged GST-Arl1 
or GST-ARF1 fusion proteins immobilized on glutathione Sepharose beads were 
incubated with 100 µM appropriate guanine nucleotide (GTPγS or GDP) and 10 µl of 
35S Methionine labeled in vitro translated POR1 at 4°C over night.  After washing, 
bound proteins were resolved by 12% SDS-PAGE and analyzed by autoradiograph.  
Upper panel: lane 1, 10% in vitro translated POR1; lane 2, GDP exchanged GST-
Arl1(T31N); lane 3, GTPγS exchanged GST-Arl1(Q71L); lane 4, GDP exchanged 
GST-ARF1; lane 5, GTPγS exchanged GST-ARF1.  Lower panel: the loading of each 
GST fusion protein. 
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and render their association with the Golgi membrane BFA resistant.  Both GDP 
forms of Arl1 and ARF1 cause opposite effects — dissociate peripheral Golgi 
membrane proteins and disassemble Golgi apparatus.  One of the possibilities to 
explain these overlapping effects is that Arl1 indirectly activates ARF1 through cross 
talk by their common shared effectors, as discussed previously (see chapter 4.11).  
Aside from POR1, MKLP1 was found to be another common effector between Arl1 
and ARF1 (Van Valkenburg et al., 2001).  There might be other undiscovered 
common effectors shared by both Arl1 and ARF1. 
 
Through the comparison of putative effectors of Arl1 and ARF1, there are proteins, 
such as GRIP domain containing Golgins and pericentrin, that specifically interact 
with active Arl1 but not ARF1, and GGA1, which interacts only with active ARF1, 
suggesting that both Arl1 and ARF1 have their unique effectors and thus carry out 
distinct cellular functions.  Active ARF1 recruits GGA1 on TGN membrane for the 
budding of vesicles en route to the late endosome (Puertollano et al., 2001).  In the 
next chapter, Arl1 will be shown to be responsible for Golgi membrane association of 
Golgin-97 and Golgin-245.  ARF5, a class II ARF, was also reported to recruit coats 
and expand Golgi apparatus upon over expression of its GTP restricted mutants.  
There is a unique effector, Arfophilin for ARF5 (Shin et al., 1999) and there is a 
shared effector, POR1, between ARF1 and ARF5 (Shin and Exton, 2001).  Similar 
cellular effect upon over expression of active mutants, shared and unique effectors 
might be common features for class I, II and Arl1 small GTPases.  POR1/Arfaptin2 
was reported to be an effector of the active form of ARFs (Kanoh et al., 1997; Shin 
and Exton, 2001) and Rho family small G protein Rac1 (Van Aelst et al., 1996), and 
is a common effector of both active Arl1 and ARF1 as well.  POR1/arfaptin-2 has 
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been shown to potently increase the affinity of ARF1 and ARF3 for GTP in vitro (Zhu 
et al., 2000).  The stoichiometry of GTP binding to ARF can be increased from about 
0.05 mol/mol to almost 0.5 mol/mol of recombinant ARF.  POR1/Arfaptin2, similar 
to its proposed role in ARF1 and Rac1 communication (Tarricone et al., 2001), could 
mediate the cross talk between Arl1 and ARF1: POR1/Arfaptin2 sequesters active 
ARF1 until Arl1-GTP binds to it and release the active ARF1.  Thus, the observed 
effects of Arl1(Q71L) on massive COPI and AP-1 Golgi association could be 
potentially mediated by POR1/arfaptin-2.  In support of these hypothesis’s, expression 
of Arl1(Q71L) was observed to result in massive recruitment of ARFs onto the Golgi 
in a BFA-resistant manner (Fig 21).  Although it might be due to an indirect effect of 
Golgi disassembly, the observed dissociation of AP-1 from the perinuclear Golgi 
upon expression of Arl1(T31N) could be a result of indirect inactivation of Golgi-
localized ARFs.  These results thus highlight a potentially important mechanism for 
cross talk among different small GTPases in regulating membrane traffic. 
 
The yeast two-hybrid screen of human brain cDNA library conducted in this study 
was not exhaustive as Golgin-245 and MKLP1, two ubiquitously expressed proteins, 
were not retrieved from the screen.  Further rounds of screening using active Arl1 as 





Active Arl1 interacts with the autoantigens Golgin-97 and Golgin-
245, and recruits them on to the Golgi membrane 
 
6.1 Arl1 interacted with Golgin-97 through its GRIP domain 
Studies were focused on defining the nature and specificity of the interaction of Arl1 
with Golgin-97.  It was found that GTP-restricted Arl1 interacted specifically with the 
C-terminal GRIP domain of Golgin-97 but not any other regions of this protein (Fig 
26).  Since GRIP domains were also present in Golgin-245, GCC1 and KIAA0336, 
these GRIP domains were systematically analyzed for their interaction with various 
forms of Arl1 using yeast two-hybrid analysis.  As shown in Fig 26A and consistent 
with results in Table 6, GTP-restricted (Arl1Q71L) but not GDP-restricted 
(Arl1T31N) Arl1 interacted strongly with the GRIP domains of Golgin-97 and 
Golgin-245.  Weaker interactions of Arl1Q71L with GRIP domains of GCC1 and 
KIAA0336 were also observed.  Neither the GTP-restricted (ARF1Q71L) nor the 
GDP-restricted form (ARF1T31N) of ARF1 interacted with these GRIP domains.  
Under similar conditions, GGA1 interacted specifically with ARF1Q71L but not 
Arl1Q71L, ARF1T31N or Arl1T31N, consistent with earlier results showing that 
GGA1 is a specific effector of ARF1 (Dell'Angelica et al., 2000; Boman et al., 2000; 
Poussu et al., 2000; Hirst et al., 2000).  POR1 interacted with GTP-restricted form of 
both Arl1 and ARF1 as it is an effector shared by Arl1, ARF1, and other small 
GTPases (such as ARF3, ARF6 and Rac1) (D'Souza-Schorey et al., 1997; Van 













Fig 26 GTP-restricted Arl1 interacts with the GRIP domains of Golgins.  (A) 
Arl1Q71L, Arl1T31N, ARF1Q71L, and ARF1T31N were tested respectively in the 
yeast two-hybrid assay for interaction with the GRIP domain of Golgin-97, Golgin-
245, GCC1p, KIAA0336, full-length POR1, or GGA1.  (B) ONPG β-galactosidase 
assay shows different interaction strength of Arl1Q71L with various GRIP domains, 
POR1, or GGA1.  (C) Golgin-97 full length but not Golgin-97∆GRIP interacts with 
Arl1-Q71L in yeast two-hybrid assay showing the interaction is only through the 
GRIP domain of Golgin-97.
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GTP-restricted Arl1 but not ARF1 can interact specifically and robustly with the 
GRIP domains of Golgin-97 and Golgin-245, while weaker interactions of Arl1 with 
GRIP domain of GCC1 and KIAA0336 were also observed.  The conclusion was 
strengthened by monitoring β-galactosidase activities (Fig 26B).  High activities were 
observed when interaction was mediated by Arl1Q71L and the GRIP domain of 
Golgin-97 or Golgin-245.  The weaker but significant interaction of Arl1Q71L with 
the GRIP domains of GCC1 and KIAA0336 was also verified by the β-galactosidase 
assay.  In Fig 26C, Full length Golgin-97 interacts with Arl1Q71L in yeast two-
hybrid assay, but not the GRIP domain deleted Golgin-97 (Golgin-97∆GRIP), 
suggesting that Arl1 interacts with Golgin-97 only through its GRIP domain. 
 
6.2 Arl1 interacted with Golgin-97 and Golgin-245 in pull down and 
immunoprecipitation experiments 
To further demonstrate the biological relevance of this observed interaction of Arl1 
with the GRIP domains, the cellular interaction of Golgin-97 and Golgin-245 with 
active Arl1 was investigated in vitro.  Various forms of Arl1 and ARF1 were 
expressed as recombinant proteins fused to GST and these GST-fusion proteins, or 
GST alone as a negative control, were immobilized onto glutathione sepharose beads.  
Cytosols prepared from HeLa cells were incubated with these beads and the amount 
of Golgin-245 and Golgin-97 retained by the beads were analyzed by 
immunoblotting.  As shown in Fig 27A, significant amounts of Golgin-245 and 
Golgin-97 in the cytosol were retained by immobilized wild type Arl1 (Lane 4) and 
Arl1Q71L charged with GTPγS (Lane 6).  Conversely, wild type Arl1 charged with 
GDP failed to retain either Golgin-245 or Golgin-97 (Lane 3).  Golgin-245 and 
Golgin-97 were not retained by immobilized Arl1T31N (Lane 5) or any forms of 
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ARF1 (Lanes 7-8) or Arl4 (Lane 9 and 10).  These results suggest that, like isolated 
GRIP domains, intact Golgin-245 and Golgin-97 can interact specifically with GTP-
restricted Arl1.  Furthermore, when the GRIP domain of Golgin-245 was expressed as 
GST fusion protein and immobilized onto glutathione beads, qualitative recovery of 
cytosolic Arl1 in the presence of GTPγS could be achieved (Fig 27B), while ARFs 
were not retained.  This confirms the interaction of GTP-restricted Arl1 with the 
GRIP domain of Golgin-245.  Finally, the evidence was provided that GTP-restricted 
Arl1 and Golgin-245 could interact in vivo as revealed by co-immunoprecipitation 
experiments (Fig 27C).  293T cells were transiently transfected with C-terminal 
EGFP tagged wild type (Arl1-wt-EGFP), GDP-restricted (Arl1-T31N-EGFP), or 
GTP-restricted (Arl1-Q71L-EGFP) form of Arl1 tagged with EGPP at its C-terminus.  
The resulting cell lysates were processed for immunoprecipitation using antibodies 
against EGFP and analyzed by immunoblotting using antibodies against Golgin-245 
(upper panel) and EGFP (lower panel).  As shown, endogenous Golgin-245 was 
specifically co-immunoprecipitated with Arl1-Q71L-EGFP (Lane 5) but not Arl1-
T31N-EGFP (lane 4).  Recombinant GRIP domain of Golgin-245 can also interact 
with recombinant Arl1 in the presence of GTPγS (data not shown), suggesting that the 
Arl1 and GRIP interaction is direct.  Taken together, these results established that 
Arl1 (in its GTP-restricted form) can interact specifically and directly with the GRIP 
domain of Golgin-97 and Golgin-245 and this interaction also occurs with intact 
































Fig 27 Arl1 interacts with the GRIP domain Golgins in pull down and 
immunoprecipitation experiments. (A), HeLa cell cytosol was incubated with 60 µg of 
various immobilized recombinant proteins as indicated.  Proteins retained by the 
beads were eluted in SDS sample buffer and subjected to immunoblotting analysis 
with the indicated antibodies. Significant amounts of Golgin-245 (first panel) and 
Golgin-97 (second panel) were retained on GTPγS (lane 4 and 6) but not GDP (lane 3 
and 5) charged forms of GST-Arl1.  As negative controls, GST (lane 2), various forms 
of GST-ARF1 (lane 7 and 8) or GST-Arl4 (lane 9 and 10) failed to retain Golgin-245 
and Golgin-97.  The endosomal EEA1 (third panel) was not retained by any of these 
beads.  The lower panel is the Coomassie blue stained SDS-PAGE gel showing the 
relative quantity of the respective GST fusion proteins used.  Lane 1 represents a 3% 
cytosol loading control for Golgin-245, Golgin-97 and EEA1. (B), Arl1 (upper panel) 
but not ARFs (middle panel, blotted with Mab 1D9) in HeLa cell cytosol was 
efficiently retained by immobilized GST-GRIP domain of Golgin-245 (lane 3) but not 
GST (lane 2).  Lane 1 shows the 5% cytosol loading control.  The lower panel is the 
Coomassie blue stained SDS-PAGE gel showing the relative quantity of the 
recombinant GST or fusion protein used.  (C), Various forms of Arl1 tagged with 
EGFP, together with EGFP alone, were expressed in transfected 293T cells.  The 
resulting cell lysates were immunoprecipitated with antibodies against EGFP and the 
immunoprecipitates were analyzed by immunoblotting to detect Golgin-245.  Golgin-
245 was selectively co-immunoprecipitated with GTP-restricted Arl1Q71L-EGFP 
(lane 5).  Lane 1 represents 3% cytosol input for the immunoprecipitation and the 







6.3 Comparison of GRIP domain sequences 
The GRIP domain is conserved evolutionally and is present in proteins from yeast, 
fly, worm and mammals (Munro and Nichols, 1999; Kjer-Nielsen et al., 1999; Barr, 
1999).  The GRIP domains of four mammalian proteins (Golgin-97, Golgin-245, 
GCC1 and KIAA0336) are able to mediate their Golgi targeting by a saturable 
mechanism, and mutations of some conserved residues were observed to abolish their 
Golgi targeting (Munro and Nichols, 1999; Kjer-Nielsen et al., 1999; Barr, 1999).  As 
shown in Fig 28, the GRIP domain is a conserved region of about 50 amino acids.  
Some residues are conserved in the GRIP domains of all four mammalian proteins 
and their putative fly counterparts, such as, in Golgin-97, Glu 696, Tyr 697, Leu 698, 
positive charged amino acids (Lys or Arg) at 699, aromatic amino acids (Phe or Tyr) 
at 705, hydrophobic amino acids (Leu, Ile, Val or Met) at 706, 720, 723 and 724 and 
Glu (or Gln) at 730.  The conservation of these residues suggests their importance for 











Fig 28 Alignment of the amino acid sequences of four GRIP domains of human 
(prefix h) and Drosophila (prefix d) Golgins defines several conserved residues.  The 
most conserved residues are indicated in red with a yellow background.  The 
intermediate conserved residues are shown in blue under light blue background and 
the residues conserved in only some GRIP domains were highlighted with green 
background.  The positions of point mutations analyzed in this study are indicated 
above the sequence of human Golgin-97.  
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6.4 Conserved amino acids in GRIP domain are essential for their interaction 
with Arl1-GTP 
To sustain the conclusion that the GRIP domains of Golgin-97 and Golgin-245 
interact with Arl1 and to establish the importance of conserved residues of GRIP 
domain in mediating this interaction, four different mutant versions of the Golgin-97 
GRIP domain were constructed.  The conserved residues E696, Y697, and K699 of 
Golgin-97 in the GRIP domain were replaced by Ala in E696A, Y697A, and K699A, 
respectively.  As a negative control, the non-conserved residue Q728 of Golgin-97 
was replaced by Ala in Q728A.  As shown in Fig 29A and B, individual mutations of 
conserved Y697 or K699 abolished interaction with Arl1Q71L, while mutation of the 
conserved E696 and the non-conserved Q728 did not affect its interaction with 
Arl1Q71L.  These results firmly established the importance of two key conserved 
residues of Golgin-97 GRIP domain in mediating interaction with GTP-restricted 
form of Arl1.  Furthermore, there is a strong correlation between interaction with Arl1 
and Golgi targeting for these mutants (Fig 29C).  The Arl1-interacting E696A and 
Q728A were targeted to the Golgi apparatus, while the Arl1 non-interacting Y697A 
and K699A were distributed in the cytosol and/or nucleus.  This correlation suggests 
that interaction with GTP-restricted Arl1 is probably necessary for the GRIP domains 
to mediate Golgi targeting. 
 
6.5 The switch II (SWII) region of Arl1 interacts with the GRIP domain 
Since both Arl1 and ARF1 share significant sequence homology as well as a common 
effector (POR1) and only Arl1 interacts specifically with the GRIP domains of 
Golgin-97 and Golgin-245, it is therefore of great interest to define the structural basis 






Fig 29 Conserved residues of the 
GRIP domain are important for 
interaction with Arl1 as well as for 
Golgi targeting.  (A), Interaction of 
various mutant forms of the Golgin-
97 GRIP domain with Arl1Q71L as 
analyzed by ONPG β-galactosidase 
assay using yeast two-hybrid.  (B),  
Interaction of various mutant forms 
of the Golgin-97 GRIP domain with 
Arl1Q71L as analyzed by cell 
growth in yeast two-hybrid assay.  
(C),  The indicated mutant forms of 
Golgin-97 GRIP domain tagged 
with EGFP were expressed in 
transfected NRK cells (upper row) 
and co-labeled with antibody 
against GM130 (Texas Red, middle 
row).  There exists a strong 
correlation between the interaction 
with Arl1Q71L and the Golgi 
targeting of these mutant GRIP 
domains.  Bar, 10µm. 
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fly, worm and budding yeast with ARF1 of rat and budding yeast revealed that there 
are some residues that are selectively conserved in all Arl1 proteins but not in ARF1, 
including Q38, K62, T72, S73, Y77, C80, A87, D98, S159 and K162 (Fig 30).  These 
differently conserved residues could contribute to Arl1 and ARF1’s differential 
interaction with GRIP domains. 
 
A chimeric protein, ARF1Q71L(1-92)Arl1(93-181), consisting of the N-terminal 
portion (residue 1-92) of ARF1Q71L followed by the C-terminal region (residue 93-
181) of Arl1, was first constructed.  This chimeric protein failed to interact with GRIP 
domains of Golgin-97 and Golgin-245, although normal interaction with POR1 was 
observed (Fig 31), suggesting that the region between residue 1 and 92 of Arl1 is 
important for its unique ability to interact with GRIP domains.  Since the majority of 
Arl1-conserved residues (T72, S73, Y77, C80, and A87) are located in the switch II 
region of Arl1, and the switch II region of small GTPases is known to participate in 
interactions with specific effectors, these residues in the switch II region were 
investigated.  Replacement of each of these residues in the switch II region 
individually by the corresponding residue in ARF1 (Q71L-T72D, Q71L-S73K; Q71L-
Y77L, and Q71L-A87G) did not affect interaction with GRIP domains, although 
Q71L-C80H significantly reduced its interacting capacity with the GRIP domain of 
Golgin-245.  These results suggest that individual residues may not be responsible for 
the observed specific interaction of Arl1 with the GRIP domains.  In this regard, 
another mutant version of Arl1 (Arl1SIIm) was created so that the entire switch II 
region (residues 67-86) of Arl1Q71L was replaced by that of ARF1Q71L.  As shown 
in Fig 31, Arl1SIIm failed to interact with the GRIP domain of Golgin-97 and Golgin-
245, although interaction with POR1 was still observed.  Conversely, when the switch 
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II region (residues 67-86) of ARF1Q71L was replaced by that of Arl1Q71L, the 
chimeric ARF1 (ARF1SIIm) showed interaction with the GRIP domain of Golgin-97 
and Golgin-245.  Taken together, these results suggest that the collective/concerted 
action of Arl1-specific residues in the switch II region is important for Arl1-specific 





















Fig 30 Alignment of N-terminal 93 residues of rat Arl1 with the corresponding 
regions of Arl1 and ARF1 of other species.  Identical residues are colored red.  
Residues conserved in 4 out of the 6 proteins were highlighted with a green 
background.  The point mutants of Arl1Q71L are indicated above.  The switch II 
















Fig 31 The switch II region of Arl1 is necessary for its interaction with GRIP 
domains. The various Arl1Q71L mutants were tested for interaction with the GRIP 




6.6 Generation of Golgin-97 polyclonal antibody 
To facilitate cellular and biochemical research of Golgin-97, rabbit polyclonal 
antibody against human Golgin-97 was generated using part of its central coiled-coil 
region (from position 334 to 666) as the immunogen (Fig 32A).  The crude serum 
collected after the fifth injection were first absorbed with excess amount of 
recombinant GST coupled to glutathione beads and subsequently affinity purified by 
recombinant antigen covalently linked to glutathione beads.  The purified Golgin-97 
polyclonal antibody detected a single band at around 100 kD molecular weight in 
HeLa lysate but not in equivalent amount of NRK cell lysate (Fig 32B), suggesting 
the polyclonal antibody is human specific.  This polyclonal antibody could efficiently 
immunoprecipitate an endogenous protein of around 100 kD from 293T cell lysate, 
which could be detected by a commercial Golgin-97 monoclonal antibody (lane 3, Fig 
32C).  Under the same condition, that monoclonal antibody did not pick up any signal 
in control rabbit IgG immunoprecipitate (lane 2, Fig 32C).  In indirect 
immunofluorescent staining of HeLa cells, the polyclonal antibody revealed a 
perinuclear staining which was colocalized well with the trans-Golgi marker Golgin-
97 (data not shown) and Golgin-245 (Fig 33).  These experiments suggest that the 
generated polyclonal antibody is specific to human Golgin-97. 
 
6.7 Golgin-97 is localized to the trans side of the Golgi apparatus or TGN 
The detailed localization of endogenous Golgin-97 has not been reported, although it 
was known as a Golgi protein (Griffith et al., 1997).  In the immunofluorescent 
staining of HeLa cells (Fig 33), endogenous Golgin-97 positive structures were 











Fig 32 Generation and characterization of Golgin-97 polyclonal antibody. (A), The 
central part of coiled-coil region of Golgin-97 was chosen as the antigen for 
raising antibody. (B), The purified polyclonal antibody recognized a single band of 
about 100 kd in HeLa lysate (lane 1), but not in NRK lyste (lane 2), suggesting the 
antibody is human specific. (C), Immunoprecipitation in 293T cell RIPA lysate 
using Golgin-97 polyclonal antibody (lane 3) or control rabbit IgG (lane 2), 
followed by detection with Golgin-97 monoclonal antibody.  Compare with the 
loading (lane 1), Golgin-97 polyclonal antibody quantitatively pulled down 



















Fig 33 Endogenous Golgin-97 is localized to the trans side of the Golgi or TGN. 
Endogenous Golgin-97 (FITC, B and E), revealed by its polyclonal antibody, showed 
good overlapping with Golgin-245 (Rhodamine, D) but not with cis-Golgi marker, 
GM130 (Rhodamine, A). 
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C).  On the other hand, Golgin-97 staining overlaps well with that of Golgin-245 
(panel D-F), a trans-Golgi or TGN maker (Gleeson et al., 1996), suggesting that 
Golgin-97 resides on the trans side of Golgi or TGN.  Thus, Arl1, Golgin-97 and 
Golgin-245 are all localized to the trans side of Golgi or TGN. 
 
6.8 The concerted Golgi dissociation kinetics of Arl1, Golgin-97 and Golgin-245 
upon BFA treatment 
In contrast to Golgi ARFs and components of COPI, which dissociate from the Golgi 
apparatus within 2 min of BFA treatment, Arl1 remains associated with the Golgi 
apparatus even after 5 min of treatment (Lowe et al., 1996).  In order to gain 
additional understanding about the potential role of Arl1-GRIP domain interaction in 
mediating Golgi association of Golgin-97 and Golgin-245, the kinetics of BFA-
induced dissociation of Arl1 and Golgin-97 was compared.  As shown in Fig 34, Arl1 
was colocalized with Golgin-97 (panel A-C).  Both Arl1 and Golgin-97 remained 
Golgi-associated after 5 min of BFA treatment (panel D-F).  After 10 min treatment, 
Arl1 was dissociated from only a subpopulation of the cells (panel G-I).  Most 
intriguingly, it was observed that Golgin-97 remained Golgi-associated in cells that 
still have Arl1 in the Golgi apparatus, while Golgin-97 was dissociated from the Golgi 
apparatus in cells whose Arl1 has also been dissociated into the cytosol (panel G-I).  
As a control, ARFs (as detected by Mab 1D9) were essentially dissociated in cells that 
still have intact Golgi labeling of Arl1 after 5 min of BFA treatment (panel M-R).  A 
similar parallel response of Golgin-245 and Arl1 to BFA treatment was also observed 
(data not shown).  The similar kinetics of Golgi dissociation of Golgin-97 and Arl1 in 
response to BFA treatment suggests that Golgi association of these two proteins are 




























Fig 34 Golgi dissociation of Golgin-97 and Arl1 are temporally coupled in response to BFA 
treatment.  HeLa cells were treated with 10 µg/ml of BFA for 0 min (A-C and M-O), 5 min 
(D-F and P-R), 10 min (G-I) and 30 min (J-L).  Cells were then processed for double-
labeling using Arl1 antibody (A, D, G, and J) and Golgin-97 Mab (B, E, H and K), or 




GRIP domain important for Arl1 interaction are crucial for GRIP-domain mediated 
Golgi targeting, it is tempting to suggest that interaction with activated Arl1 is an 
underlying mechanism for GRIP domain-driven Golgi recruitment. 
 
6.9 Arl1-GTP recruits Golgin-97 and Golgin-245 to the Golgi apparatus, while 
Arl1-GDP dissociates them from the Golgi 
To directly examine whether Arl1 plays a role in the recruitment of Golgin-97 onto 
the Golgi, a gain-of-function approach was first used (Fig 35).  As shown, when 
Arl1Q71L was over expressed in transfected cells, it was massively recruited onto the 
Golgi apparatus as described previously (panel A) (see Chapter 4.6).  Interestingly, 
massive recruitment onto the Golgi apparatus was similarly observed for Golgin-97 
(panel B), suggesting that Arl1 could effect a recruitment of Golgin-97 onto the Golgi 
membrane.  Furthermore, the recruited Arl1Q71L and Golgin-97 became resistant to 
BFA treatment (panels D-F).  Although Arl1SIIm was recruited onto the Golgi 
apparatus in transfected cells (panel G), it exhibited no effect on recruitment of 
Golgin-97 (panel H).  In fact, the amount of Golgi-associated Golgin-97 was reduced 
by the expression of Arl1SIIm, probably due to a competition of Arl1SIIm with 
endogenous Arl1 for regulatory factors.  This result suggests that the switch II region 
of Arl1 is not only important for interaction with GRIP domains but also essential for 
Arl1-mediated Golgi recruitment of Golgin-97.  Similar recruiting effects by Arl1-
GTP were also observed for Golgin-245 (data not shown). 
 
On the other hand, in cells expressing GDP-restricted Arl1 (Arl1T31N) (Fig 36), both 





























Fig 35 GTP-restricted Arl1 recruits Golgin-97 onto the Golgi apparatus in a switch II 
region-dependent manner.  A431 cells were transiently transfected with expressing 
plasmid for Arl1Q71L (A-F) or Arl1SIIm (G-L).  The resulting cells were either not 
treated (A-C and G-L) or treated with 10 µg/ml BFA for 60 min (D-F) and then 
processed for double-labeling using a limiting amount of Arl1 antibody that 
selectively detect over expressed protein (A, D, G and J) and Mab against Golgin-97 



























Fig 36 GDP-restricted Arl1T31N abolishes Golgi association of Golgin-97 and 
Golgin-245 but not GM130 and p115.  Arl1T31N was expressed transiently in A431 
cells.  Cells were then processed for the double-labeling with a limiting amount of 
Arl1 antibody (A, D, G and J) and Mab against Golgin-97 (B), Golgin-245 (E), 
GM130 (H), or p115 (K).  Bar, 10µm. 
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(panel H) and p115 (panel K) remained on the Golgi structure.  These results 
strengthen the notion that Arl1-mediated interaction with the GRIP domain of Golgin-
97 and Golgin-245 could be responsible for Golgi recruitment of Golgin-97 and 
Golgin-245. 
 
6.11 Golgin-97 and Golgin-245 translocate to endosomes upon artificially 
tethering active Arl1 to the endosome 
To directly examine whether Arl1 plays a sufficient and decisive role in mediating 
membrane recruitment of Golgin-97, two chimeric proteins  [Myc-SNX3-
Arl1(Q71L)] and [Myc-SNX3-ARF1(Q71L)] were engineered so that they could be 
targeted to the early and recycling endosome compartment by their fused SNX3 PX 
domains (Xu et al., 2001).  As shown in Fig 37, myc-SNX3 was delivered to the 
spotty endosomes (panel A), while Golgin-97 was detected in the Golgi apparatus 
(panel B).  Both Myc-SNX3-Arl1(Q71L) (panel D) and Myc-SNX3-ARF1(Q71L) 
(panel G) were delivered to dotty endosomes.  Interestingly, in these cells, a 
significant amount of Golgin-97 was redistributed onto the endosomal structures 
marked by Myc-SNX3-Arl1(Q71L) (panels D-F for x-y confocal section and panels 
D’-F’ for an indicated x-z section), establishing that activated Arl1 residing at 
endosomes could mediate recruitment of Golgin-97 onto this non-residential new 
compartment.  However, endosomal-targeted Myc-SNX3-ARF1(Q71L) (panels G-I 
for x-y section and G’-I’ for an defined x-z section) did not change the Golgi 































Fig 37 Ectopic targeting of Arl1Q71L but not ARF1Q71L onto endosomes results in 
selective recruitment of Golgin-97 onto the endosomal membrane.  A431 cells were 
transiently transfected with expressing construct for Myc-SNX3 (A-C), Myc-SNX3-
Arl1Q71L (D-F’, J-R) or Myc-SNX3-ARF1Q71L (G-I’).  Cells were double-labeled 
with antibody against Myc to reveal the exogenously expressed SNX3 or its fusion 
proteins and antibodies against Golgin-97 (B, E, E’, H, and H’), p115 (K), GT (N and 
N’) or β-COP (Q).  Images D’-F’, G’-I’ and M’-O’ are the indicated x-z sections of 
the x-y images of D-F, G-I and M-O, respectively.  Bar, 10µm. 
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There is a possibility that in cells with the expression of Myc-SNX3-Arl1(Q71L), the 
Golgi apparatus may fuse with the endosomal compartment, thus resulting in the 
observed colocalization of Golgin-97 and Golgin-245 with Myc-SNX3-Arl1(Q71L).   
The image in panel K demonstrated that the cis-Golgi, which was marked by p115, 
did not colocalize with Myc-SNX3-Arl1(Q71L).  Furthermore, the trans-Golgi 
residential membrane marker GT did not colocalize with myc-SNX3-Arl1(Q71L) 
(panel N) either.  Thus these two markers demonstrated that the cotranslocation of 
Golgin-97 and Golgin-245 onto endosomes was due to the recruitment by the active 
Arl1, which was artificially located to endosomal compartment by its fused PX 
domain.   Collectively, these data suggest that Arl1, but not its close homolog ARF1, 
has a decisive and direct role in membrane recruitment of GRIP Golgins, such as 
Golgin-97 and Golgin-245, onto membranes. 
 
Interestingly, the Golgi apparatus marked by p115 (panel K), GT (panel N), and β-
COP (panel Q) was fragmented in cells expressing Myc-SNX3-Arl1(Q71L).  The 
mis-targeting of Arl1 effectors to the endosomes could be the molecular basis for the 
observed Golgi fragmentation upon Myc-SNX3-Arl1(Q71L) expression, implying an 
essential role of Arl1 effectors in maintaining an intact Golgi structure. 
 
6.12 Knocking down of Arl1 dissociated Golgin-97 and Golgin-245 from the 
Golgi apparatus but not vice versa 
To provide complementary evidence for a role of Arl1 in recruiting Golgin-97 and 
Golgin-245 onto the Golgi apparatus, a loss-of-function approach by employing the 
21 bp duplex small interfering RNA (siRNA) technique was used (Elbashir et al., 




























Fig 38 Knocking down of Arl1 levels by its siRNA dissociates Golgin-97 and Golgin-
245 from the Golgi apparatus.  (a), HeLa cells were transfected with the indicated 
siRNA.  After 48 hours, the total cell lysates were subjected to SDS-PAGE and 
immunoblotting analysis to detect Arl1 and β-tubulin.  (b), HeLa cells were 
transfected with Arl1 siRNA (D-F and  J-O) or control siRNA (A-C and G-I).   After 
48 hrs, cells were double-labeled with Arl1 antibody (E6P3) (A, D, G, J and M)) and 






Golgi association of both Golgin-97 and Golgin-245.  As revealed in Fig 38a, Arl1 
level was specifically reduced in the entire population of cells transfected with Arl1 
siRNA, while the cellular levels of both Golgin-97 and Golign-245 remained 
unchanged (data not shown).  When analyzed by indirect immunofluorescence 
microscopy, siRNA of Arl1 had a spectrum of knock down effects, ranging from 
reduced levels of Arl1 in some cells to undetectable levels of Arl1 in others.  This 
variability provided a useful internal control on the effect of Arl1 knockdown.  As 
shown in Fig 38b, Golgin-97 (panels D-F) and Golgin-245 (panels J-L) became 
dissociated from the Golgi into the cytosol in cells with no detectable Arl1.  However, 
reduced levels of Golgin-97 and Golgin-245 were clearly detected in the Golgi of 
cells with also reduced but detectable Golgi Arl1.  The knocking down of endogenous 
Arl1 did not disassemble the Golgi apparatus since the morphological distribution of 
the cis and trans Golgi markers, such as GM130, β-COP, GT and γ-adaptin, was 
normal in these cells (data not shown).  In contrast to Golgin-97 and Golgin-245, 
GM130 (panels M-O), another member of the Golgin family which does not contain a 
GRIP domain, was not dissociated into the cytosol but remained associated with the 
Golgi apparatus in cells with no detectable levels of Arl1.  On the other hand, when 
the cellular level of Golgin-97 was knocked down using the same approach, 
endogenous Arl1 was still associated with Golgi apparatus (data not shown).  These 
results suggest that Arl1 is specifically required for Golgi association of Golgin-97 
and Golgin-245 but not vice versa. 
 
6.13 Discussion 
The experiments described in this chapter attempted to address two important 
biological questions.  The first relates to the cellular function and molecular 
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mechanism of Arl1 action, while the second focuses on the molecular mechanism 
underlying the process of GRIP domain-mediated Golgi targeting of autoantigens 
Golgin-97 and Golgin-245.  Results suggested that Golgin-97 and Golgin-245 are 
probably downstream effectors of Arl1, based on several lines of evidence.  First, 
Golgin-97 and Golgin-245 uncovered by yeast two-hybrid screens using GTP-
restricted form of Arl1 were shown to interact with Arl1 through their GRIP domains, 
which were previously shown to mediate their Golgi targeting (Barr, 1999; Munro 
and Nichols, 1999; Kjer-Nielsen et al., 1999).  Secondly, the importance of the GRIP 
domain in mediating interaction with Arl1 was further established by the experiment 
that mutation of two conserved residues (Y697 and K699) of the GRIP domain of 
Golgin-97 abolished this interaction, suggesting that Arl1 interacts with the intact 
GRIP domains.  Since these two mutations also abolished the Golgi targeting property 
of the GRIP domain, it seems that Golgi targeting of Golgin-97 (and probably Golgin-
245 as they share the same conserved residues) is mediated through direct interaction 
of its GRIP domain with activated form of Arl1.  Thirdly, the specificity of Arl1 
interaction with GRIP domains is strengthened by the fact that its homologous Golgi-
localized ARF1 did not interact with GRIP domains.  Mutagenesis studies described 
in 6.5 uncovered the importance of switch II region in conferring this unique ability to 
Arl1.  Since GRIP domains interact specifically with GTP-restricted form of Arl1, 
interaction with GRIP domains of Golgins would be triggered by guanine nucleotide 
exchange of GDP for GTP of Arl1.  Finally, the biological relevance of GRIP 
domain-Arl1 interaction was underscored by the observation that Arl1 interacted with 
intact cellular Golgin-97 and Golgin-245 and this interaction is similarly dependent 
on GTP-restricted status of Arl1.  Furthermore, co-immunoprecipitation of 
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endogenous Golgin-245 with transiently expressed Arl1 in a GTP-restricted manner 
provides strong support that Golgi-245 and Arl1 can interact in intact cells. 
 
The physiological relevance/function of the interaction of GRIP domains with Arl1 
was further demonstrated by several experiments described in Chapter 6.8-6.12.  
Firstly, as various proteins of the Golgi apparatus and endosomal pathway respond 
differently to BFA treatment in mammalian cells (Klausner et al., 1992), the kinetics 
of Arl1, Golgin-97 and Golgin-245 redistribution during BFA treatment was 
compared and found to have an unique concerted dissociation kinetics.  Unlike ARF1 
and COPI components which are dissociated from the Golgi apparatus even within 2 
min of BFA treatment (Klausner et al., 1992); Arl1, Golgin-97 and Golgin-245 
remain Golgi-associated after 5 min of BFA treatment.  After 10 min of treatment, 
Arl1, Golgin-97 and Golgin-245 were found dissociated from the Golgi in only some 
cells.  Remarkably, there is a perfect correlation between the distribution of Arl1 and 
that of Golgin-97 and Golgin-245 in response to BFA.  This heterogeneity of cellular 
response to BFA at 10 min of treatment and the identical behavior of Arl1, Golgin-97 
and Golgin-245 within the heterogeneous population provide sound evidence for a 
concerted kinetics of Golgi association / dissociation of these proteins.  Secondly, 
mutations of conserved residues in the GRIP domain of Golgin-97 not only abolished 
interaction with Arl1, but also abrogated their ability to mediate Golgi targeting, 
suggesting that interaction with Arl1 is probably necessary for GRIP domain to 
mediate Golgi targeting.  Thirdly, over expression of Arl1Q71L elicited a massive 
recruitment of Golgin-97 onto the Golgi, suggesting that GTP-restricted Arl1 could 
mediate Golgi recruitment of Golgin-97.  Since this effect depends on switch II region 
of Arl1, it is likely that the observed recruitment is a result of a direct interaction 
  
140
between Arl1Q71L and the GRIP domain.  In support of this view, over expression of 
GDP-restricted form of Arl1 was observed to result in redistribution of Golgin-97 and 
Golgin-245 into the cytosol, while two other Golgins GM130 and p115 that do not 
contain the GRIP domain remained associated with Golgi-like structure.  Fourthly, 
Arl1 was shown to play a direct and decisive role in membrane recruitment of Golgin-
97 and Golgin-245.  When Arl1(Q71L) but not ARF1(Q71L) was ectopically targeted 
to the endosomes by linking to SNX3, a significant amount of Golgin-97, but not 
p115, GT or β-COP, was mis-targeted to the endosomes.  Furthermore, over 
expression of Myc-SNX3-Arl1(Q71L) also caused fragmentation of the Golgi 
apparatus, probably due to mis-targeting of most putative effectors of this small 
GTPase to the endosomes.  Finally, a loss-of-function approach has revealed an 
essential role of endogenous Arl1 in mediating Golgi targeting of Golgin-97 and 
Golgin-245, as revealed by data obtained from siRNA-mediated knock down of Arl1 
that had resulted in selective dissociation of Golgin-97 and Golgin-245 into the 
cytosol, while Golgi association of GM130 was not affected.  These results 
collectively suggest that one of Arl1’s cellular functions is to mediate Golgi targeting 
of Golgin-97 and Golgin-245, a process that is linked tightly to Arl1’s guanine 
nucleotide exchange-driven interaction with the GRIP domains. 
 
Contrary to the multiple effects of over expression of Arl1 mutants, such as coat 
protein recruitment for active Arl1 and Golgi disassembly for negative Arl1, knocking 
down of Arl1 did not significantly affect the morphology of Golgi apparatus as 
assessed by various Golgi markers, such as GM130, β-COP, GT and γ-adaptin.  One 
possible explanation is that the residual amount of Arl1 in knock down cells is 
sufficient to maintain the normal morphology of Golgi complex.  In fact, careful 
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examination revealed the existence residual amount of Arl1 in the perinulcear region 
even in the most significant knock down cells.  To overcome this problem, a 
screening of siRNA oligos could be necessary to search for a siRNA oligo which can 





Conclusion and future perspectives 
 
The research described in this thesis attempts to characterize and define the cellular 
roles of the small GTPase  Arl1.  The cellular characterization of Arl1 showed that 
it is very similar to its close homolog ARF1 in the following ways. 
1. Both have an average cellular abundance of about 10-4 to 10-5 of total cellular 
proteins. 
2. Both are localized to the Golgi apparatus. 
3. While the GDP restricted mutant forms of both disrupt, the GTP restricted 
mutant forms of both increase Golgi association of coat proteins, such as AP-1 
and COPI coat proteins. 
4. The GTP restricted mutants of both Arl1 and ARF1 transform the Golgi 
apparatus into an extensive vesicular-tubular structure and the normal 
secretory functions of Golgi are impaired. 
5. Both share a common set of effectors including POR1, MKLP1 and PLD. 
 
Yet, Arl1 is different from ARF1 in at least two other aspects: 
1. The Golgi association of Arl1 is much less sensitive to BFA treatment than 
that of ARF1. 
2. Arl1, but not ARF1, interacts with the GRIP domain Golgins and pericentrin. 
 
The observations listed above indicate that similar to ARF1, Arl1 is a regulator of 
Golgi structure and function.  The similarities found between Arl1 and ARF1 are 
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surprising, for Arl1 was long believed to behave differently from ARFs (Tamkun et 
al., 1991; Pacheco-Rodriguez et al., 1999).  However, Arl1 is the only member of 
Arls that is Golgi localized and most identical to ARFs in its primary sequence.  The 
findings thus suggest that Arl1 could be classified as a member of a new class of 
ARFs – class IV ARFs.  Nonetheless, Arl1 is apparently not a redundant small 
GTPase of ARF1 (in yeast, ARF1p and ARF2p are redundant).  The different Golgi 
dissociation kinetics from ARF1 upon BFA treatment suggests that Arl1 could be 
regulated by different GEF(s), which is (are) less sensitive to BFA.  Furthermore, 
Arl1 has specific effectors, implying that Arl1 possesses cellular functions distinct 
from ARF1. 
 
The detailed cellular and biochemical study of Arl1 and GRIP domain containing 
Golgins established a molecular mechanism of Arl1’s action – to interact and recruit 
GRIP domain containing Golgins on to Golgi membrane.  The finding defined the 
GRIP domain as an Arl1-GTP interacting domain and implied that the function of 
Arl1 on Golgi apparatus could be exerted by these Golgins, which are believed to 
function as Golgi matrix or tethering molecules.  The elucidation of the cellular 
functions of GRIP domain Golgins would therefore greatly help in understanding the 
cellular functions of Arl1. 
 
It should be noted that the cellular functions of GRIP Golgins were not explored in 
this study.  At this moment, there are only limited reports about GRIP domain Golgins 
and their cellular functions are still not known (Fritzler et al., 1995; Griffith et al., 
1997; Barr, 1999; Barr, 1999; Munro and Nichols, 1999; Kjer-Nielsen et al., 1999a; 
Kjer-Nielsen et al., 1999b; Setty et al., 2003; Panic et al., 2003).  In yeast, there is 
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only one GRIP domain containing Golgin — Imh1p (Munro and Nichols, 1999; Kjer-
Nielsen et al., 1999; Barr, 1999).  Imh1p was reported to interact with the 
Ric1p/Rgp1p complex (Siniossoglou et al., 2000) and Ypt6p (Li and Warner, 1996; 
Siniossoglou et al., 2000) genetically.  Ypt6p is the yeast homolog of mammalian 
Rab6 GTPase and was shown to regulate retrograde membrane trafficking from 
endosome to late Golgi in yeast (Tsukada and Gallwitz, 1996; Tsukada et al., 1999; 
Siniossoglou and Pelham, 2001; Bensen et al., 2001; Luo and Gallwitz, 2003).  Ric1p 
and Rgp1p form a complex which was shown to catalyze guanine nucleotide 
exchange of Ypt6p (Siniossoglou et al., 2000).  Recent studies in yeast also suggested 
a link of Arl1p to retrograde membrane trafficking from endosome to late Golgi.  
Over expression of Arl1p rescued the temperature sensitive growth defect of ric1∆ or 
ypt6∆ yeast (Bensen et al., 2001).  Jochum et al. (2002) reported that Arl1p 
genetically interacted with Ysl2p, the deletion of which caused the endosomal 
trafficking defects.  Furthermore, GARP (Golgi associated retrograde protein 
complex) or Vps51p/52p/53p/54p complex was found to bind to immobilized 
recombinant Arl1p-GTP (Panic et al., 2003).  Studies suggested that the GARP 
complex is a tethering factor which is required for two distinct retrograde transport 
pathways, from early or late endosome to late Golgi (Conibear et al., 2003).  It was 
reported that the deletion of Arl1p or Arl3p results in mis-sorting of carboxypeptidase 
Y (CPY) (Bonangelino et al., 2002).  Collectively, the data mentioned above suggest 
that both Arl1p and Imh1p could function in endosome to late Golgi retrograde 
membrane trafficking pathway.  The mechanism is possibly well conserved in 
mammalian cells and thus both Arl1 and GRIP domain containing Golgins (Golgin-
97, Golgin-245, GCC1 and KIAA0336) could participate in the endosome to TGN 
(equivalent to late Golgi in yeast) trafficking.  It is possible to test this hypothesis in 
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yeast by tracking the localization of Snc1p, Snc2p, Vps10p or Kex2p in Arl1 or Imh1 
deletion yeast cells.  Yeast SNAREs Snc1p and Snc2p are mainly plasma membrane 
localized, and Vps10p and Kex2p are Golgi localized at steady state (Bryant et al., 
1997; Cooper at al., 1996; Lewis et al., 2000).  Snc1p and Snc2p cycle between the 
plasma membrane and the Golgi apparatus via early endosome to late Golgi pathway.  
Vps10p and Kex2p cycle between PVC (pre-vacuolar compartment, equivalent to late 
endosome in mammalian cells) and late Golgi.  A shift in their localization from 
Golgi to periphery will indicate a disruption of retrograde trafficking from endosome 
to late Golgi. 
 
The roles played by Arl1 and GRIP Golgins in retrograde trafficking from endosome 
to Golgi could also be tested in the mammalian system using a novel in vitro transport 
assay, which measures the retrograde transport of STxB from endosome to TGN 
(Mallard et al., 2002). 
 
This study indirectly addressed the interaction between Arl1 and the GRIP domain 
using mutagenesis in both Ar1l and GRIP domain.  To gain further insight of this Arl1 
and GRIP interaction at atomic level, it would be essential to solve the X-ray 
crystallographic structure of Arl1-GTP/GRIP complex. 
 
The elucidation of both Arl1/GRIP X-ray crystallographic structure and their role in 
retrograde trafficking from endosome to TGN would greatly contribute to the 








Antoshechkin, I. and Han, M. (2002). The C. elegans evl-20 gene is a homolog of the 
small GTPase ARL2 and regulates cytoskeleton dynamics during cytokinesis and 
morphogenesis. Dev. Cell 2, 579-591. 
 
Barbieri, M.A., Hoffenberg, S., Roberts, R., Mukhopadhyay, A., Pomrehn, A., 
Dickey, B.F. and Stahl, P.D. (1998). Evidence for a symmetrical requirement for 
Rab5-GTP in in vitro endosome-endosome fusion. J. Biol. Chem. 273, 25850-25855. 
 
Barr, F.A. (1999). A novel Rab6-interacting domain defines a family of Golgi-
targeted coiled-coil proteins. Curr. Biol. 9, 381-384. 
 
Benard, V. and Bokoch, G.M. (2002). Assay of Cdc42, Rac, and Rho GTPase 
activation by affinity methods. Methods Enzymol. 345, 349-359. 
 
Bensen, E.S., Yeung, B.G. and Payne, G.S. (2001). Ric1p and the Ypt6p GTPase 
function in a common pathway required for localization of trans-Golgi network 
membrane proteins. Mol. Biol. Cell 12, 13-26. 
 
Bhamidipati, A., Lewis, S.A. and Cowan, N.J. (2000). ADP ribosylation factor-like 
protein 2 (Arl2) regulates the interaction of tubulin-folding cofactor D with native 
tubulin. J. Cell Biol. 149, 1087-1096. 
 
Bobak, D.A., Nightingale, M.S., Murtagh, J.J., Price, S.R., Moss, J. and Vaughan, M. 
(1989). Molecular cloning, characterization, and expression of human ADP-
ribosylation factors: two guanine nucleotide-dependent activators of cholera toxin. 
Proc. Natl. Acad. Sci. 86, 6101-6105. 
 
Boman, A.L., Kuai, J., Zhu, X., Chen, J., Kuriyama, R. and Kahn, R.A. (1999). Arf 
proteins bind to mitotic kinesin-like protein 1 (MKLP1) in a GTP-dependent fashion. 




Bonangelino, C.J., Chavez, E.M. and Bonifacino, J.S. (2002). Genomic screen for 
vacuolar protein sorting genes in Saccharomyces cerevisiae. Mol. Biol. Cell 13, 2486-
2501. 
 
Breiner, M., Schurmann, A., Becker, W. and Joost, H.G. (1996). Cloning of a novel 
member (ARL5) of the ARF-family of Ras-related GTPases. Biochim.Biophys Acta. 
1308, 1-6. 
 
Brown, H.A., Gutowski, S., Moomaw, C.R., Slaughter, C. and Sternweis, P.C. (1993). 
ADP-ribosylation factor, a small GTP-dependent regulatory protein, stimulates 
phospholipase D activity. Cell 75, 1137-1144. 
 
Bryant, N.J., and Stevens, T.H. (1997). Two separate signals act independently to 
localize a yeast late Golgi membrane protein through a combination of retrieval and 
retention. J. Cell Biol. 136, 287-297. 
 
 
Burgering, B.M., Medema, R.H., Maassen, J.A., van de Wetering, M.L., van der Eb,  
A.J., McCormick, F. and Bos, J.L. (1991). Insulin stimulation of gene expression 
mediated by p21ras activation. EMBO J., 10, 1103-1109. 
 
 
Buttitta, L., Tanaka, T.S., Chen, A.E., Ko, M.S. and Fan,C.M. (2003). Microarray 
analysis of somitogenesis reveals novel targets of different WNT signaling pathways 
in the somitic mesoderm. Dev. Biol. 258, 91-104. 
 
Cavenagh, M.M., Breiner, M., Schurmann, A., Rosenwald, A.G., Terui, T., Zhang, C., 
Randazzo, P.A., Adams, M., Joost, H.G. and Kahn, R.A. (1994). ADP-ribosylation 
factor (ARF)-like 3, a new member of the ARF family of GTP-binding proteins 
cloned from human and rat tissues. J. Biol. Chem. 269, 18937-18942. 
 
Cavenagh, M.M., Whitney, J.A., Carroll, K., Zhang, C., Boman, A.L., Rosenwald, 
A.G., Mellman,I. and Kahn, R.A. (1996). Intracellular distribution of Arf proteins in 
mammalian cells. Arf6 is uniquely localized to the plasma membrane. J. Biol. Chem. 
271, 21767-21774. 
 
Chardin, P. and McCormick, F. (1999). Brefeldin A: the advantage of being 




Chavrier, P. and Goud, B. (1999). The role of ARF and Rab GTPases in membrane 
transport. Curr. Opin. Cell Biol. 11, 466-475. 
 
Christoforidis, S. and Zerial, M. (2000). Purification and identification of novel Rab 
effectors using affinity chromatography. Methods 20, 403-410. 
 
Clark, J., Moore, L., Krasinskas, A., Way, J., Battey, J., Tamkun, J. and Kahn,R.A. 
(1993). Selective amplification of additional members of the ADP-ribosylation factor 
(ARF) family: cloning of additional human and Drosophila ARF-like genes. Proc. 
Natl. Acad. Sci. 90, 8952-8956. 
 
Collins, R.N. and Brennwald, P. (2000) GTPases (edited by Hall, A.), Oxford 
University  Press, pp137-175. 
 
 
Conibear, E., Cleck, J.N. and Stevens, T.H. (2003). Vps51p mediates the association 
of the GARP (Vps52/53/54) complex with the late Golgi t-SNARE Tlg1p. Mol. Biol. 
Cell 14, 1610-1623. 
 
Cooper, A.A. and Stevens, T.H. (1996). Vps10p cycles between the late-Golgi and 
prevacuolar compartments in its function as the sorting receptor for multiple yeast 
vacuolar hydrolases. J. Cell Biol. 133, 529-541. 
 
 
Cuvillier, A., Redon, F., Antoine, J.C., Chardin, P., DeVos, T. and Merlin, G. (2000). 
LdARL-3A, a Leishmania promastigote-specific ADP-ribosylation factor-like protein, 
is essential for flagellum integrity. J. Cell. Sci. 113 ( Pt 11), 2065-2074. 
 
D'Souza-Schorey, C., Boshans, R.L., McDonough, M., Stahl, P.D. and Van Aelst, L. 
(1997). A role for POR1, a Rac1-interacting protein, in ARF6-mediated cytoskeletal 
rearrangements. EMBO J. 16, 5445-5454. 
 
Daro, E., Sheff, D., Gomez, M., Kreis, T. and Mellman, I. (1997). Inhibition of 
endosome function in CHO cells bearing a temperature-sensitive defect in the 




Dascher, C. and Balch, W.E. (1994). Dominant inhibitory mutants of ARF1 block 
endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi 
apparatus. J. Biol. Chem. 269, 1437-1448. 
 
de Rooij, J. and Bos, J.L. (1997). Minimal Ras-binding domain of Raf1 can be used as 
an activation-specific probe for Ras. Oncogene 14, 623-625. 
 
Dell'Angelica, E.C., Puertollano, R., Mullins, C., Aguilar, R.C., Vargas, J.D., 
Hartnell, L.M. and Bonifacino,J.S. (2000). GGAs: a family of ADP ribosylation 
factor-binding proteins related to adaptors and associated with the Golgi complex. J. 
Cell Biol. 149, 81-94. 
 
Dictenberg, J.B., Zimmerman, W., Sparks, C.A., Young, A., Vidair, C., Zheng, Y., 
Carrington, W., Fay, F.S. and Doxsey,S.J. (1998). Pericentrin and γ-tubulin form a 
protein complex and are organized into a novel lattice at the centrosome. J. Cell Biol. 
141, 163-174. 
 
Ding, M., Vitale, N., Tsai, S.C., Adamik, R., Moss, J. and Vaughan, M. (1996). 
Characterization of a GTPase-activating protein that stimulates GTP hydrolysis by 
both ADP-ribosylation factor (ARF) and ARF-like proteins. Comparison to the ARD1 
gap domain. J. Biol. Chem. 271, 24005-24009. 
 
Donaldson, J.G., Finazzi, D. and  Klausner, R.D. (1992). Brefeldin A inhibits Golgi 
membrane-catalysed exchange of guanine nucleotide onto ARF protein. Nature 360, 
350-352. 
 
Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl,T. 
(2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature 411, 494-498. 
 
Faundez, V., Horng, J.T. and Kelly, R.B. (1997). ADP ribosylation factor 1 is 
required for synaptic vesicle budding in PC12 cells. J. Cell. Biol. 138, 505-515. 
 
Fleming, J.A., Vega, L.R. and Solomon, F. (2000). Function of tubulin binding 




Fritzler, M.J., Lung, C.C., Hamel, J.C., Griffith, K.J. and Chan, E.K. (1995). 
Molecular characterization of Golgin-245, a novel Golgi complex protein containing a 
granin signature. J. Biol. Chem. 270, 31262-31268. 
 
Gasman, S., Chasserot-Golaz, S., Bader, M.F. and Vitale, N. (2003). Regulation of 
exocytosis in adrenal chromaffin cells: focus on ARF and Rho GTPases. Cell Signal. 
15, 893-899. 
 
Gleeson, P.A., Anderson, T.J., Stow, J.L., Griffiths, G., Toh, B.H. and Matheson, F. 
(1996). p230 is associated with vesicles budding from the trans-Golgi network. J. Cell 
Sci. 109, 2811-2821. 
 
Godi, A., Pertile, P., Meyers, R., Marra, P., Di Tullio, G., Iurisci, C., Luini, A., Corda, 
D. and De Matteis, M.A. (1999). ARF mediates recruitment of PtdIns-4-OH kinase-β 
and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex. Nat. Cell Biol. 1, 
280-287. 
 
Grayson, C., Bartolini, F., Chapple, J.P., Willison, K.R., Bhamidipati, A., Lewis, 
S.A.,  Luthert, P.J., Hardcastle, A.J., Cowan, N.J. and Cheetham, M.E. (2002). 
Localization in the human retina of the X-linked retinitis pigmentosa protein RP2, its 
homologue cofactor C and the RP2 interacting protein Arl3. Hum. Mol. Genet. 11, 
3065-3074. 
 
Griffith, K.J., Chan, E.K., Lung, C.C., Hamel, J.C., Guo, X., Miyachi, K. and Fritzler, 
M.J. (1997). Molecular cloning of a novel 97-kd Golgi complex autoantigen 
associated with Sjogren's syndrome. Arthritis Rheum. 40, 1693-1702. 
 
Gu, F. and Gruenberg, J. (2000). ARF1 regulates pH-dependent COP functions in the 
early endocytic pathway. J. Biol. Chem. 275, 8154-8160. 
 
Hanzal-Bayer, M., Renault, L., Roversi, P., Wittinghofer, A. and Hillig, R.C. (2002). 





Hawadle, M.A., Folarin, N., Martin, R. and Jackson, T.R. (2002). Cytohesins and 
centaurins control subcellular trafficking of macromolecular signaling complexes: 
regulation by phosphoinositides and ADP-ribosylation factors. Biol. Res. 35, 247-265. 
 
Helms, J.B. and Rothman, J.E. (1992). Inhibition by brefeldin A of a Golgi membrane 
enzyme that catalyses exchange of guanine nucleotide bound to ARF. Nature 360, 
352-354. 
 
Hirst, J., Lui, W.W., Bright, N.A., Totty, N., Seaman, M.N. and Robinson,M.S. 
(2000). A family of proteins with γ-adaptin and VHS domains that facilitate 
trafficking between the trans-Golgi network and the vacuole/lysosome. J. Cell Biol. 
149, 67-80. 
 
Hoffenberg, S., Nikolova, L., Pan, J.Y., Daniel, D.S., Wessling-Resnick, M., Knoll, 
B.J. and Dickey, B.F. (1995). Functional and structural interactions of the Rab5 
D136N mutant with xanthine nucleotides. Biochem. Biophys. Res. Commun. 215, 241-
249. 
 
Hong, J.X., Lee, F.J., Patton, W.A., Lin, C.Y., Moss, J. and Vaughan, M. (1998). 
Phospholipid- and GTP-dependent activation of cholera toxin and phospholipase D by 
human ADP-ribosylation factor-like protein 1 (HARL1). J. Biol. Chem. 273, 15872-
15876. 
 
Hong, W. (1996) Protein trafficking along the exocytotic pathway. Speringer-verlag. 
 
 
Huang, C.F., Buu, L.M., Yu, W.L. and Lee, F.J. (1999). Characterization of a novel 
ADP-ribosylation factor-like protein (yARL3) in Saccharomyces cerevisiae. J. Biol. 
Chem. 274, 3819-3827. 
 
 
Ingley, E., Williams, J.H., Walker, C.E., Tsai, S., Colley, S., Sayer, M.S., Tilbrook, 
P.A., Sarna,M., Beaumont, J.G. and Klinken, S.P. (1999). A novel ADP-ribosylation 
like factor (ARL-6), interacts with the protein-conducting channel SEC61β subunit. 
FEBS Lett. 459, 69-74. 
 
Jacobs, S., Schilf, C., Fliegert, F., Koling, S., Weber, Y., Schurmann, A. and Joost, 
H.G. (1999). ADP-ribosylation factor (ARF)-like 4, 6, and 7 represent a subgroup of 
  
152
the ARF family characterization by rapid nucleotide exchange and a nuclear 
localization signal. FEBS Lett. 456, 384-388. 
 
Jacobs, S., Schurmann, A., Becker, W., Bockers, T.M., Copeland, N.G., Jenkins, N.A. 
and Joost, H.G. (1998). The mouse ADP-ribosylation factor-like 4 gene: two separate 
promoters direct specific transcription in tissues and testicular germ cell. Biochem. J. 
335, 259-265. 
 
Kahn, R.A. and Gilman, A.G. (1984). Purification of a protein cofactor required for 
ADP-ribosylation of the stimulatory regulatory component of adenylate cyclase by 
cholera toxin. J. Biol.Chem. 259, 6228-6234. 
 
Kahn, R.A. and Gilman, A.G. (1986). The protein cofactor necessary for ADP-
ribosylation of Gs by cholera toxin is itself a GTP binding protein. J. Biol. Chem. 261, 
7906-7911. 
 
Kahn, R.A., Goddard, C. and Newkirk, M. (1988). Chemical and immunological 
characterization of the 21-kDa ADP-ribosylation factor of adenylate cyclase. J. Biol. 
Chem. 263, 8282-8287. 
 
Kahn, R.A., Kern, F.G., Clark, J., Gelmann, E.P. and Rulka, C. (1991). Human ADP-
ribosylation factors. A functionally conserved family of GTP-binding proteins. J. 
Biol. Chem. 266, 2606-2614. 
 
Kanoh, H., Williger, B.T. and Exton, J.H. (1997). Arfaptin 1, a putative cytosolic 
target protein of ADP-ribosylation factor, is recruited to Golgi membranes. J. Biol. 
Chem. 272, 5421-5429. 
 
Kirchhausen, T. (1999). Adaptors for clathrin-mediated traffic. Annu. Rev. Cell Dev. 
Biol. 15, 705-732. 
 
Kjer-Nielsen, L., Teasdale, R.D., van Vliet, C. and Gleeson, P.A. (1999a). A novel 
Golgi-localisation domain shared by a class of coiled-coil peripheral membrane 




Kjer-Nielsen, L., van Vliet, C., Erlich, R., Toh, B.H. and Gleeson, P.A. (1999b). The 
Golgi-targeting sequence of the peripheral membrane protein p230 
1. J Cell Sci 112 ( Pt 11), 1645-1654. 
 
Klausner, R.D., Donaldson, J.G. and Lippincott-Schwartz, J. (1992). Brefeldin A: 
insights into the control of membrane traffic and organelle structure. J. Cell Biol. 116, 
1071-1080. 
 
Kubota, S., Kobayashi, A., Mori, N., Higashide, T., McLaren, M.J. and Inana, G. 
(2002). Changes in retinal synaptic proteins in the transgenic model expressing a 
mutant HRG4 (UNC119). Invest. Ophthalmol.Vis.Sci. 43, 308-313. 
 
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227, 680-685. 
 
Lee, F.J.S., Huang, C.F., Yu, W.L., Buu, L.M., Lin, C.Y., Huang, M.C. and Moss, J., 
Vaughan,M. (1997). Characterization of an ADP-ribosylation factor-like 1 protein in 
Saccharomyces cerevisiae. J. Biol. Chem. 272, 30998-31005. 
 
Lewis, M.J.,Nichols, B.J., Prescianotto-Baschong, C., Riezman.H. and Pelham,H.R. 
(2000). Specific retrieval of the exocytic SNARE Snc1p from early yeast 
endosomes. Mol. Biol. Cell. 11, 23-38. 
 
Li,B. and Warner, J.R. (1996). Mutation of the Rab6 homologue of Saccharomyces 
cerevisiae, YPT6, inhibits both early Golgi function and ribosome biosynthesis 
1. J. Biol. Chem. 271, 16813-16819. 
 
Lin, C.Y., Huang, P.H., Liao, W.L., Cheng, H.J., Huang, C.F., Kuo, J.C., Patton, 
W.A., Massenburg, D., Moss, J. and Lee,F.J. (2000). ARL4, an ARF-like protein that 
is developmentally regulated and localized to nuclei and nucleoli. J. Biol. Chem. 275, 
37815-37823. 
 
Lin, C.Y., Li, C.C., Huang, P.H. and Lee, F.J. (2002). A developmentally regulated 
ARF-like 5 protein (ARL5), localized to nuclei and nucleoli, interacts with 




Linari, M., Hanzal-Bayer, M. and Becker, J. (1999). The delta subunit of rod specific 
cyclic GMP phosphodiesterase, PDEδ, interacts with the Arf-like protein Arl3 in a 
GTP specific manner. FEBS Lett. 458, 55-59. 
 
Lowe, S.L., Wong, S.H. and Hong, W.J. (1996). The mammalian ARF-like protein 1 
(Arl1) is associated with the Golgi complex. J. Cell Sci. 109, 209-220. 
 
Luo, Z. and Gallwitz, D. (2003). Biochemical and genetic evidence for the 
involvement of yeast Ypt6-GTPase in protein retrieval to different Golgi 
compartments. J. Biol. Chem. 278, 791-799. 
 
Mallard, F., Tang, B.L., Galli, T., Tenza, D., Saint-Pol, A., Yue, X., Antony, C., 
Hong, W., Goud, B. and Johannes, L. (2002). Early/recycling endosomes-to-TGN 
transport involves two SNARE complexes and a Rab6 isoform. J. Cell Biol. 156, 653-
664. 
 
Malsam, J., Gommel, D., Wieland, F.T. and Nickel, W. (1999). A role for ADP 
ribosylation factor in the control of cargo uptake during COPI-coated vesicle 
biogenesis. FEBS Lett. 462, 267-272. 
 
Martin, T.F. (1997). Phosphoinositides as spatial regulators of membrane traffic. 
Curr. Opin. Neurobiol. 7, 331-338. 
 
Mishima, K., Tsuchiya, M., Nightingale, M.S., Moss, J. and Vaughan, M. (1993). 
ARD 1, a 64-kDa guanine nucleotide-binding protein with a carboxyl-terminal ADP-
ribosylation factor domain. J. Biol. Chem. 268, 8801-8807. 
 
Moss, J. and Vaughan, M. (1998). Molecules in the ARF orbit. J. Biol. Chem. 273, 
21431-21434. 
 
Mueller, A.G., Moser, M., Kluge, R., Leder, S., Blum, M., Buttner, R., Joost, H.G. 
and Schurmann, A. (2002). Embryonic lethality caused by apoptosis during 
gastrulation in mice lacking the gene of the ADP-ribosylation factor-related protein 1. 




Munro, S. and Nichols, B.J. (1999). The GRIP domain - a novel Golgi-targeting 
domain found in several coiled-coil proteins. Curr. Biol. 9, 377-380. 
 
Nie, Z., Hirsch, D.S. and Randazzo, P.A. (2003). Arf and its many interactors. Curr. 
Opin. Cell Biol. 15, 396-404. 
 
Norman, J.C., Jones, D., Barry, S.T., Holt, M.R., Cockcroft, S. and Critchley, D.R. 
(1998). ARF1 mediates paxillin recruitment to focal adhesions and potentiates Rho-
stimulated stress fiber formation in intact and permeabilized Swiss 3T3 fibroblasts. J. 
Cell Biol. 143, 1981-1995. 
 
 
Osterop, A.P., Medema, R.H., Bos, J.L., vd Zon, G.C., Moller, D.E., Flier, J.S., 
Moller, W. and Maassen, J.A. (1992). Relation between the insulin receptor number 
in cells, autophosphorylation and insulin-stimulated Ras.GTP formation. J. Biol. 
Chem., 267, 14647-14653. 
 
 
Pacheco-Rodriguez, G., Meacci, E., Vitale, N., Moss, J. and Vaughan, M. (1998). 
Guanine nucleotide exchange on ADP-ribosylation factors catalyzed by cytohesin-1 
and its Sec7 domain. J. Biol. Chem. 273, 26543-26548. 
 
Pacheco-Rodriguez, G., Patton, W.A., Adamik, R., Yoo, H.S., Lee, F.J., Zhang, G.F., 
Moss, J. and Vaughan,M. (1999). Structural elements of ADP-ribosylation factor 1 
required for functional interaction with cytohesin-1. J. Biol. Chem. 274, 12438-12444. 
 
Palmer, D.J., Helms, J.B., Beckers, C.J., Orci, L. and Rothman, J.E. (1993). Binding 
of coatomer to Golgi membranes requires ADP-ribosylation factor. J. Biol. Chem. 
268, 12083-12089. 
 
Panic, B., Whyte, J.R. and Munro, S. (2003). The ARF-like GTPases Arl1p and Arl3p 
Act in a Pathway that Interacts with Vesicle-Tethering Factors at the Golgi Apparatus. 




Pasqualato, S., Renault, L. and Cherfils, J. (2002). Arf, Arl, Arp and Sar proteins: a 
family of GTP-binding proteins with a structural device for 'front-back' 
communication. EMBO Rep. 3, 1035-1041. 
 
Pelham, H.R. and Rothman, J.E. (2000). The debate about transport in the Golgi–two 
sides of the same coin? Cell 102, 713-719. 
 
Pelletier, L., Jokitalo, E. and Warren,G. (2000). The effect of Golgi depletion on 
exocytic transport. Nat. Cell Biol. 2, 840-846. 
 
Peyroche, A., Antonny, B., Robineau, S., Acker, J., Cherfils, J. and Jackson, C.L. 
(1999). Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein 
complex: involvement of specific residues of the Sec7 domain. Mol. Cell. 3, 275-285. 
 
Poussu, A., Lohi, O., Lehto, V.P. (2000). Vear, a novel Golgi-associated protein with 
VHS and γ-adaptin "ear" domains. J. Biol. Chem. 275, 7176-7183. 
 
Puertollano, R., Aguilar, R.C., Gorshkova, I., Crouch, R.J. and Bonifacino, J.S. 
(2001). Sorting of mannose 6-phosphate receptors mediated by the GGAs. Science 
292, 1712-1716. 
 
Radcliffe, P.A., Vardy, L. and Toda, T. (2000). A conserved small GTP-binding 
protein Alp41 is essential for the cofactor-dependent biogenesis of microtubules in 
fission yeast. FEBS Lett. 468, 84-88. 
 
Randazzo, P.A., Nie, Z., Miura, K. and Hsu, V.W. (2000). Molecular aspects of the 
cellular activities of ADP-ribosylation factors. Sci. STKE 2000 RE1. 
 
Randazzo, P.A., Weiss, O. and Kahn, R.A. (1995). Preparation of recombinant ADP-
ribosylation factor. Methods Enzymol. 257, 128-135. 
 
Robinson, M.S. and Kreis, T.E. (1992). Recruitment of coat proteins onto Golgi 
membranes in intact and permeabilized cells: effects of brefeldin A and G protein 




Roth, M.G. (2000) GTPases (edited by Hall, A.), Oxford University Press, pp 176-
197. 
 
Santy, L.C. and Casanova, J.E. (2001). Activation of ARF6 by ARNO stimulates 
epithelial cell migration through downstream activation of both Rac1 and 
phospholipase D. J. Cell Biol. 154, 599-610. 
 
Schurmann, A., Breiner, M., Becker, W., Huppertz, C., Kainulainen, H., Kentrup, H. 
and Joost, H.G. (1994). Cloning of two novel ADP-ribosylation factor-like proteins 
and characterization of their differential expression in 3T3-L1 cells. J. Biol. Chem. 
269, 15683-15688. 
 
Schurmann, A., Koling, S., Jacobs, S., Saftig, P., Krauss, S., Wennemuth, G., Kluge, 
R. and Joost, H.G. (2002). Reduced sperm count and normal fertility in male mice 
with targeted disruption of the ADP-ribosylation factor-like 4 (Arl4) gene. Mol. Cell 
Biol. 22, 2761-2768. 
 
Schurmann, A., Massmann, S. and Joost, H.G. (1995). ARP is a plasma membrane-
associated Ras-related GTPase with remote similarity to the family of ADP-
ribosylation factors. J. Biol. Chem. 270, 30657-30663. 
 
Schurmann, A., Schmidt, M., Asmus, M., Bayer, S., Fliegert, F., Koling, S., 
Massmann, S., Schilf, C., Subauste, M.C., Voss, M., Jakobs, K.H. and Joost, H.G. 
(1999). The ADP-ribosylation factor (ARF)-related GTPase ARF-related protein 
binds to the ARF-specific guanine nucleotide exchange factor cytohesin and inhibits 
the ARF-dependent activation of phospholipase D. J. Biol. Chem. 274, 9744-9751. 
 
Sebald, E., Krueger, R., King, L.M., Cohn, D.H., Krakow, D. (2003). Isolation of a 
new member of the ADP-ribosylation like factor gene family, ARL8, from a cartilage 
cDNA library. Gene 311, 147-151. 
 
Seemann, J., Jokitalo, E., Pypaert, M. and Warren, G. (2000). Matrix proteins can 
generate the higher order architecture of the Golgi apparatus. Nature 407, 1022-1026. 
 
Serafini, T., Orci, L., Amherdt, M., Brunner, M., Kahn, R.A. and Rothman, J.E. 
(1991). ADP-ribosylation factor is a subunit of the coat of Golgi-derived COP-coated 




Setty, S.R., Shin, M.E., Yoshino, A., Marks, M.S. and Burd, C.G. (2003). Golgi 
Recruitment of GRIP Domain Proteins by Arf-like GTPase 1 Is Regulated by Arf-like 
GTPase 3. Curr. Biol. 13, 401-404. 
 
Sewell, J.L. and Kahn, R.A. (1988). Sequences of the bovine and yeast ADP-
ribosylation factor and comparison to other GTP-binding proteins. Proc. Natl. Acad. 
Sci. 85, 4620-4624. 
 
Sharer, J.D. and Kahn, R.A. (1999). The ARF-like 2 (ARL2)-binding protein, BART. 
Purification, cloning, and initial characterization. J. Biol. Chem. 274, 27553-27561. 
 
Sharer, J.D., Shern, J.F., Van Valkenburgh, H., Wallace, D.C. and Kahn, R.A. (2002). 
ARL2 and BART enter mitochondria and bind the adenine nucleotide transporter. 
Mol. Biol. Cell 13, 71-83. 
 
Shiba, T., Kawasaki, M., Takatsu, H., Nogi, T., Matsugaki, N., Igarashi, N., Suzuki, 
M., Kato, R., Nakayama, K. and Wakatsuki, S. (2003). Molecular mechanism of 
membrane recruitment of GGA by ARF in lysosomal protein transport 
1. Nat. Struct.Biol. 10, 386-393. 
 
Shin, O.H. and Exton, J.H. (2001). Differential binding of arfaptin 2/POR1 to ADP-
ribosylation factors and Rac1. Biochem. Biophys. Res. Commun. 285, 1267-1273. 
 
Shinotsuka, C., Yoshida, Y., Kawamoto, K., Takatsu, H. and Nakayama, K. (2002). 
Overexpression of an ADP-ribosylation factor-guanine nucleotide exchange factor, 
BIG2, uncouples brefeldin A-induced adaptor protein-1 coat dissociation and 
membrane tubulation. J. Biol. Chem. 277, 9468-9473. 
 
Simonsen, A., Wurmser, A.E., Emr, S.D. and Stenmark, H. (2001). The role of 
phosphoinositides in membrane transport. Curr. Opin. Cell Biol. 13, 485-492. 
 
Siniossoglou, S., Peak-Chew, S.Y. and Pelham, H.R. (2000). Ric1p and Rgp1p form a 




Siniossoglou, S. and Pelham, H.R. (2001). An effector of Ypt6p binds the SNARE 
Tlg1p and mediates selective fusion of vesicles with late Golgi membranes. EMBO J. 
20, 5991-5998. 
 
Smith, S.A., Holik, P.R., Stevens, J., Melis, R., White, R. and Albertsen, H. (1995). 
Isolation and mapping of a gene encoding a novel human ADP-ribosylation factor on 
chromosome 17q12-q21. Genomics 28, 113-115. 
 
Sprang, S.R. (1997). G protein mechanisms: insights from structural analysis. Annu. 
Rev. Biochem. 66, 639-678. 
 
Stamnes, M.A. and Rothman, J.E. (1993). The binding of AP-1 clathrin adaptor 
particles to Golgi membranes requires ADP-ribosylation factor, a small GTP-binding 
protein. Cell 73, 999-1005. 
 
Stearns, T., Willingham, M.C., Botstein, D. and Kahn, R.A. (1990). ADP-ribosylation 
factor is functionally and physically associated with the Golgi complex. Proc. Natl. 
Acad. Sci. 87, 1238-1242. 
 
Stephens, D.J. and Pepperkok, R. (2001). Illuminating the secretory pathway: when 
do we need vesicles? J. Cell Sci. 114, 1053-1059. 
 
Storrie, B., White, J., Rottger, S., Stelzer, E.H., Suganuma, T. and Nilsson, T. (1998). 
Recycling of golgi-resident glycosyltransferases through the ER reveals a novel 
pathway and provides an explanation for nocodazole-induced Golgi scattering. J. Cell 
Biol. 143, 1505-1521. 
 
Subramaniam, V.N., bin Mohd Yusoff, A.R., Wong, S.H., Lim, G.B., Chew, M. and 
Hong,W. (1992). Biochemical fractionation and characterization of proteins from 
Golgi-enriched membranes. J. Biol. Chem. 267, 12016-12021. 
 
Subramaniam, V.N., Peter, F., Philp, R., Wong, S.H. and Hong, W. (1996). GS28, a 





Takai, Y., Sasaki, T. and Matozaki, T. (2001). Small GTP-binding proteins. Physiol. 
Rev. 81, 153-208. 
 
 
Takeya, R., Takeshige, K. and Sumimoto, H. (2000). Interaction of the PDZ domain 
of human PICK1 with class I ADP-ribosylation factors. Biochem. Biophys. Res. 
Commun. 267, 149-155. 
 
Tamkun, J.W., Kahn, R.A., Kissinger, M., Brizuela, B.J., Rulka, C., Scott and M.P., 
Kennison, J.A. (1991). The arflike gene encodes an essential GTP-binding protein in 
Drosophila. Proc. Natl. Acad. Sci. 88, 3120-3124. 
 
Tang, B.L., Zhang, T., Low, D.Y., Wong, E.T., Horstmann, H. and Hong, W. (2000). 
Mammalian homologues of yeast sec31p. An ubiquitously expressed form is localized 
to endoplasmic reticulum (ER) exit sites and is essential for ER-Golgi transport. J. 
Biol. Chem. 275, 13597-13604. 
 
Tarricone, C., Xiao, B., Justin, N., Walker, P.A., Rittinger, K., Gamblin, S.J. and 
Smerdon, S.J. (2001). The structural basis of Arfaptin-mediated cross-talk between 
Rac and Arf signalling pathways. Nature 411, 215-219. 
 
Tsuchiya, M., Price, S.R., Tsai, S.C., Moss, J. and Vaughan, M. (1991). Molecular 
identification of ADP-ribosylation factor mRNAs and their expression in mammalian 
cells. J. Biol. Chem. 266, 2772-2777. 
 
Tsukada, M. and Gallwitz, D. (1996). Isolation and characterization of SYS genes 
from yeast, multicopy suppressors of the functional loss of the transport GTPase 
Ypt6p. J. Cell Sci. 109, 2471-2481. 
 
Tsukada, M., Will, E. and Gallwitz,D. (1999). Structural and functional analysis of a 
novel coiled-coil protein involved in Ypt6 GTPase-regulated protein transport in 
yeast. Mol. Biol. Cell 10, 63-75. 
 
Tzafrir, I., McElver, J.A., Liu Cm, C.M., Yang, L.J., Wu, J.Q., Martinez, A., Patton, 
D.A. and Meinke,D.W. (2002). Diversity of TITAN functions in Arabidopsis seed 




Van Aelst, L., Joneson, T. and Bar-Sagi, D. (1996). Identification of a novel Rac1-
interacting protein involved in membrane ruffling. EMBO J. 15, 3778-3786. 
 
Van Valkenburgh, H., Shern, J.F., Sharer, J.D., Zhu, X. and Kahn, R.A. (2001). ADP-
ribosylation factors (ARFs) and ARF-like 1 (ARL1) have both specific and shared 
effectors: characterizing ARL1-binding proteins. J. Biol. Chem. 276, 22826-22837. 
 
Vitale, N., Ferrans, V.J., Moss, J. and Vaughan, M. (2000). Identification of 
lysosomal and Golgi localization signals in GAP and ARF domains of ARF domain 
protein 1. Mol. Cell Biol. 20, 7342-7352. 
 
Vitale, N., Horiba, K., Ferrans, V.J., Moss, J. and Vaughan, M. (1998). Localization 
of ADP-ribosylation factor domain protein 1 (ARD1) in lysosomes and Golgi 
apparatus. Proc. Natl. Acad. Sci. 95, 8613-8618. 
 
Vitale, N., Moss, J. and Vaughan, M. (1996). ARD1, a 64-kDa bifunctional protein 
containing an 18-kDa GTP-binding ADP-ribosylation factor domain and a 46-kDa 
GTPase-activating domain. Proc. Natl. Acad. Sci. 93, 1941-1944. 
 
Wittinghofer, A. and Valencia, A. (1995) Three-dimensional structure of Ras and Ras 
related proteins. Guidebook to the small GTPases (edited by Zerial, M., and Huber, 
L.). Oxford University Press. pp 20-29. 
 
 
Xu, Y., Hortsman, H., Seet, L., Wong, S.H. and Hong, W. (2001). SNX3 regulates 
endosomal function through its PX-domain-mediated interaction with PtdIns(3)P. Nat. 
Cell Biol. 3, 658-666. 
 
Yoshihara, Y., Kawasaki, M., Tamada, A., Nagata, S., Kagamiyama, H. and Mori, K. 
(1995). Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: 
four members of an axon-associated cell adhesion molecule subgroup of the 
immunoglobulin superfamily. J. Neurobiol. 28, 51-69. 
 
Zeng, Q., Tan, Y.H. and Hong, W. (1998). A single plasmid vector (pSTAR) 





Zhang, C.J., Rosenwald, A.G., Willingham, M.C., Skuntz, S., Clark, J. and Kahn, 
R.A. (1994). Expression of a dominant allele of human ARF1 inhibits membrane 
traffic in vivo. J. Cell Biol. 124, 289-300. 
 
Zhang, G.F., Patton, W.A., Lee, F.J., Liyanage, M., Han, J.S., Rhee, S.G., Moss, J. 
and Vaughan, M. (1995). Different ARF domains are required for the activation of 
cholera toxin and phospholipase D. J. Biol. Chem. 270, 21-24. 
 
Zhao, L., Helms, J.B., Brugger, B., Harter, C., Martoglio, B., Graf, R., Brunner, J.  
and Wieland, F.T. (1997). Direct and GTP-dependent interaction of ADP ribosylation 
factor 1 with coatomer subunit β. Proc. Natl. Acad. Sci. 94, 4418-4423. 
 
Zhong, J.M., Chen-Hwang, M.C. and Hwang, Y.W. (1995). Switching nucleotide 
specificity of Ha-Ras p21 by a single amino acid substitution at aspartate 119. J. Biol. 
Chem. 270, 10002-10007. 
 
Zhu, X., Boman, A.L., Kuai, J., Cieplak, W. and Kahn, R.A. (2000). Effectors 
increase the affinity of ADP-ribosylation factor for GTP to increase binding. J. Biol. 







Vesicle-mediated transport plays a fundamental role in the
secretory and endocytic pathways and is roughly divided into
three steps: vesicle budding/formation mediated by the coat
protein complex, which is intimately involved in cargo
packaging; vesicle targeting/tethering mediated by specific
tethering factors so that vesicles are delivered to the acceptor
compartment; and vesicle docking and fusion mediated by the
interaction of vesicle-SNARE (v-SNARE) and SNAREs on
the target membrane (t-SNAREs) (Palade, 1975; Rothman
and Wieland, 1996; Schekman and Orci, 1996; Hong, 1998;
Mellman and Warren, 2000; Pelham and Rothman, 2000).
GTPases of the heterotrimeric type, as well as members of
the Ras-like small GTPase superfamily, participate in various
steps of vesicular transport. Among the Ras-like small
GTPase superfamily, the Rab/Ypt1/Sec4 family represents
the largest family and its members are associated with distinct
compartments of the secretory and endocytic pathways
(Zerial and McBride, 2001; Novick and Zerial, 1997;
Chavrier and Goud, 1999; Nuoffer and Balch, 1994;
Schimmoller et al., 1998). The current view is that Rab
proteins participate in targeting/tethering of vesicles to
acceptor compartments through the action of their effectors,
initiating the first layer of interaction between the vesicles
and the target compartment and facilitating SNARE
interactions (Zerial and McBride, 2001; Chavrier and Goud,
1999; Waters and Pfeffer, 1999).
Various GTPases are involved in vesicle formation. Sar1
regulates protein export from the ER mediated by the COPII
coat protein complex (Springer et al., 1999; Aridor et al.,
2001). The ADP ribosylation factor (ARF) family includes six
highly homologous members (Chavrier and Goud, 1999;
Boman and Kahn, 1995; Donaldson and Jackson, 2000; Moss
and Vaughan, 1998). The key regulators such as guanine
nucleotide exchange factors and GTPase-activating proteins
for ARFs have been identified and studied extensively
(Chavrier and Goud, 1999; Donaldson and Jackson, 2000;
Moss and Vaughan, 1998; Jackson and Casanova, 2000). ARFs
were originally identified as cofactors required for cholera-
toxin-catalyzed ADP-ribosylation of the stimulatory
component of adenylate cyclase Gs (Kahn and Gilman, 1984)
and are important for membrane trafficking at several stages of
the exocytotic/endocytotic pathway (Chavrier and Goud, 1999;
Boman and Kahn, 1995; Donaldson and Jackson, 2000; Moss
and Vaughan, 1998; Jackson and Casanova, 2000; Dascher and
Balch, 1994; Zhang et al., 1994). ARF1 regulates COPI vesicle
budding and is a component of the coat in the early secretory
pathway (Serafini et al., 1991; Palmer et al., 1993).
Specifically, ARF1 (in its active GTP-bound form) interacts
directly with the b subunit of coatomer (Zhao et al., 1997) and
also participates in the packaging of cargo proteins into
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Arl1 is a member of the ARF-like protein (Arl) subfamily
of small GTPases. Nothing is known about the function of
Arl1 except for the fact that it is essential for normal
development in Drosophila and that it is associated with the
Golgi apparatus. In this study, we first demonstrate that
Arl1 is enriched at the trans side of the Golgi, marked by
AP-1. Association of Arl1 with the Golgi is saturable in
intact cells and depends on N-terminal myristoylation.
Over-expression of Arl1(T31N), which is expected to be
restricted to the GDP-bound form and thus function as a
dominant-negative mutant, causes the disappearance of the
Golgi apparatus (marked by Golgi SNARE GS28),
suggesting that Arl1 is necessary for maintaining normal
Golgi structure. Overexpression of Arl1(Q71L), a mutant
restricted primarily to the activated GTP-bound form,
causes an expansion of the Golgi apparatus with massive
and stable Golgi association of COPI and AP-1 coats.
Interestingly, Golgi ARFs also become stably associated
with the expanded Golgi. Transport of the envelope protein
of vesicular stomatitis virus (VSV-G) along the secretory
pathway is arrested at the expanded Golgi upon expression
of Arl1(Q71L). The structure of stacked cisternae of the
Golgi is disrupted in cells expressing Arl1(Q71L), resulting
in the transformation of the Golgi into an extensive
vesicule-tubule network. In addition, the GTP form of Arl1
interacts with arfaptin-2/POR1 but not GGA1, both of
which interact with GTP-restricted ARF1, suggesting that
Arl1 and ARF1 share some common effectors in regulating
cellular events. On the basis of these observations, we
propose that one of the mechanisms for the cell to regulate
the structure and function of the Golgi apparatus is
through the action of Arl1.
Key words: GTPase, Vesicular transport, Arl1, Golgi apparatus,
Endoplasmic reticulum
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A cellular role and the mechanism of action for small GTPase Arl1 have been defined. Arl1-GTP
interacts with the GRIP domains of Golgin-97 and Golgin-245, a process dependent on conserved
residues of the GRIP domains that are important for Golgi targeting. The switch II region of Arl1
confers the specificity of this interaction. Arl1-GTP mediates Golgi recruitment of Golgin-97 in a
switch II-dependent manner, whereas tethering Arl1-GTP onto endosomes can mediate endoso-
mal targeting of Golgin-97. Golgin-97 and Golgin-245 are dissociated from the Golgi when Arl1 is
knocked-down by its siRNA. Arl1-GTP thus functions to recruit Golgin-97 and Golgin-245 onto
the Golgi via interacting with their GRIP domains.
INTRODUCTION
Members of the Ras-like small GTPase superfamily partici-
pate in many cellular processes ranging from signal trans-
duction, cell cycle control, membrane traffic, cytoskeleton
organization, transport between cytosol and nucleus, and
development (Boman and Kahn, 1995; Bar-Sagi and Hall,
2000; Aridor et al., 2001; Zerial and McBride, 2001; Hetzer et
al., 2002). ADP ribosylation factors (ARF1–6) and ARF-like
proteins (Arl1–7) consist a unique family of proteins sharing
significant amino acid identities and have been shown to
participate in signaling, membrane traffic, cell motility, and
mitochondria function (Boman and Kahn, 1995; Sharer et al.,
2002). The ARFs are 60% identical to each other and have
been classified into three classes. Class I members consisting
of ARF1, 2, and 3 are mainly associated with the Golgi
apparatus and endosomes and regulate vesicle budding of
several transport events. Class II consists of ARF4 and 5,
whose locations and functions are less well defined. ARF6 is
the only member of class III and has been shown to coordi-
nate actin cytoskeleton with membrane traffic and cell mo-
tility (Turner and Brown, 2001). Arls are 40–60% identical
to each other and to ARFs (Schurmann et al., 1994; Boman
and Kahn, 1995; Lowe et al., 1996; Ingley et al., 1999; Jacobs
et al., 1999). The major differences between Arls and ARFs
are that ARFs but not Arls are able to serve as cofactors in
cholera toxin-catalyzed ADP-ribosylation of Gs, to activate
phospholipase D and to rescue simultaneous deletion of
ARF1 and ARF2 genes in yeast. Among Arls, only Arl1 has
been shown to be associated with the Golgi apparatus (par-
ticularly the trans-side of the Golgi apparatus; Lowe et al.,
1996; Lu et al., 2001). Overexpression of mutant forms of Arl1
affected Golgi structure and function (Lu et al., 2001; Van
Valkenburgh et al., 2001). Drosophila Arl1 plays an essential
role in fly development (Tamkun et al., 1991), whereas Arl4
plays a regulatory role in the development of normal sperm
count and fertility in mice (Schurmann et al., 2002). Other
members of Arls are distributed in the cytosol, mitochon-
dria, and/or nucleus (Schurmann et al., 1994; Boman and
Kahn, 1995; Lowe et al., 1996; Ingley et al., 1999; Jacobs et al.,
1999) and their biological and physiological functions re-
main to be further established.
Golgin-97 and Golgin-245/p230 are two autoantigens
identified by antibodies from patients suffering from
Sjogren’s syndromes and they are enriched in the trans-
Golgi network (TGN; Fritzler et al., 1995; Erlich et al., 1996;
Griffith et al., 1997). Golgin-97, Golgin-245, and other Gol-
gins such as GM130, Golgin-45, p115, and giantin contain
extensive coiled-coil regions. Golgin-97 and Golgin-245 are
targeted to the trans-face of the Golgi by their C-terminal
GRIP domains, an evolutionally conserved motif of 50
amino acids (Barr, 1999; Kjer-Nielsen et al., 1999; Munro and
Nichols, 1999; Brown et al., 2001). Four mammalian proteins
(Golgin-97, Golgin-245, GCC1p, and KIAA0336) contain
GRIP domains (Luke et al., 2002). The molecular mechanism
underlying Golgi targeting by the GRIP domain remains
elusive, although a possible role of Rab6 has been implicated
(Barr, 1999).
In this report, we provide insightful understanding of the
role and mechanism of Arl1 action as well as GRIP domain-
mediated Golgi targeting of Golgin-97 and Golgin-245. Our
results have thus established a key cellular role for Arl1 and
have defined the underlying mechanism.
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